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II. ABSTRACT: 
 
Blood-based biomarkers are commonly used in veterinary patients; however, 
cardiac blood testing is a relatively new concept in Small Animal Medicine and 
the correct use of these circulating substances remains uncertain. This Masters 
project includes two retrospective studies investigating the association 
between cardiac troponin I (cTnI) and survival in dogs and cats with cardiac 
disease and one prospective study exploring the relationship between cTnI, B-
type prohormone natriuretic peptide (NT-proBNP) and acute phase proteins 
(APP) in cats with cardiac and non-cardiac diseases. 
The first retrospective study included 94 dogs with cardiac diseases. Higher cTnI 
concentrations were associated with shorter median survival times. Dogs with 
cardiac disease and cTnI concentrations above the reference range 
(>0.16ng/ml) had a median survival time of 29 months whereas dogs with cTnI 
concentrations within the reference range (<0.16ng/ml) had a median survival 
time of 44 months. However, there was a significant overlap of cTnI 
concentrations between survivors and non-survivors. The contribution of 
arrhythmias to cTnI release remains uncertain as some dogs with severe 
arrhythmias and high cTnI values survived long periods.  
The second retrospective study included 51 cats with cardiac disease, 9 with 
hyperthyroidism and 8 with systemic diseases. Increased cTnI concentrations 
were associated with shorter median survival time in cats with cardiac disease. 
Cats with cTnI concentrations above 5ng/ml survived a median of 1 month 
whereas cats with cTnI concentrations between 0.5-5ng/ml survived a median 
of 15 months. 
Finally, in a prospective study, two cardiac biomarkers (cTnI and NTproBNP) and 
four APP (Serum Amyloid A, SAA; Haptoglobin, Hp; C-reactive protein, CRP; α₁-
acid glycoprotein, AGP) were measured in 99 cats with cardiac and non-cardiac 
diseases. Signficantly higher concentrations of hscTnI, NT-proBNP and AGP were 
found in cats in congestive heart failure (CHF). Concentrations of cardiac 
biomarkers were commonly increased in cats with non-cardiac diseases. Some 
of these animals were non-anaemic, non-azotaemic and had normal 
echocardiographic examinations. No associations were found between cardiac 
and inflammatory markers.  
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Introduction to Cardiac and Inflammation 
markers 
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1.INTRODUCTION 
1.1 CARDIAC BIOMARKERS 
Time to treatment plays a critical role in human patients with ischaemic coronary 
heart disease. Morbidity and mortality rates decrease significantly in those patients 
undergoing early intervention [Moscucci and Eagle, 2006]. In consequence, 
scientists have been looking for a reliable and sensitive blood marker that could give 
an early indicator of patients suffering from acute myocardial infarction (AMI). 
The National Cancer Institute defines a “biomarker” as a biological molecule found 
in blood, body fluids or tissues that is a sign of a normal or abnormal process, or of 
a condition or disease. The Biomarkers Definitions Working Group stated in 2001 that 
a biological marker is a “characteristic that is objectively measured and evaluated 
as an indicator of normal biological processes, pathogenic processes or 
pharmacologic responses to a therapeutic intervention” [Atkinson et al, 2001]. 
 
1.1.1 HISTORY 
When cardiomyocytes die the proteins inside the cells are released. Because the 
major function of the heart is pumping, the proteins involved in contraction and 
producing the energy to support it have been traditionally tested as candidates for 
cardiac biomarkers [Ladenson, 2007]. 
The first cardiac biomarker used was serum glutamic oxaloacetic transaminase 
(SGOT), now called aspartate amino-transferase (AST).  Increased concentrations of 
SGOT after AMI were reported in 1954 for the first time [Karmen et al. 1955]. It 
was the starting point for assaying substances discharged from necrotized 
myocardium into blood. 
As SGOT became more widely used, increased concentrations in patients with liver 
damage, and thus the lack of specificity, were appreciated. Today, it is known that 
AST is not cardiac specific as it is found in liver, skeletal muscle, red blood cells and 
many other tissues [Dolci and Panteghini, 2006]. 
In the 1960s, creatine kinase (CK) and lactate dehydrogenase (LD) and its isoenzymes 
were demonstrated to be possible markers of cardiac damage [Wróblewski et al. 
1956; Wróblewski et al. 1960]. LD was found in nearly all human tissues but CK 
gave the cardiologist the opportunity to make a diagnosis of AMI within 24 hours of 
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admission. Rapid appearance, marked increase in the serum concentration after AMI 
and higher specificity when compared with AST and LD made CK the “first cardiac 
biomarker”.  However, CK was not fully specific and it was proven that CK was 
present in greater concentrations in skeletal muscle than in myocardium in the 
human body [Jaffe et al.1984, Brancaccio et al.2007]. 
Electrophoretic methods for separation of CK and LD isoenzymes were first described 
in 1972 [Roe et al. 1972]. The clinical value of CK isoenzymes stems from the fact 
that skeletal and myocardial muscle have different isoenzyme distribution. CK-MM 
is present in both but only trace levels of CK-MB are present in the skeletal muscle 
and a higher percentage in the myocardium [Wu, 2002]. CK-MB isoenzyme showed 
the highest diagnostic accuracy for AMI. The discovery of the relatively higher 
concentration of CK-MB in the myocardium (22% in myocardium, 1-3% in the skeletal 
muscle) made it the most important biomarker of cardiac injury in the 1980s [Dolci 
and Panteghini, 2006].  
New immunoinhibition assays for CK-MB were soon developed. The availability of a 
rapid and automated assay for CK-MB determination made this test popular and 
widely adopted for several years. In 1979, the World Health Organization (WHO) 
included cardiac biomarkers in the triad of diagnostic tools for AMI [World Health 
Organization, 1979]. However, the results were far from satisfactory. The major 
problem was the high rate of false positive results. CK-MB was increased in 20% of 
patients following general surgery interventions in the absence of myocardial 
damage [Adams et al. 1993]. In the 1980s scientists started to measure the protein 
concentration instead of catalytic activity using antibody-assisted techniques. 
Radioimmunoassays (RIA) and sandwich assays were developed, but even if measured 
immunochemically as protein, CK-MB was not totally cardiac specific and did not 
differentiate the origin of the damage [Chan et al. 1985; Wu et al. 1985]. This 
prompted investigators to turn their attention to other cardiac proteins and the 
troponin era began. 
In 1987, a RIA for detecting the subunit I of the troponin complex (TnI) was 
developed [Cummins et al. 1987] and, two years later, an enzyme-linked 
immunoassay for the T subunit (TnT) was designed [Katus et al. 1989]. However, 
these first-generation assays for the cardiac isoform of TnT (cTnT) showed 
significant cross reactivity with skeletal isoforms. Moreover, it was proven that cTnT 
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was re-expressed during diseases that involve skeletal muscle regeneration 
(muscular dystrophy, polymyositis or uremic myopathy) [Bodor et al. 1997; Muller-
Bardoff et al. 1997]. In consequence, cTnI came into the limelight. 
Clinical studies with isoform I (cTnI) led to a few surprises. While CK-MB returned to 
the baseline after a few days, cTnI was still detectable 7-10 days after the cardiac 
insult. This turned out to be an advantage to detect cardiac damage in patients seen 
late after their MI [Jaffe et al. 1996]. Secondly, troponins were shown to be 
elevated in about one third of patients in whom AMI was ruled out by WHO criteria. 
These patients were believed to have sustained “minor myocardial injury”, later 
described as “unstable coronary disease” [Galvani et al. 1997]. The prognosis for 
these patients was definitively worse compared with those with troponin levels 
within the normal limits. The only indication of myocardial injury in these patients 
was the increase in cTnI concentration. Early therapy in patients with unstable 
coronary disease reduced the risk of major cardiac events, making early detection 
and risk stratification critical .Laboratory information classified as falsely positive 
only ten years before now had therapeutic implications.  
Finally, the criteria for diagnosis of myocardial infarction changed in 2000, now 
defined as detection of a rise and/or fall of cardiac biomarker values (preferably 
cardiac troponin) with at least one of the following: symptoms of ischaemia, changes 
in the electrocardiogram (ECG), imaging evidence of new loss of viable 
myocardium/wall motion abnormality and identification of an intracoronary 
thrombus by angiography or autopsy [Alpert et al. 2000].  
The discovery of Troponin as a biomarker changed the foundations of human 
cardiology. A simple blood test measuring a cardiac protein became the cornerstone 
for myocardial infarction diagnosis.  
 
1.1.2 BIOCHEMICAL BACKGROUND 
Troponins are muscle proteins that are only present in striated muscle [Wells et al. 
2008]; they are restricted to the skeletal muscles and the heart. Troponins are not 
present in the smooth muscle [Collinson et al. 2001; Wells et al. 2008]. 
The striated pattern in skeletal and cardiac muscle results from the arrangement of 
the filaments within the myofibrils. Two types of these protein structures are 
identified, “thick” and “thin” filaments. The thick filaments are composed almost 
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entirely of the contracting protein “myosin”. The thin filaments contain the 
contractile protein “actin” as well as two other regulatory proteins: “tropomyosin” 
and “troponin” [Fox, 2006]. 
Troponins are a hetero-trimeric complex, which lies at regular intervals along the 
thin filament [Solaro et al. 2008]. This is shown in Figure 1.1. The complex consists 
of 3 interacting and functionally distinct proteins:  troponin C, troponin T and 
troponin I.  The structure resembles a tadpole, with the head comprising a dumb-
bell-shaped troponin C, a globular troponin I and the C-terminal region of troponin 
T; the tail is made up of the N-terminal region of troponin T [Collinson et al. 2001]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The subunits or proteins that form the troponin complex have different function, 
structure and molecular weight. Troponin C (“C” for calcium, TnC) is the calcium-
binding subunit of the troponin complex. Structural studies of TnC revealed a 
dumbbell-shaped molecule with two globular N and C-terminal domains connected 
by a central helical linker. Its molecular weight is 18 kDa. Troponin T (“T” for 
tropomyosin, TnT) binds the troponin complex to the tropomyosin and two regions 
are recognized, N-terminal region which attaches the troponin complex to 
FIGURE 1.1 Structure of the muscle. The troponin complex (green),tropomyosin (purple) and actin 
(yellow) constitute the thin filaments. Thin and thick filaments (myosin) form cylindrical bundles known 
as myofibrils. The cytoplasm of cardiomyocytes is filled with myofibrils and they are responsible for 
contraction in the cardiac muscle.  
 
Heart 
Cardiomyocyte 
Myofibril 
Thin filament 
Troponin 
complex 
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tropomyosin and C-terminal region which interacts with TnI and TnC in a calcium-
dependent manner. This protein is heavy and is 37 kDa. Troponin I (“I” for inhibition, 
TnI) is the inhibitory subunit of the troponin complex and it is a rod-like flexible 
protein. Its molecular weight is 22 kDa [Collinson et al.2001]. 
Many authors described troponin I as the most sensitive of the three subunits. 
Commonly, cTnI levels increase with less severe disease than cTnT, suggesting that 
cTnI is more sensitive to myocardial injury [Langhorn et al. 2013].  Several 
veterinary studies have measured both troponin T and troponin I in parallel in the 
same population of animals [Burgener et al. 2006, Carretón et al. 2011, Langhorn 
et al. 2013 and Langhorn et al. 2014 (b)]. In all of them cTnI was detectable and 
above the reference range in a higher proportion of the animals included in 
comparison with troponin T results. These authors hypothesized this could be due to 
a difference in protein size and molecular weight or because cTnT may have a 
structurally closer binding to the tropomyosin chain than cTnI. 
 
1.1.2.1 Isoforms and specificity 
Troponin C (TnC) is present in 2 isoforms. There are 2 known TnC genes, one 
encoding for the fast skeletal muscle isoform (fTnC) and the other expressing both 
cardiac (cTnC) and slow skeletal (sTnC) isoforms. The amino sequences of human 
cTnC, sTnC and fTnC are 66% identical. This homology between cardiac and skeletal 
isoforms reduces the cardiac specificity of TnC [Gomes et al. 2002]. 
Troponin T (TnT) has multiple isoforms. Several are present in skeletal muscle and 
4 isoforms exist in cardiac tissue, although only one is characteristic of the adult 
heart. The other 3 are expressed in fetal tissue and may be re-expressed during 
heart failure or in damaged skeletal muscle [Wells et al. 2008]. Studies have 
documented the lack of specificity of the capture antibody in the first-generation 
TnT assay. This assay detected both fetal cardiac isoforms and some skeletal muscle 
cTnT isoforms re-expressed in skeletal muscle in response to injury. These fetal 
isoforms were then characterized and a new antibody was developed. Experiments 
conducted by different groups concluded that cTnT had unique cardiac specificity 
that was equal to that of cTnI [Thygesen et al.2010]. However, it has been recently 
demonstrated that TnT expressed in diseased skeletal muscle is detected by the 
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antibodies used in both the fourth-generation and high-sensitivity assays [Jaffe et 
al. 2011] 
Three isoforms exist for TnI. There are three known TnI genes, which encode for 
cardiac, fast and slow skeletal troponin isoforms (cTnI, fTnI and sTnI, respectively) 
[Parmacek and Solaro, 2004] . The amino acid sequences of these three isoforms 
are highly homologous with the exception of a unique 32-residue N–terminal 
extension that is only present in the cardiac one. This unique extension is present in 
all cTnI isoforms across species and is highly conserved among them. Both canine 
and feline troponin genes have been cloned and sequenced [Rishniw et al. 2004]. 
Compared with the human gene, canine cTnI had one additional amino acid, which 
is also detected in rodents (mouse and rat). This “extra” amino acid was also present 
in feline cTnI but cats lack of a single amino acid - Glutamate/ Glycine (position 4). 
Therefore there is a high degree of homology in the coding region among dogs, cats, 
humans, mice and rats and commercial human cTnI analyzers can be used to measure 
serum cTnI in dogs and cats. Unlike TnT, cTnI is not expressed after damage and 
regeneration in adult skeletal muscle. Therefore, cTnI is the most cardio-specific 
protein of the troponin complex and the main target of the analytical assays 
[O´Brien et al. 1997]. 
 
1.1.2.2. Function 
Troponins are essential regulatory proteins of the muscle contractile apparatus. 
Striated muscle contraction is regulated by intracellular calcium concentration via 
the thin filament regulatory proteins: troponin and tropomyosin [Solaro et al.2007]. 
This system prevents interaction of actin and myosin in the absence of calcium. At 
rest, the concentration of calcium in the cytoplasm is very low due to calcium pumps 
in the sarcoplasmic reticulum. With low levels of calcium, troponin and tropomyosin 
are located on the outer domain of the actin, covering the myosin-binding sites. This 
is known as the “blocked state” [Gomes et al. 2002]. 
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On depolarization of the sarcolemma, calcium is released from the sarcoplasmic 
reticulum and binds to TnC. Because TnC does not interact directly with actin or 
tropomyosin, the signal must be transmitted via the other two troponin subunits 
(TnT and TnI). TnI and TnC bind with higher affinity in the presence of calcium, 
which triggers a conformational change and the tropomyosin is moved away from its 
blocking position on actin, changing to the “open state” [Craig and Lehman, 2001; 
Geeves and Lehrer, 2002]. Figure 1.2 illustrates the structural changes in the Tn 
complex and thin filament following calcium activation. 
1.1.2.3. Biomarker release 
There are 2 populations of cTn within the cell. The majority of cTn is found as 
structural proteins in the contractile apparatus, bound within the thin myofilaments. 
However, a small percentage (2-4%) remains free in the cytosol [Hickman et al. 
2010, Lippi et al. 2011]. It is believed that the cytosolic pool is released first 
resulting in an early rise in blood and a rapid washout. The half-life of TnI in blood 
is 2 hours. A rapid rise and fall within 24 hours may be consistent with the release 
of this pool and “reversible damage”.  In contrast, if Tn levels remain elevated for 
4-10 days, this might be due to continued breakdown of contractile proteins [White, 
2011]. Figure 1.3 shows the mechanisms of troponin release in transient and 
permanent ischaemia.  
 
 
  
  
TnT 
ACTIN 
TnI 
TnC 
 
 
 
 
 
 
 
TnT 
ACTIN 
TnI 
TnC 
 
 
FIGURE 1.2. Calcium regulation of muscle contraction. Calcium induces a conformational change 
on Tn, exposing the myosin binding region of the actin (colored in red) which allows the interaction 
between the filaments. A, blocked state; B, open state. 
CALCIUM 
A 
B 
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Proteolytic degradation is mandatory for the structural troponin to be released, 
whether the cytosolic pool could be released in the presence of ischaemia rather 
than necrosis alone is a matter of debate. Troponin has been proven to be elevated 
in several non-cardiac conditions. For example, 94% of athletes undergoing 
endurance sports had measurable high sensitivity troponin levels – this is thought to 
mirror increased membrane permeability rather than a clinically threatening 
myocardial injury [Lippi et al. 2011]. 
There are 6 potential major pathobiological mechanisms for troponin release: 
1. MYOCYTE NECROSIS: ischaemia, inflammation, infiltrative disease, 
trauma and toxic causes (including sepsis) [French and White, 2004]. 
2. APOPTOSIS: programmed cell death [Narula et al.1996] . 
TROPONIN IN BLOOD 
REVERSIBLE INJURY 
 
IRRREVERSIBLE INJURY 
 
INSULT 
PERMANENT TRANSIENT 
FIGURE 1.3. Mechanisms of release of troponin in transient or permanent ischaemia. 
• HIGH 
INCREASES 
•
• MILD –MOD INCREASES 
• 24 HOURS 
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3. NORMAL MYOCYTE TURNOVER: cardiac myocytes regenerate although 
they do it slowly (1% annual turnover at the age of 25). Whether such low-
grade turnover results in release of troponin is unknown [Bergmann et al. 
2009]. 
4. PROTEOLYTIC DEGRADATION: proteolysis to create small fragments 
could allow these to pass through an intact membrane [Gao et al.1997 and 
Feng et al.2001] 
5. INCREASED WALL PERMEABILITY: simulation of stretch-responsive 
integrins has been shown to result in release of troponin from intact cultured 
cardiomyocytes. Rat models have demonstrated that increased pre-load is 
associated with troponin release, independent of ischaemia [Hessel et 
al.2008] 
6.    BLEBS: cardiac myocytes develop blebs (active secretion vesicles) during 
anoxia, with release of cytoplasmic enzymes without cell necrosis [Schwartz 
et al.1984]. 
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1.2 TROPONINS IN SMALL ANIMALS 
1.2.1 TROPONINS IN CANINE MEDICINE 
The literature reviewing the usefulness of troponins in canine patients in both 
cardiac and non-cardiac conditions is extensive, detailed and confusing. The lack of 
standardization of the cTnI assays employed in scientific research has resulted in a 
wide variety of proposed reference ranges, significant differences in detection limits 
of the assays and it is not uncommon to find controversial conclusions. 
 
1.2.1.1 CARDIAC DISEASE 
A. Pericardial disease 
The most common cause of clinically significant pericardial effusions (PE) in dogs is 
neoplasia [French, 2010], most often haemangiosarcoma. Due to the diagnostic 
challenge of finding small masses by echocardiography and the poor prognosis for 
haemangiosarcoma, three studies have explored the value of troponin in the 
diagnosis of cardiac neoplasia.  
In one study, samples from 37 dogs with PE and 5 controls were collected 
prospectively. Eighteen dogs with HSA, 6 with idiopathic pericardial effusion (IPE), 
1 heart base tumour and 1 mesothelioma were finally included; in 11 cases a 
definitive clinical or histopathological diagnosis was not made [Shaw et al. 2004]. 
Dogs with PE had significantly higher concentrations of cTnI than did the controls.  
Dogs with HSA had significantly higher cTnI concentrations than did dogs with IPE. 
There was no difference in cTnT concentrations between the groups. Thus cTnI 
might be a useful marker by discriminating between idiopathic pericardial effusions 
and those caused by HSA. 
In contrast, a second study concluded that cTnI could not act as a discriminator in 
dogs with PE. Twenty-five dogs with PE were included (neoplastic PE= 21; non-
neoplastic PE= 4) and cTnI was measured in both pericardial effusion and peripheral 
blood. Dogs with HSA (n=14), heart base tumours (n=2), carcinomas (n=2), lymphoma 
(n=1) and mesothelioma (n=1) were included. The four dogs with non-neoplastic PE 
included fungal and bacterial pericarditis and lymphocytic-plasmacytic pericardial 
inflammation (possible foreign body). 
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No significant difference was identified between dogs with right atrial tumours 
(n=14) and other types of neoplasia (n=7). The median cTnI level in PE from dogs 
with neoplastic and non-neoplastic disease was not significantly different [Linde et 
al. 2006]. 
A third study prospectively recruited 57 dogs, of which 18 had cardiac HSA (5 
confirmed, 13 suspected), 14 had non-cardiac HSA, 10 had PE not caused by HSA and 
15 had non-cardiac, non-HSA neoplasms. The plasma cTnI concentration was higher 
in dogs with cardiac HSA compared with dogs with HSA at other sites, dogs with other 
neoplasms and dogs with PE not caused by HSA. cTnI concentrations were therefore 
considered useful in identifying cardiac HSA in dogs with PE. Plasma concentrations 
above 0.25ng/ml indicated that HSA was likely in dogs with PE (sensitivity 81%, 
specificity 100%) and levels above 2.45ng/ml indicated cardiac involvement in dogs 
with HSA at other sites [Chun et al. 2010]. 
Finally, in a retrospective survival study of 120 dogs, most dogs with IPE had cTnI 
between 0.151 and 1.0 ng/ml whereas dogs with PE associated with neoplasia had 
cTnI levels above 1.01 ng/ml, suggesting that cTnI might be useful to distinguish the 
aetiology [Fonfara et al. 2010]. 
 
B. Cardiomyopathies 
Dilated cardiomyopathy (DCM) is the most common type of cardiomyopathy in dogs. 
It is a disease of cardiac muscle of unknown origin, often familial, characterized by 
slowly progressive ventricular dilation and loss of cardiac contractibility. 
Approximately 25% of Irish Wolfhounds, 50% of male Doberman Pinschers and 33% of 
female Doberman Pinschers develop DCM. Sudden cardiac death caused by 
ventricular tachycardia-fibrillation occurs in at least 25-30% of affected Dobermans 
[Oyama, 2008]. 
B.1) DOBERMAN PINSCHERS 
Serum cTnI concentrations in Dobermans in various stages of cardiomyopathy (CM) 
have been evaluated. Dobermans (n=336) without evidence of systemic disease were 
recruited for this prospective study. Dogs were classified in 4 different groups: a 
“control group” (no clinical signs, no arrhythmia, no morphological changes), an 
“incipient group” (initially with no signs, no arrhythmia and normal echo at the time 
of examination, but abnormal at the next examination within 1.5 years), a “VPC 
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(ventricular premature complex) group” (no clinical signs, normal echo but >100 
VPCs/24h on Holter), an “ECHO group” (no signs, <50 VPCs/24h but abnormal M 
mode measurements), a “VPC and ECHO group” (no clinical signs, >100 VPCs/24h 
and abnormal M-mode measurements) and a “Clinical group” (dogs showing clinical 
signs with abnormal ECG and echo). 
Troponin I was significantly higher in all disease groups compared with the control 
group. Moreover the “clinical group”, animals with the most advanced disease, had 
the highest cTnI levels. No significant association between the number of VPCs and 
cTnI levels was found. 
Animals with initial normal echo and Holter results that developed DCM within 1.5 
years had increased troponin levels at the time of examination. Therefore the ability 
to detect the “incipient stage”, which the currently “gold standard” methods were 
unable to detect, suggests that cTnI is a useful additional screening test for 
cardiomyopathy in Doberman Pinschers. It was recommended that dogs with 
increased cTnI levels should be re-examined more frequently [Wess et al. 2010]. 
B.2) PORTUGUESE WATER DOGS  
Juvenile DCM (JDCM) in Portuguese Water Dogs (PWD) is an early onset disease with 
a poor prognosis. The usefulness of cardiac biomarkers to detect JDCM was evaluated 
in one study of 4 affected and 4 unaffected age-matched puppies. There was no 
significant difference in results and cTnI was not considered useful in the diagnosis 
of JDCM of PWD [Sleeper et al. 2002]. 
B.3) BOXERS 
Myocardial disease in boxers is often characterized by ventricular arrhythmias, 
rather than the ventricular dilation and systolic dysfunction seen in DCM of other 
breeds.  Due to similarities with arrhythmogenic right ventricular cardiomyopathy 
(ARVC) in humans, boxer cardiomyopathy is often referred to as ARVC [Meurs, 
2004]. Three different stages are commonly recognized: asymptomatic dogs with 
ventricular tachyarrhythmias; dogs with syncope; dogs with systolic dysfunction and 
heart failure. Sudden cardiac death may occur without previous clinical signs [Hariu 
and Carpenter, 2010]. 
In a study evaluating the use of non-invasive techniques for the early diagnosis of 
ARVC in Boxers, serum cTnI concentrations from 30 dogs, 10 boxers with early ARVC 
(>1000 VPCs/24h and echocardiographic variables within the normal range), 10 
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control boxers (<5 VPCs/24h and normal echo) and 10 control non-boxer dogs, were 
compared [Baumwart et al. 2007]. 
A significant (P=0.01) difference in cTnI concentrations was found between Boxers 
with ARVC and control boxers. Mean serum cTnI concentration was 0.142 ± 
0.05ng/ml for boxers with early ARVC, 0.079 ±0.03 for control boxers and 0.023 ± 
0.01ng/ml for non-boxers. A significant difference was observed for cTnI 
concentration between groups. Because of the difference between the two control 
groups (Boxers and non-Boxer dogs), it was suggested that Boxers, as a breed, may 
have higher reference range values for serum cTnI concentrations. 
A significant correlation (P <0.001) was found between the serum cTnI concentration 
and number of VPCs/24h for the combined Boxer population. Furthermore a 
significant  (P <0.001) correlation was also identified between the concentration of 
cTnI and the grade of arrhythmia, suggesting that cTnI could be an indicator of 
severity of the disease. However there was an overlap between the apparently 
unaffected (control) and ARVC Boxers. 
 B.4) SURVIVAL, CHF AND ARRHYTHMIAS IN CARDIOMYOPATHIES 
Another study, published in 2004, evaluated plasma cTnI concentrations in 269 
canine patients with naturally occurring heart disease: 176 were determined to be 
healthy, 26 were diagnosed with CM, 37 with mitral valve disease (MVD) and 30 with 
congenital subaortic stenosis (SAS) [Oyama and Sisson, 2004]. 
The median cTnI concentrations in dogs with CM were significantly greater than in 
healthy dogs and those with SAS. Within the healthy population a weak but 
significant correlation between age and cTnI was found. In dogs with CM there was 
no difference in median cTnI between dogs with and without congestive heart failure 
(CHF) and between those with and without arrhythmias. The median survival time 
of dogs with CM and cTnI >0.20ng/ml (11/26) was 112 days versus 357 days in 15 
dogs with cTnI <0.20ng/ml. 
 B.5) OCCULT CARDIOMYOPATHY 
A study evaluating alternative methods for the early detection of CM in Boxers, 
Doberman Pinschers and Great Danes looked at the ability of atrial natriuretic 
peptide (ANP), brain natriuretic peptide (BNP) and cTnI to detect occult CM in a 
high-risk population [Oyama et al. 2007]. 
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One hundred and eighteen dogs were prospectively enrolled; occult DCM was 
diagnosed in 21 dogs and the remaining 97 were considered healthy based on ECG 
and echocardiographic findings. Dogs with occult DCM had significantly greater 
plasma concentrations of ANP, BNP and cTnI compared with clinically normal dogs. 
Analysis of the area under the curve (AUC) of the receiver operator characteristic 
curve (ROC) analysis revealed, however, that only BNP had sufficient sensitivity and 
specificity to be of diagnostic use. 
 
C. Mitral valve disease 
Myxomatous degeneration leading to mitral valve regurgitation is the most common 
acquired cardiac disease in the dog. Mitral valve disease (MVD) may affect any breed 
of dog, but the clinical consequences are observed primarily in elderly and small-
breed dogs [Abbott, 2008]. 
 C.1) CRP AND cTnI IN DOGS WITH MVD  
CRP and cTnI were measured in 81 dogs of which 11 were healthy with unremarkable 
echocardiograms, 39 were dogs with mild MVD, 13 had moderate MVD and 18 had 
severe MVD (based on left atrial and mitral jet size [Ljungwall et al. 2010].  
Plasma cTnI was found to increase with increasing severity of MVD. Significantly 
higher concentrations of cTnI were measured in dogs with moderate (P=0.0011) and 
severe (P=0.0001) MVD, compared with healthy dogs. Dogs with severe MVD had 
significantly higher concentrations of cTnI than dogs with mild (P<0.0001) and 
moderate (P=0.0019) MVD. There was also a strong correlation between age and 
cTnI. Therefore the age of the patient needs consideration when interpreting results 
of cTnI in canine patients. 
 C.2) cTnI IN DOGS WITH MVD & CLASS IV CONGESTIVE HEART FAILURE: 
In this prospective study cTnI and cTnT were measured in dogs with MVD and class 
IV CHF (New York Heart Association classification system) [Linklater et al. 2007]. 
Only 6/15 dogs had a detectable level of cTnI and just 1/15 had cTnT above the 
detection limit. Long-term survival data was available for 14 of 15 dogs (1 dog was 
still alive 2.5yrs after presentation). The dogs with detectable concentrations of 
cTnI had a median survival time of 67.5 days whereas patients with non-detectable 
troponins survived for a median of 390 days. This difference was statistically 
significant. 
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 C.3) cTnI AND SURVIVAL IN DOGS WITH MVD 
The prognostic potential of high-sensitivity troponin I (hscTnI) and NT-proBNP was 
assessed in a prospective study of 202 dogs with MVD and 30 controls [Hezzell et al. 
2012]. The relationship between hscTnI and survival was found to be non-linear, as 
dogs with hscTnI concentrations >0.025 had shorter survival times regardless of the 
exact concentration. A ROC curve was constructed and the AUC was 0.629.  
Multivariable analysis indicated that left ventricular end-diastolic diameter 
(LVEDDN), age, heart rate and hscTnI were significantly and independently 
associated with decreased survival time for all-cause mortality in dogs with naturally 
occurring MVD. Importantly, hscTnI was not found to be independently associated 
with survival time in dogs that died or were euthanized because of cardiac disease. 
Combining serum hscTnI and NT-pro BNP measurements more accurately identified 
those dogs with a shorter survival time than did either measurement alone. 
However, when other variables (including echocardiographic variables) were known, 
the independent prognostic value of including both serum values was lost. 
Repeated measures models indicated that the rate of increase of both NT-pro BNP 
and hscTnI was more rapid in dogs that died because of cardiac disease than in those 
that died because of non-cardiac conditions. The increase in cTnI occurred late in 
the course of cardiac disease whereas NT-proBNP increased earlier. 
 C.4) MYOCARDIAL ARTERIOSCLEROSIS IN DOGS WITH MVD AND CHF 
The degree of arteriosclerotic and fibrotic changes was studied in the myocardium 
at necropsy of 50 dogs with MVD and CHF [Falk et al. 2013].  
cTnI concentrations increased with increasing grade of both global fibrosis and 
fibrosis in the papillary muscles. The type of fibrosis seen in this study was of 
“replacement type” where myocardial tissue is replaced by fibrous tissue in larger 
or smaller areas. This type of fibrosis is almost invariably caused by ischaemia and 
pathologists refer to it as “infarction” [Jönsson, 1972]. Serum cTnI concentrations 
seem to reflect the presence of both intramyocardial fibrosis and arteriosclerosis. 
This lends support to the hypothesis that arteriosclerosis may cause myocardial 
damage and may play a role in the pathogenesis of heart failure in MVD in dogs. 
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D. Congenital cardiac disease 
Two published studies [Spratt et al. 2005, Fonfara et al. 2010] have shown that 
congenital disease cases tend to have lower cTnI values than dogs with acquired 
disease. However, a study of 30 dogs with congenital SAS (Ao velocity >2.1 m/s) 
showed a median cTnI of 0.08ng/ml (interquartile range 0.01-0.94ng/ml), which was 
significantly higher than the controls [Oyama et al. 2004].  
 
E. Survival in canine cardiac disease 
A retrospective study by Fonfara et al. [2010] focused on the use of cTnI 
concentrations to assess the severity of disease, survival and prognosis in 120 dogs 
with different cardiac diseases (MVD, CM, congenital disease and arrhythmias) 
Survival analysis, using Kaplan Meier curves, showed that dogs with cTnI between 
0.151 and 1ng/ml had a median survival time of 24 months whereas dogs with a cTnI 
concentration higher than 1ng/ml had a median survival time of 3 months. Longer 
survival times with lower cTnI concentrations were confirmed in dogs with median 
concentrations of 0.18, 0.07 and 0.05ng/ml that survived more than 1 year, 2 years 
and 3 years, respectively. 
Subsequently, cTnI assays were repeated in 30 animals. Initial cTnI concentrations 
in dogs with the highest cTnI values that died were not statistically different to those 
that survived. However, in dogs that survived cTnI concentrations at follow-up were 
significantly reduced compared to the initial value (P=0.015). Repeat cTnI analysis 
during follow-up investigations may be useful to assess progression and response to 
treatment in dogs with cardiac disease. Cardiac conditions were increasingly severe 
in animals with higher cTnI results and this was accompanied by significantly reduced 
survival. Interestingly, most dogs with bradyarrhythmias had higher cTnI values, but 
the underlying cause for this is not known. (See also B.4 and C.4 above). 
 
1.2.1.2 NON-CARDIAC CAUSES OF INCREASED cTnI 
A. Breed and exercise 
Greyhounds, whether racing or non-racing, have increased left ventricular 
dimensions and wall thicknesses compared to other breeds of the same weight 
[Boon, 2011]. In man the effects of exercise on the heart regress after several 
weeks of exercise cessation but increased dimensions persist in retired racing 
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greyhounds. This cardiac enlargement in greyhounds is thought to have both 
congenital and exercise-induced components [Pape et al. 1984]. 
One study reported that cTnI concentrations in healthy retired greyhounds were 
significantly higher than in non-greyhound control dogs [LaVecchio et al. 2009]. 
The authors warned that a variable proportion of normal/healthy greyhounds could 
be erroneously diagnosed with having myocardial disease based on the presence of 
a functional heart murmur, higher vertebral heart score (VHS) on radiographs and 
increased cTnI concentrations. 
In another study cTnI and CK-MB were measured in racing greyhounds [Tharwat et 
al. 2013]. The median cTnI concentration in the racing dogs was not significantly 
different from that of the non-racing controls. However, within 2 hours of racing 
7km, cTnI concentrations were significantly higher than pre-race values in 97% of 
the animals. The cTnI levels had dropped back to the pre-race values 24hrs later. 
The causes of race-induced cTnI elevations are unclear, may be explained by mild 
hypoxia during exercise and may indicate that racing cause reversible cardiac injury 
in healthy greyhounds. 
Finally, another research group collected blood samples from ten Alaskan sled dogs 
exercised for 160 km for 5 successive days (day plan: 80 km in 5h – 7-8 h resting – 80 
km return journey). For all dogs, serum cTnI was below the level of detection of the 
immunoassay prior to exercise. Using 0.11ng/ml as a cutoff (analyzer: Immulite 
troponin I), exercise resulted in high cTnI in all dogs, peaking after the first day of 
exercise but persisting throughout the 5 days of training [McKenzie et al. 2007]. 
B. Infectious diseases 
B.1) LEPTOSPIROSIS 
Acute renal failure remains the most common clinical finding in 90% of reported 
cases of leptospirosis in domestic small animals. However, other organs may be 
involved and hepatic disease occurs concurrently with acute renal failure in 10-20% 
of cases [Harkin, 2009]. Epicarditis and endocarditis have been described in dogs 
with experimentally induced leptospiral infection [Greenlee et al. 2005]. 
One retrospective case study assessed the relationship of the concentrations of cTnI 
and the acute phase proteins C-reactive protein (CRP) and haptoglobin (Hp) with 
outcome in dogs naturally infected with Leptospira interrogans [Mastrorilli et al. 
2007]. Twenty dogs met the inclusion criteria (a positive leptospiral microscopic 
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agglutination test), of which 16 were symptomatic; three dogs had ventricular 
arrhythmias. Eleven of the 16 symptomatic dogs had increased cTnI concentrations 
(0.4 to 60.1ng). The cTnI concentration was significantly correlated with CK 
(P=0.005) and AST (P=0.001) activities, but not with urea (P=0.118). Furthermore, 
cTnI, CRP/Hp ratio, urinary albumin to creatinine ratio (UAC) and urinary total 
protein to creatinine ratio (UPC) were significantly higher in non-survivors than in 
survivors. 
The lack of correlation between urea and cTnI in this study could suggest that 
myocardial damage was due to direct myocyte injury rather than being secondary to 
azotaemia (“uraemic syndrome”), although urea will increase for many reasons.  As 
cTnI concentrations were higher in non-survivors, cTnI was proposed as a potential 
prognostic marker in leptospirosis infections. It was also noted that coagulation 
abnormalities and DIC were common findings in the dogs of this study. 
 
B.2) DIROFILARIASIS (Heartworm) 
cTnI, cTnT, myoglobin and D-dimer were measured in dogs with and without adult 
heartworm infection [Carretón et al. 2011]. Levels of cTnT in all dogs were below 
the limit detection. cTnI concentrations were significantly lower in dogs without 
clinical signs (group 1: microfilaraemic, negative for D. immitis antigen) compared 
to group 2 (positive for D. immitis antigen but not microfilaraemic) and group 3 
(positive for D. immitis antigens and microfilaraemic). No statistically significant 
difference was found between group 2 and 3. 
The hearts of 24 naturally infected dogs were examined by the same group using 
routine histology and immunohistochemistry with anti-myoglobin and anti-cTnI 
antibodies [Carretón et al. 2012]. There was no apparent association between 
worm burden and the presence of myocardial lesions and there was no correlation 
between the plasma levels of cardiac biomarkers and the presence of myocardial 
lesions  
This group also measured cTnI, myoglobin, CK-MB and AST in dogs infected with D. 
immitis during adulticide treatment with ivermectin, doxycycline and melarsomine. 
In this study dogs with a high worm burden (n=6) showed increased cTnI 
concentrations; dogs with a low burden (n=9) had similar levels to that of healthy 
dogs. After 60 days of treatment concentrations of cTnI decreased in all dogs, but 
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in those animals with high burdens the concentrations of cTnI, although decreased, 
remained above the reference range [Carretón et al., 2013]. 
Increased cTnI concentrations have been also demonstrated in dogs with other 
vector-borne diseases such as: Babesiosis [Moore and Williams, 1979, Lobetti et 
al. 2002 and Taboada and Lobetti, 2006], Ehrlichiosis [Lakkawar et al. 2003, 
McQuiston et al. 2003, Diniz et al. 2008, Mylonakis et al. 2010, Koutinas et al. 
2012 and Champion et al. 2013] and Chagas disease, also known as “American 
trypanosomiasis”, [Barr et al. 2005, Kjos et al. 2008 and Spikler, 2009].  
 
C. Anaemia 
Mortality of up to 70% has been reported in dogs diagnosed with immune-mediated 
haemolytic anaemia (IMHA) and often is associated with thromboembolism 
[Tircoveanu and Van Der Linden, 2008]. Lesions due to coagulopathy 
(macrothrombi, microthrombi, fibrin deposition and haemorrhage) and cholestasis 
were the most common abnormalities at postmortem examination of 34 dogs with 
IMHA, 10 having lesions in the heart: myocardial necrosis (n=6) and myocarditis (n=4) 
[McManus et al. 2001].  
cTnI concentrations have been determined in dogs with IMHA to analyze the 
incidence of myocardial damage in this population [Gow et al. 2011]. Eleven 
healthy, 27 IMHA and 49 hospitalized dogs without cardiac, renal or haematological 
disease were included in this study. A significant difference was found between the 
serum cTnI concentrations of dogs with primary IMHA and the hospitalized dogs 
(P<0.005) and healthy dogs (P<0.01). There was no significant difference in the cTnI 
concentrations between dogs with marked anaemia compared to those with 
moderate anaemia. The median serum cTnI concentration was higher in non-
survivors compared to dogs that survived for at least 4 weeks, although this was not 
significantly different (only 4 dogs died in the follow up period thus the study was 
severely underpowered). 
 
D. Renal failure 
cTnI concentrations have been analyzed in dogs with renal failure in the absence of 
concurrent cardiac disease. In the first study, 39 dogs with renal failure were 
included and 28 animals (71%) had cTnI concentrations above the reference interval 
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[Porciello et al. 2008]. The median cTnI concentration in dogs with azotaemia 
(creatinine >152µmol/L and isosthenuria) was 0.43ng/ml (range: 0.02-396ng/ml) and 
no correlation was found between the degree of azotaemia and cTnI. Canine patients 
with other systemic illnesses (diabetes, peritonitis, lymphoma, leishmaniasis, 
hepatitis, hyperadrenocorticism, neoplasia and intestinal foreign bodies), without 
evidence of cardiac disease, were also evaluated in this study. cTnI was also 
increased in 12/17 (70%) of these patients, confirming that increased cTnI levels are 
not uncommon in many diseases without obvious antemortem evidence of cardiac 
involvement. 
Another study compared cTnI concentrations in dogs with renal failure (and without 
evidence of cardiac disease) with those in healthy dogs [Sharkey et al. 2009]. Of 
the dogs with renal failure, 66% had cTnI concentrations above the reference range 
and cTnI levels were significantly higher in dogs with renal failure when compared 
to healthy dogs. The systolic blood pressure in dogs with renal failure was also 
significantly higher when compared with control dogs (P<0.001), but there was no 
significant correlation between serum cTnI concentration and systolic arterial blood 
pressure. The necropsy performed on 3 out of 4 dogs that died revealed cardiac 
lesions in all 3 (multifocal fibrosis with lymphocytic infiltration, endocardiosis and a 
focal haemorrhagic infarct with necrotizing myocarditis). 
 
E. Gastric dilatation-volvulus 
The severe distension of the stomach results in hypovolemic shock, and 
endotoxaemia secondary to portal vein occlusion contributes to the shock syndrome. 
Altered microvascular perfusion with hypoxemia and endotoxaemia also favours the 
development of disseminated intravascular coagulation (DIC) [Gibson, 2015]. 
Myocardial ischaemia may cause cardiac arrhythmias, which are frequently seen in 
dogs with GDV (40-70%) and may contribute to death [Schober et al. 2002]. 
In this study by Schober et al. 85 dogs with GDV were prospectively recruited to 
assess the usefulness of cTnI and cTnT as outcome predictors and to evaluate the 
correlation with the presence of arrhythmias. cTnI was detected in 74 patients (87%) 
whereas cTnT was measurable in 43 (51%). ECG abnormalities were identified in 68 
(80%) dogs, ventricular arrhythmias being most prevalent. For both cTnI and cTnT, 
serum concentrations in dogs with no or mild ECG changes were significantly lower 
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than values for dogs with moderate or severe ECG abnormalities, values for dogs 
with moderate ECG abnormalities being significantly lower than for dogs with severe 
ECG changes. Sixteen (19%) dogs died and 10 of those had ventricular arrhythmias. 
Serum cTnI and cTnT concentrations were significantly higher in dogs that died than 
in dogs that survived (P <0.05). Serum cTnI and ALT activity 48 hours after surgery 
were independent predictors of outcome with an accuracy of 91% [Schober et al. 
2002]. 
 
F. Pyometra 
A serious consequence of the uterine infection in pyometra is endotoxaemia and 
possible progression into a systemic inflammatory response syndrome (SIRS). 
Myocardial injury and failure secondary to endotoxaemia, inflammation, 
disseminated bacterial infection and infarction are suspected to be contributing 
factors to unexpected deaths in bitches with pyometra [Maretta et al. 1989]. 
cTnI concentrations have been measured in bitches with pyometra in two studies. 
The first compared cTnI results between 58 bitches with pyometra and 9 controls 
[Hagman et al. 2007]. Detectable levels of cTnI were found in 7 (12%) of the 58 
cases. One of the two dogs with the highest cTnI levels had an arrhythmia on the 
first day post-surgery and died later during that day. Myocarditis and disseminated 
bacterial infection was demonstrated on post-mortem examination. There was a 
trend for increased mortality in the pyometra patients with detectable cTnI levels. 
A second study evaluated the occurrence of myocardial damage in dogs with 
pyometra pre- and post-operatively, as well as its relation to the presence of SIRS 
[Pelander et al. 2008]. Fifteen bitches undergoing surgery for neutering (n=12) and 
mammary tumour removal (n=3) were used as controls. All controls had 
undetectable pre-operative cTnI concentrations, whereas 13/46 (28%) bitches with 
pyometra had increased cTnI values.  After surgery, 2 controls and 18 pyometra 
cases had increased serum cTnI levels. Thirty seven out of 46 pyometra cases met 
two or more criteria for SIRS. There was no statistically significant difference 
between SIRS positive and SIRS negative animals. 
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G. Blunt chest trauma 
Concentrations of cTnI, cTnT, α-hydroxybutyrate dehydrogenase and CK-MB were 
determined in 33 dogs with severe blunt chest trauma [Schober et al. 1999]. These 
were compared with values from healthy controls (n=40) and correlated with the 
presence of ECG abnormalities. cTnI was detected in 21/33 (64%), above the 
reference range in 18 (55%) and above the cut off of 2ng/ml (used to separate minor 
and major cardiac lesions in humans) in 16 dogs (48%). In contrast, cTnT was 
increased in 9/33 dogs (27%) and was above 0.1ng/ml in four dogs (12%). Relevant 
arrhythmias were found in only 5 dogs (15%) although ECG records were taken 12 to 
24 hours after injury and some abnormalities may have disappeared. Nevertheless, 
no correlation was found between the occurrence of ECG abnormalities and 
biochemically detectable myocardial cell damage. 
 
H. Systemic inflammation 
Langhorn and colleagues have assessed myocardial injury and survival in critically ill 
dogs admitted to an intensive care unit (ICU) with evidence of systemic inflammation 
(CRP concentrations greater than 35 mg/L), and two studies have been published 
(2013, 2014) involving the same population of dogs [Langhorn et al. 2013, 2014 
(c)].  Animals with evidence of structural cardiac disease or those receiving 
cardiotoxic drugs before admission were excluded. cTnI and cTnT were compared in 
8 healthy controls and the 42 dogs with trauma, neoplasia, respiratory disease, 
neural conditions, haematological disorders, splenic haematoma, peritonitis, GDV 
and mucocele that met the inclusion criteria. 
The first study focused on short-term survival (28 days) [Langhorn et al. 2013]. 
Forty of the 42 dogs (95.2%) had cTnI concentrations above the reference range at 
the time of ICU admission. Non-survivors had significantly higher cTnI concentrations 
than survivors and control dogs (P <0.001). Twenty one dogs had cTnT concentrations 
above the detection limit of the assay. Non-survivors had significantly higher cTnT 
than survivors. Admission cTnI and cTnT concentrations were highly correlated. Both 
cardiac troponins were found to be good prognostic markers, however, cTnI was the 
best short-term marker. 
Their second study aimed to determine the long-term (1-12mths) prognostic 
potential of cTnI and cTnT and also evaluated the value of daily troponin 
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measurements in the ICU [Langhorn et al. 2014 (c)]. One year outcome was 
available for 38/42 dogs. The 1-year mortality rate was 47% (18/38); 11 died within 
the first 28 days post-admission. Non-survivors had significantly higher cTnI and cTnT 
concentrations than survivors. Peak cTnI concentrations were not significantly 
higher than admission concentrations (serial determination of cTnT was not possible 
due to ethical regulation and serum volume restrictions). The median day of ICU 
hospitalization that cTnI peaked was day 1.5. There was no significant difference 
between admission cTnI, peak cTnI and admission cTnT between short and long-term 
non-survivors. 
It was concluded that daily measurements of troponins in the ICU were of value as 
peak cTnI concentration, but not admission cTnI, was related to 1yr case mortality. 
In addition, changes in circulating cTnI did not distinguish non-survivors from 
survivors. In contrast to the previous study, admission cTnT was the best long-term 
prognostic marker. 
 
J. Cardiotoxicity 
J.1) SNAKE ENVENOMATION 
Cardiac arrhythmias are commonly seen in humans and animals bitten by venomous 
snakes, and myocardial damage, including haemorrhage and necrosis, is suspected 
to have a negative impact in their outcome [Blum et al. 2004]. The presence of 
myocardial damage as a contributing factor to morbidity and mortality in dogs bitten 
by the European viper (Vipera berus) has been evaluated. Blood samples and 2-
minute ECG recordings were collected at presentation, and at 12, 24 and 36 hours 
in 24 envenomed dogs. Eight dogs had an increased serum cTnI concentration at one 
or more of the four sampling time points after the snake bite. Six dogs had abnormal 
ECGs but only 3 of these 6 dogs had increased cTnI concentrations [Pelander et al. 
2010]. 
A collaborative study between the University of Pretoria (South Africa) and the 
University of Copenhagen (Denmark) documented myocardial injury and systemic 
inflammation in dogs envenomed by 3 different snake species (V. berus, Bitis 
arietans and Naja annulifera). cTnI concentrations were correlated with CRP. These 
results suggest that myocardial damage is secondary to the inflammatory reaction 
rather than a direct cardiotoxic effect of the venom. Interestingly, a higher degree 
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of cardiac injury (higher cTnI concentration) was not present in dogs that presented 
with or developed arrhythmias [Langhorn et al. 2014a]. 
 
J.2) CHEMOTHERAPY  
Anthracyclines (doxorubicin and epirubicin) are commonly used in oncology as they 
are among the most potent chemotherapeutic agents. Unfortunately, their cardiac 
toxicity is well characterized in human, laboratory and small animals limiting their 
use in both human and veterinary medicine [Adamcova et al. 2005]. Anthracycline 
cardiotoxicity is cumulative, irreversible, acute or delayed, and in a small 
percentage of the patients fatal. In humans, the prognosis of patients who develop 
CHF is poor (50% mortality in 1 year) [Von Hoff et al. 1979].  Prevention is, 
therefore, the best approach and monitoring for early detection of cardiomyopathy 
is of paramount importance in the management of patients undergoing anthracyline 
chemotherapy. The percentage of cardiac complications in dogs at standard doses 
is approximately 3-18%. [Selting et al. 2004, Takemura et al. 2007 and Chatterjee 
et al. 2010]. 
cTnT has been measured in dogs undergoing doxorubicin treatment.  The study 
included 64 dogs with untreated neoplasia, asymptomatic DCM, advanced CHF, 
muscoskeletal trauma and dogs receiving doxorubicin [DeFrancesco et al. 2002]. 
Two dogs with lymphosarcoma on doxorubicin were studied. Both dogs had 
detectable concentrations of cTnT. In this study, normal dogs and dogs with 
untreated neoplasia had cTnT concentrations below the detection limits. After a 
cumulative doxorubicin dose of 150mg/m² the highest cTnT concentration ocurred 
after 3.5 weeks, whereas after a cumulative dose of 180 mg/m², the highest 
concentrations were seen after 2 weeks. One of the dogs died from suspected 
doxorubicin-induced cardiotoxicity (ventricular arrhythmia)  
Another report analyzed the usefulness of cTnI to predict cardiac complications in 
dogs with lymphoma and osteosarcoma undergoing doxorubicin chemotherapy 
[Selting et al. 2004]. Serum cTnI increased in some dogs treated with doxorubicin. 
Several dogs did not show evidence of heart disease following doxorubicin 
administration during the monitoring period but had increased cTnI concentrations. 
cTnI failed to predict cardiac adverse events in dogs treated with doxorubicin. 
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K. Non-cardiac dyspnoea 
NT-proANP, BNP and endothelin-1 have been demonstrated to be useful for 
distinguishing between dogs with cardiac (CHF) and non-cardiac causes of dyspnoea, 
whereas cTnI failed to distinguish these causes [Prosek et al. 2007]. Twenty six 
dogs with non-cardiac diseases such as pneumonia (n=11), pulmonary neoplasia 
(n=8), neoplastic pleural effusion (n=3), laryngeal paralysis (n=2) and chronic 
bronchitis (n=2) were included in that study. The authors hypothesized that severe 
hypoxia due to respiratory disease may result in secondary cardiac injury or may be 
a consequence of endothelial damage in the pulmonary vasculature or a result of 
the activation of angiotensin-converting enzyme. 
 
A diagrammatic representation of the non-cardiac causes of increased cTnI in the 
dog is shown in Figure 1.4. 
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1.2.2 TROPONINS IN FELINE MEDICINE 
1.2.2.1 CARDIAC DISEASE 
A. CARDIOMYOPATHIES AND TROPONIN IN CATS 
Cardiomyopathies are highly prevalent in the feline population and represent a 
heterogeneous group of disorders that result in structural and functional impairment 
of the heart muscle [Fox,2003]. 
Hypertrophic cardiomyopathy (HCM) is the most common cardiomyopathy in cats 
[Schober and Todd, 2010].  The left ventricle is hypertrophied and develops 
excessive scar tissue in the absence of secondary causes (hyperthyroidism, systemic 
hypertension, aortic stenosis or acromegaly). As a result, there is poor relaxation  
leading to diastolic dysfunction with resulting CHF, arterial thromboembolism (ATE) 
or sudden death [Fox, 2003 and Factor et al.1991] . 
The aetiology of HCM remains unknown in many cats. Mutations in the myosin binding 
protein C gene have been described in families of certain breeds such as Maine Coon 
and Ragdoll. Therefore, HCM is a primary and likely dominant heritable myocardial 
disorder. It is a developmental disease that occurs as the cat ages, at any time during 
its life span, from adolescent to geriatric [Kienle, 2008 and Côté et al. 2011 (a)]. 
Several studies have reported increased troponin values in cats with HCM. One study, 
included 33 healthy cats free of cardiac disease and 20 animals with moderate to 
severe HCM.  The median cTnI in the control group was < 0.03 ng/ml whereas it was 
0.66 ng/ml in cats with HCM. Two animals with ATE showed the highest cTnI.  In 
addition, a weak correlation between cTnI and the thickness of the left ventricular 
posterior wall in diastole (LVPWd) was seen, suggesting a possible association with 
disease severity [Herndon et al. 2002]. Another study, published in 2003, recruited 
16 HCM/hypertrophic obstructive cardiomyopathy (HOCM) affected and 18 healthy 
cats. The median cTnI in the controls was < 0.20 ng/ml (below the detection limit), 
0.91 ng/ml for the HCM group and 1.30 ng/ml for the HOCM group. There was a weak 
correlation between cTnI level and LVPWd [Connolly et al. 2003]. 
Discordant results were obtained regarding CHF when the two studies are compared. 
cTnI concentrations were  significantly higher in cats in CHF in the former study 
whereas there was not significant association in the latter study. 
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B. MYOCARDIAL DAMAGE IN FELINE HCM 
In none of the studies mentioned were histopathological examinations performed on 
the hearts from cats included, thus correlation of high cTnI concentrations with 
myocardial damage was not definitively made. 
There are several pathophysiologic mechanisms in cats with HCM that could explain 
high troponin values. Firstly, microvessel or intramural coronary artery disease is 
commonly seen in feline, canine and human hypertrophic hearts. Cats with HCM have 
abnormally thick intramural/ small coronary arteries with enlarged media and intima 
layers and markedly narrowed lumen. The arterial wall thickening results from 
cellular hyperplasia of connective/fibrous tissue. The abnormal intramural coronary 
arteries are commonly associated with areas of fibrosis, suggesting that these 
changes are significant and may produce myocardial ischaemia, necrosis and fibrotic 
replacement. A majority of cats with HCM (74%) have abnormal coronary arteries 
[Liu et al. 1993, Herndon et al. 2002, Connolly et al. 2003 and Ferasin, 2012]. 
The hallmarks of HCM in cats are myofibre disorientation, hypertrophy of the 
cardiomyocytes and increased matrix or replacement fibrosis. The presence of 
myocardial hypertrophy in the absence of adequate increases in myocardial capillary 
density could contribute to ischaemia, myocyte death and subsequent cTnI release. 
Abnormal coronary flow dynamics due to compression applied by thickened muscle 
and abundant connective tissue could decrease the coronary reserve [Krams et al. 
1998] . Finally, neurohormonal activation may induce further myocyte damage due 
to the cardiac remodeling effects (angiotensin II, aldosterone and endothelin) [Krum 
2000, Weber 2001 and Connolly et al. 2003]. 
 
C. DYSPNOEA AND TROPONIN IN CATS 
Cats with cardiomyopathies can be presented to the clinician as respiratory 
emergencies due to pulmonary oedema or pleural effusion, the final consequence of 
left-sided CHF. Dyspnoea in cats may be attributable to many other causes such as 
airway diseases, neoplasia, infection and pleural space diseases [Starybrat and 
Tappin, 2016].  
In order to clarify if cTnI could help practitioners in the management of dyspnoeic 
cats, 3 different studies have been carried out and all reached the same conclusion 
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that cTnI is not useful to distinguish between cardiac and non-cardiac dyspnoea in 
cats. 
In the first study, all cats with cardiogenic dyspnoea had cTnI concentrations > 0.2 
ng/ml. Conversely, of the 12 cats with non-cardiogenic dyspnoea, 6 had plasma cTnI 
concentrations < 0.2 ng/ml but 6 values exceeded >0.2ng/ml, the reference limit 
for healthy cats. Dyspnoeic cats with plasma cTnI concentrations that exceeded 1.42 
ng/ml most likely had CHF as the cause of respiratory distress. In dyspnoeic cats 
with plasma cTnI concentrations between 0.2-1.42 ng/ml, the cause of dyspnoea 
remained uncertain and thoracic radiographs or echocardiography were indicated 
[Herndon et al. 2008]. 
In 2009, a second study included 30 animals in respiratory distress due to non-cardiac 
diseases and 23 in CHF. Significantly higher cTnI concentrations were found in 
animals in CHF when compared with dyspnoeic animals without cardiac disease. 
Significant overlap between the 2 groups was present thereby reducing the clinical 
value of the assay [Connolly et al. 2009 (a)]. 
Finally, a third study evaluated the use of a point-of-care multiuse analyser for cTnI, 
employing from 16 to 22 µL of blood and with a turnaround time of 10 minutes. 
Thirty seven healthy cats and 39 dyspnoeic cats were included.  Similar findings to 
the two previous studies were reported. Cats with cardiac disease had significantly 
higher values of cTnI than did healthy cats and cats with a non-cardiac cause of 
dyspnoea. However, there was overlap of cTnI concentrations between the 2 groups 
of cats with dyspnoea [Wells et al. 2014]. 
 
1.2.2.2 NON-CARDIAC DISEASE 
Increased cTn levels indicate cardiac cell injury but do not define the cause of the 
injury.  Elevations are not uncommon in patients with conditions other than primary 
cardiac disease. In humans, cTnI has been proven to be elevated in renal 
insufficiency, septic shock, gastrointestinal bleeding, cirrhosis, diabetic 
ketoacidosis, hypothyroidism, chronic obstructive pulmonary disease, stroke, 
seizure, strenuous exercise, chemotherapy, rhabdomyolysis, pregnancy, 
rheumatological disease and non-cardiac surgery [De Gennaro et al. 2008]. 
In consequence, many recent investigations on cTnI in cats have focused their 
attention on non-cardiac disease as a source of increased troponin. 
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A. Hyperthyroidism 
In 2005, a study with 23 hyperthyroid cats showed that 50% of them had cTnI 
concentrations within the detectable level of the assay at the first visit. In contrast, 
only 3 out of 18 cats that completed 4 weeks of treatment using radioactive iodine 
had detectable concentrations [Connolly et al. 2005] 
Another publication concluded that both cardiac biomarkers, NT-proBNP and cTnI, 
are increased in cats with HCM and cats with hyperthyroidism. Importantly, neither 
NT-proBNP nor cTnI appeared to distinguish hypertrophy associated with 
hyperthyroidism from primary HCM. Increased cTnI levels in hyperthyroid patients 
decreased with treatment, supporting Connolly´s findings [Sangster et al. 2014]. 
B. Azotaemia 
Following previous findings in humans, a retrospective observational study in 2008 
demonstrated that dogs and cats with acute or chronic azotaemic renal failure often 
have elevated cTnI levels [Porciello et al. 2008]. Approximately 72% of cats with 
chronic kidney disease had cTnI levels above published reference intervals. 
Interestingly, the severity of renal failure did not correlate with the cTnI 
concentration. 
The underlying mechanism that correlates cTnI and renal disease remains unknown. 
Secondary cardiac toxicity due to uraemia, decreased renal excretion of troponin or 
myocardial dysfunction caused by severe systemic disease are some of the 
hypotheses suggested . 
C. Anaemia 
A recent paper, published in 2014, revealed that anaemic cats had significantly 
higher cTnI concentrations compared with cats with non-anaemic, non-cardiac and 
non-renal illnesses [Lalor et al. 2014]. 
It was impossible to establish a causal association between anaemia and myocyte 
damage because of the cross-sectional study design.  Two hypotheses were proposed 
for the higher cTnI:  left sided cardiac enlargement as a result of haemodynamic 
compensatory mechanisms or direct cardiac myocyte damage. 
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D. Hypertension 
Although nothing is known about the effect of hypertension on cTnI in veterinary 
patients, individuals with elevated blood pressure are routinely excluded in 
veterinary cTnI studies [Borgeat et al. 2014, Langhorn et al. 2014(b)] 
In December 2012 a paper published in the Journal of Hypertension demonstrated 
that cTnI was elevated in 32.7% of human patients with hypertensive crises.  
Importantly, a significant majority (76%) of the patients with elevated troponin 
levels had underlying obstructive coronary artery disease [Pattanshetty et al. 
2012]. 
E. Blunt chest trauma 
Cats with blunt chest trauma (BCT) have been shown to have increased cTnI 
concentrations [Kirbach et al. 2000]. One study included 31 cats with BCT, which 
were evaluated at 12-24h and 60-72h after the event. Alpha-hydroxybutyrate 
deshydrogenase (HBDH), CK-MB, cTnT and cTnI were measured and all were 
significantly increased 12-24h after trauma. 
F. Chemotherapy 
Anthracycline induced cardiomyopathy (AICM) is well characterized in dogs and 
people in contrast to few reports of doxorubicin toxicity in cats.  A difference in 
susceptibility to doxorubicin exists between species and dogs appear to be more 
prone to suffer from AICM than cats or people. Cardiac arrhythmias do not seem to 
be a major concern in cats whereas atrial and ventricular arrhythmias are well 
recognized in dogs and people receiving doxorubicin [O´Keefe et al. 1993]. 
Unsurprisingly, cTnI levels have been proven to be elevated in dogs and people 
treated with anthracyclines [Selting et al. 2004 and Granger, 2006]. To the 
author’s knowledge no results have been published for cats. 
 
A diagrammatic representation of the non-cardiac causes of increased cTnI in the 
cat is shown in Figure 1.5. 
 
 33 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
N
O
N
-C
A
R
D
IA
C
 D
Y
S
P
N
O
E
A
 
H
e
rn
d
o
n
 e
t a
l. (2
0
0
8
) 
C
o
n
n
o
lly e
t a
l. (2
0
0
9
) 
W
e
lls e
t a
l. (2
0
1
4
) 
A
N
A
E
M
IA
 
L
a
lo
r e
t a
l. (2
0
1
4
) 
H
Y
P
E
R
T
H
Y
R
O
ID
ISM
 
C
o
n
n
o
lly e
t a
l. (2
0
0
5
) 
Sa
n
g
ste
r e
t a
l. (2
0
1
4
) 
R
E
N
A
L FA
IL
U
R
E
 
P
o
rc
ie
llo
 e
t a
l. (2
0
0
7
) 
B
L
U
N
T
 C
H
E
ST
 T
R
A
U
M
A
 
K
irb
a
c
h
 e
t a
l. (2
0
0
0
) 
F
IG
U
R
E
 1
.5
. N
o
n
-c
a
rd
ia
c
 c
a
u
se
s o
f in
c
re
a
se
d
 c
T
n
I in
 th
e
 c
a
t. 
 34 
 
1.3 INFLAMMATION, ACUTE PHASE PROTEINS AND CARDIAC 
DISEASE IN CATS. 
Acute phase response in feline medicine 
The acute phase reaction (APR) is considered a dynamic process, which involves 
systemic and metabolic changes providing an early non-specific defence mechanism 
in animals exposed to a pathogenic insult [Petersen et al. 2004]. 
APR begins as a local reaction induced by cytokines synthesised by activated 
macrophages. Monocytes activate in the presence of bacterial toxins or local tissue 
injury and synthetise and release the pro-inflammatory cytokines (IL-1, IL-6 and TNF-
α). These cytokines are soluble mediators which function as “messengers” between 
the local site of injury and organs involved in homeostasis (central nervous system, 
autonomic nervous system and adrenal glands) [Paltrinieri, 2008].Therefore, 
cytokines induce both local and systemic effects to establish a rapid and intense 
protective response [Paltrinieri, 2007]. 
These mediators have multiple sources, multiple targets and act together through 
overlapping pathways [Gabay et al. 1999] finally producing the hallmarks of the 
APR:  
1. Fever 
2. Leucocytosis 
3. Behavioural changes  
4. Changes in the concentration of APP 
 
i. FEVER  
Pro-inflammatory cytokines are unable to pass through the blood-brain barrier thus 
they induce the synthesis of leptin (adipocytes) and prostaglandins (all nucleated 
cells) which act as intermediate molecules and modulate the activity of the thermo-
regulation center in  the hypothalamus [Sirko et al. 1989 and Paltrinieri, 2008]. 
ii. LEUCOCYTOSIS 
The APR-induced leukocytosis is biphasic. The first wave of leucocytes is released 
from the marginal pool due to the increased levels of cortisol. Cytokines induce the 
release of corticotropin releasing factor (CRF) at the hypothalamus, CRF activates 
the hypophysis that synthetizes adrenocorticotrophic hormone (ACTH) which 
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stimulate the adrenal glands to produce cortisol. Cortisol reduces the adhesiveness 
of the white blood cells to endothelium. The marginal pool is remarkable in the 
feline species as the circulating/marginal leucocytes ratio is 1:3 [Smith, 2000; 
Cowell and Decker, 2000]. The second and long-lasting wave is the consequence of 
the direct stimulation of IL-1 and TNF-α on the bone marrow. They increase the 
replication and differentiation of myeloid precursors [Paltrinieri, 2008]. 
Only about 50% of cats with subacute or chronic inflammation actually have 
increased numbers of neutrophils [Segev et al. 2006]. The degree of neutrophilia is 
usually higher when inflammation is localized rather than in generalized infections 
where neutropenia frequently occurs [Cowell and Decker 2000]. 
Hyperacute leukocytosis is a common event in cats. Leukocytosis can also be seen 
as a consequence of excitement, fear or stress. A rapid increase in leucocytes is not 
absolutely specific for inflammation [Cowell and Decker 2000].  
 
iii. BEHAVIOURAL CHANGES 
The cytokine-induced stimulation of the central nervous system results in the 
activation of the hypothalamo-pituitary-adrenal and the hypothalamo-pituitary-
gonadal axes resulting in lethargy, anorexia, adipsia and disinterest in social and 
sexual activities [Karrow,2006]. 
 
iv. ACUTE PHASE PROTEINS 
Cytokines modulate protein synthesis by the hepatocytes [Cerón et al. 2005]. 
During the APR, the blood concentration of certain proteins changes dramatically as 
a result of a complex pattern of induction involving cytokines and glucocorticoids. 
These proteins are known as “acute phase proteins” (APP).  Some will increase, 
called “positive” whereas others decrease, “negative APP” [Paltrinieri, 2008]. The 
main positive and negative feline APP are summarised in table 1.1. 
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 iv.a) NEGATIVE APP 
No data about the possible role of albumin as a negative APP are available in cats. 
It has been reported to decrease in many feline inflammatory conditions although it 
is unknown if this decrease is the result of extravasation of the albumin from the 
vessels to inflamed tissues or true decreased hepatic production [Paltrinieri, 2008]. 
 iv.b) POSITIVE APP 
The magnitude of the increase is highly variable between the different proteins and 
among different animal species (See Figure 1.6). Depending on the fold increase 
from the base line (they are usually unmeasurable in blood) the APP are further 
classified in “major”, “moderate” and “minor”. 
1) MAJOR – 10 to 100-fold increase 
2) MODERATE – 2 to 10-fold increase 
3) MINOR – only a slight increase 
Major proteins are often observed to increase within the first 48 hours and show a 
rapid decline whereas moderate and minor both increase more slowly but are more 
prolonged in duration. Moderate and minor APP are more often observed during 
chronic inflammatory processes [Cray et al. 2009]. 
Measuring the changes in the APP concentration is used as a “molecular 
thermometer”. The serial quantification of APP can provide an assessment of the 
response to a pathogenic insult. To optimize their use, it is recommended that APP 
profiles should include at least one positive major and one positive moderate APP. 
A basic profile for a cat should include SAA (as a major APP) and Hp (as moderate) 
[Cerón et al. 2008]. 
 
 
 
1. NEGATIVE APP:   
- Albumin (?) 
- Transferrin 
- Apolipoprotein A1 
- Retinol binding protein 
- Cortisol binding protein 
- Transthyretin 
2. POSITIVE APP:   
- C-Reactive protein (?) 
- α-acid glycoprotein  
- Haptoglobin 
- Serum Amyloid A  
- Complement fractions ( C3,C4) 
- LPS binding protein 
- Ceruloplasmin 
- α-globulins with antiprot. activity 
TABLE 1.1. Acute phase proteins in Feline Medicine 
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Data regarding APP levels in cats are scarce and mostly focused on general aspects 
of feline APP biology. Most of the studies have been focused on AGP, SAA and, to a 
lesser extent, Hp. These three molecules are considered most important APP in the 
cat. CRP does not seem to be involved in the acute response in this species [Cerón 
et al. 2005, Paltrinieri, 2008, Eckersall and Bell. 2010 and Eckersall and Schmidt, 
2014]. 
 
 
 
 
 
 
 
 
 
 
 
1.3.1 SERUM AMYLOID A  
Serum amyloid A proteins are a family of closely related apolipoproteins. SAA 
proteins range in size from 104 to 112 amino acids and are considered the precursors 
of amyloid A, the main component of the proteinaceous plaques deposited in major 
organs as occasional consequence of chronic inflammatory diseases (“Amyloidosis”) 
[Husby et al. 1994]. The liver is the primary source of circulating SAA although 
extrahepatic production has been described in several species [Upragarin et al. 
2005]. Expression and production have been detected in atherosclerotic lesions 
[Meek et al. 1994; Yamada et al. 1996]; brain of patients with Alzheimer´s disease 
[Liang et al. 1997; Chung et al. 2000] and epithelial cells from several normal 
tissues such as breast lobule, colon mucosa, prostate, kidney and lung in human 
patients [Urieli-Shoval et al. 1998]. The functions of SAA are thought to involve 
lipid metabolism, lipid transport, chemotaxis and regulation of the inflammatory 
process [Upragarin et al. 2005]. 
CRP /SAA 
Fibrinogen- Complement 
 
Hp /SAA 
AGP – Macroglobulin - Comp 
Hp/pigMAP/SAA 
Fibrinogen -Complement 
CRP/SAA 
Hp-AGP-Ceruplasmin 
AGP/SAA 
Hp-Complement 
FIGURE 1.6. Major and minor positive APP in domestic animal species. The APP pattern may 
vary from one species to another. Species differences in classification of major/minor positive APP 
are apparent.  
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a) FELINE AMYLOIDOSIS 
Amyloidosis results from extracellular deposition of insoluble, fibrillar and 
proteinaceous amyloid in multiple organs [Jimenez et al. 2011]. Reactive systemic 
amyloidosis is the most common in the cat [Van der Linde-Sipman et al. 1997 and 
Gruys, 2004]. Deposition of amyloid causes pressure atrophy of adjacent cells. 
Usually, the kidney is the organ most commonly involved [Grant Maxie and Newman 
2007]. In Abyssinian cats, the high degree of deposition in the kidney leads to renal 
failure at a young age [Van der Linde-Sipman et al. 1997]. In contrast, systemic 
amyloidosis in Siamese occurs in the liver leading to hepatic rupture and intra-
abdominal hemorrhage [Beatty et al. 2002, Khoshnegah and Movassaghi, 2010 and 
Chew et al. 2011].   
DiBartola et al. evidenced in 1989 that Abyssinian cats with amyloidosis had 
significantly higher (P=0.05) SAA concentrations than healthy Abyssinian cats and 
hospitalized Abyssinian cats. In addition, healthy non-Abyssinians had significantly 
(P=0.05) lower SAA concentrations than healthy Abyssinians and hospitalized 
Abyssinians. However, affected and healthy Abyssinian cats could not reliably be 
distinguished on the basis of SAA concentration because of the wide range of SAA 
values in these 2 groups of cats [DiBartola et al, 1989]. 
 
b) INFECTION 
b.1) Mycoplasma 
Haemotropic mycoplasmas are small, unculturable, pleomorphic and gram-negative 
bacteria which parasitise red blood cells to survive. Haemotropic mycoplasmosis 
causes what is commonly known as “Feline Infectious Anaemia”. Mycoplasma 
haemofelis (Mhf), previously known as “Ohio strain”, is the most pathogenic 
organism and causes anaemia in immunocompetent animals. On the other hand, 
Candidatus Mycoplasma haemominutum (CMhm), known as “California strain” 
before, and Candidatus Mycoplasma turicensis do not cause anaemia unless 
concurrent disease or immunosuppression is present [Hagiwara, 2009 and Korman 
et al. 2012]. 
The APR to experimental infection with haemotropic mycoplasmas (Mhf and CMhm) 
was characterized in a collaborative study in 2012.  Three acute phase proteins were 
measured in feline serum: SAA, AGP and Hp [Korman et al. 2012]. 
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SAA was significantly elevated during both Mhf and CMhm infections. Peak 
concentrations were reached on days 16-23 post infection (pi). Mhf was associated 
with significantly higher SAA concentrations than CMhm infection, consistent with 
Mhf being more pathogenic. SAA levels usually returned close to pre-infection values 
by day 44 pi consistent with a self-limiting APR, despite sustained circulating 
haemoplasma copy numbers. This finding indicates than an elevated SAA 
concentration suggests acute (less than 44 days post-exposure) rather than chronic 
infection. Increases in SAA mirrored the development of anaemia. 
b.2) Bordetella bronchiseptica 
A Japanese group inoculated Bordetella bronchiseptica into the bronchi of 6 healthy 
cats and measured both AGP and SAA. Although no signs of bronchopneumonia were 
observed on physical examination, both APP were slightly increased after 
inoculation. SAA peak serum concentrations were observed sooner when compared 
to AGP in infected animals [Shida et al. 2012]. 
b.3) Feline infectious peritonitis 
Concentration of SAA, AGP and Hp were studied in cats exposed to Feline 
Coronavirus (FCoV) and cats that developed Feline Infectious Peritonitis (FIP). Cats 
were recruited (n=67) and allocated in 3 groups: 24 cats were classified as controls 
or “specific pathogen free”, 11 were FCoV-exposed (without clinical signs) and 32 
suffered from FIP (25 “wet” and 7 “dry” form). SAA was measured in 64 samples 
from 50 animals. Mean SAA concentration in controls was 10.21 ± 8.32 µg/ml, 7.92 
± 7.12 µg/ml for FCoV-exposed and 82.22 ± 50.23 µg/ml for FIP cats. The highest 
SAA concentration was found in FIP cats. Results from cats with wet FIP did not differ 
from those with dry FIP patients.  Compared to controls, a 10-fold increase of SAA 
was detectable in affected cats. Repeated samplings from FIP and FCoV-exposed 
cats showed that when FIP appeared in the group, all cats had increased SAA, AGP 
and Hp levels. This increase was persistent in FIP cats whilst it was transient in the 
FCoV-exposed cats. These results concluded that SAA might also be a marker of FIP 
and highlighted its possible role in the diagnosis and monitoring of the disease 
[Giordano et al. 2004]. 
b.4) Chlamydiae 
Both SAA and AGP have been determined in cats subclinically infected with 
Chlamydiae. Sixty two cats were recruited and SAA concentrations were assessed in 
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54 individuals. SAA concentrations were above the reference range in 16 cats (30%). 
SAA concentrations were higher in subclinical shedders than they were in cats that 
did not shed Chlamydiae [Holst et al. 2011]. 
 b.5) Retrovirus and interferon- ω therapy 
A collaborative study, involving researchers from Portugal, United Kingdom and 
France assessed the ability of recombinant feline interferon-ω to produce a 
stimulation of innate host defence system in cats. To quantify this response, changes 
in the concentrations of SAA, AGP and CRP in naturally infected retroviral positive 
cats were determined. Sixteen cats were recruited and divided in 3 groups: FIV 
positive cats (n=7), FeLV positive cats (n=6) and co-infected animals (n=3). All the 
animals received 3 cycles of injections. For SAA, all the cats behaved similarly. A 
significant increase of SAA concentration was observed after therapy. On day 65, 
mean SAA concentration was 1.6 times higher than day 0, proving the effectiveness 
of this immune therapy [Leal et al. 2014]. 
 
c) PANCREATITIS 
SAA concentrations were monitored over an 831-day period in a cat with 
pancreatitis. SAA levels were increased at the onset of the disease. Long term 
monitoring from days 68 to 831 revealed a good correlation between SAA 
concentrations and the relapse of clinical signs in the cat.  It was suggested that SAA 
might be a useful tool for monitoring the disease and its response to treatment 
[Tamamoto et al. 2009]. 
 
d) INFLAMMATORY MARKER: SURGERY & VARIOUS DISEASES 
A Japanese team analyzed concentrations of SAA in sera from clinically normal cats, 
hospitalized cats, cats with experimentally induced inflammation and cats that 
underwent urinary surgery. Concentrations of SAA were significantly higher in 
hospitalized cats than in normal cats. Cats with experimentally induced 
inflammation received an intramuscular injection of turpentine oil or 
lipopolysaccharide of Escherichia coli (LPS). Concentrations of SAA began to increase 
8h after injection and reached peak values 36-48h after administration. In view of 
these results, SAA was considered a responsive protein in the early stage of the acute 
phase reaction in cats [Kajikawa et al. 1999]. 
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In 2003, another Japanese group determined SAA concentrations in 3 healthy cats 
undergoing ovariohysterectomy before and after surgery. The concentrations of SAA 
were found to increase at approximately 3-6hr and reached peak values at 21-24hr 
after surgery. These results suggested that SAA reacts rapidly to inflammatory 
stimuli and can be a useful marker of inflammation.  This group also compared SAA 
concentrations from normal healthy cats (n=45) and cats with various diseases 
(n=312). The concentrations from normal cats were statistically different from the 
diseased cats (P<0.001). It was concluded that SAA could be a useful marker for 
some, but not for all diseases [Sasaki et al. 2003]. 
SAA  has been also measured in cats having experimental surgeries. That study 
included 11 healthy subjects that had ovariohysterectomy (n=5) or gastrotomy (n=6). 
Peak concentrations of SAA after the procedures were 4.8 to 26.8 times higher for 
neutering and 11.5 to 23.4 times higher for gastrotomy in comparison with pre-
treatment concentrations. These peak serum concentrations were observed at 1 or 
2 days after surgical treatment and SAA was undetectable after 5 days post-surgery 
in most of the cats. [Shida et al. 2012]. 
 Finally, in a recent report APP concentrations (SAA, AGP and Hp) were compared 
between “sick” and “healthy” cats (based on clinical history and clinical signs). APP 
were measured in 67 cats (33 were sick and 34 were healthy) and haematology and 
biochemistry results were available from 15 sick cats. Log transformed serum 
amyloid A was found to be higher in sick, older and female cats. Median SAA 
concentration in healthy individuals (n=34) was 1.2µg/mL (range: 0.1-12.7) whereas 
median SAA concentration in sick cats (n=32) was 2.1µg/mL (range: 0.4-124.8) [Kann 
et al. 2012]. 
 
e) PROGNOSTIC MARKER 
The relationship between SAA concentration and prognosis in cats has been recently 
evaluated. 175 Cats were recruited and divided into 2 groups according to their SAA 
concentration. Median survival time of the non-elevated SAA group was 571 days 
compared with 72 days for the elevated SAA group. The animals were further 
subclassified according to diagnostic category:  neoplasia (n=65), inflammatory 
(n=64) and other diseases (n=46). There was no difference in the distribution of 
disease type between non-elevated SAA and elevated SAA groups (P=0.106). 
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According to these results, SAA was considered as a significant and independent 
prognostic marker in cats with a wide variety of diseases [Tamamoto et al. 2013]. 
 
1.3.2 α₁-ACID GLYCOPROTEIN (AGP)  
Human AGP was first described in 1950. AGP is mainly secreted by hepatocytes 
although extra-hepatic synthesis exists in several tissues such as breast epithelial 
cells [Gendler, 1982], placenta [Thomas, 1989], endothelial cells [Sörensson, 
1999], granulocytes and monocytes [Shibata, 1984; Fournier, 1999]. Although its 
exact biological function remains obscure, AGP has been shown to inhibit several 
activities of the neutrophils, down-regulating the local inflammatory response. It 
also seems to inhibit platelet aggregation, enhance the cytokine secretion from 
monocytes and interacts with endothelium leading to changes in its permeability 
[Hochepied, 2003]. 
Most of the studies on feline AGP have focused on infectious diseases, with a 
particular interest in FIP. 
a) INFECTIOUS DISEASES 
a.1) Feline infectious peritonitis 
FIP is mainly a disease of domestic cats although it has been recognized in several 
wild feline species as lion, leopard, cheetah, jaguar, lynx, serval, caracal, European 
wild cat, Sand cat and Pallas cat [Colby and Low, 1970; Colly, 1973; Poelma et al. 
1974; Theobald, 1978; Tuch et al. 1974; Pedersen, 1983; Pfeifer et al. 1983; 
Watt et al. 1993 and Juan-Sallés et al. 1998].  
Currently, there is no effective treatment for FIP and mortality is extremely high 
once clinical signs appear. Some cats live with the disease for weeks, months or, 
rarely, years [Pedersen, 2014]. 
A definitive ante-mortem diagnosis of FIP can be challenging [Pedersen, 2014]. The 
presence of effusion in the abdomen or, less frequently, in the pleural space is one 
of the most diagnostic features of the effusive (wet) form of FIP [Pedersen, 2014]. 
Measuring coronavirus antibody titers in serum or plasma is still controversial. FIP 
virus (FIPV) is a mutation in feline enteric coronavirus (FECV). FECV and FIPV are 
virtually identical and thus evoke the same antibody responses. Titers higher than 
1:3200 are highly suggestive of FIP [Hartmann et al. 2003]. 
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AGP has been extensively used as a test for FIP. High levels of AGP in cats with 
experimentally induced FIP were first described in 1988 [Stoddart, 1988]. Later on, 
AGP and Hp were studied in view to distinguish between healthy cats, cats with 
naturally occurring FIP, cats with similar signs to FIP but negative diagnosis on 
histopathological examination and FIV cats. Although both were significantly higher 
in FIP animals, only AGP was useful to distinguish between groups. FIV cats had 
significantly elevated AGP and Hp levels too, illustrating they are not pathognomonic 
for FIP. AGP was thought to be of considerable value in the diagnosis of FIP, 
particularly in conjunction with the clinical signs, antibody titer and 
albumin:globulin ratio [Duthie et al. 1997]. More recently, it has been 
demonstrated that three different APP (SAA, AGP and Hp) are increased in cats with 
FIP. Importantly, those cats exposed to FCoV but asymptomatic had a transient 
increase in APP concentration in contrast to FIP subjects, which experienced 
persistent elevation [Giordano et al. 2004]. 
A recent study has focused on the value of AGP to differentiate symptomatic FIP 
from non-FIP cats. The non FIP cats were subdivided into 5 categories: inflammatory 
processes other than FIP (n=26), asymptomatic FCoV infection (n=49), injection site 
sarcoma (n=19), post-vaccination (n=7) and clinically healthy cats (n=3). AGP was 
higher in animals with symptomatic FIP than in the whole non-FIP group. In addition 
AGP was higher in FIP animals than in each subcategory of the non-FIP group (P=0.01) 
[Paltrinieri et al, 2007a]. 
a.2) Chlamydia 
Controversial information has been published regarding AGP concentrations in cats 
infected with Chlamydiae. In one experimental infection study all the cats with 
conjunctivitis demonstrated a febrile response accompanied by elevations of AGP 
[TerWee et al. 1998]. In another study of infected cats only 9/57 cats had AGP 
concentrations above the reference range [Holst et al. 2011]. 
a.3) Retrovirus and interferon- ω therapy 
The effect of recombinant interferon-ω therapy in naturally retroviral infected cats 
has been recently investigated.  Along with SAA and CRP, AGP levels were measured 
at day 0, 20, 30 and day 65 of treatment. There was an overall increase of AGP 
concentrations from day 0 to day 65. As APP increased during interferon therapy, 
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this treatment may actually modulate pro-inflammatory innate mechanisms in cats 
[Leal et al. 2014]. 
b) NEOPLASTIC DISEASE 
b.1) Lymphoma 
AGP concentrations were measured in 25 healthy cats and 9 cats with lymphoma 
prior to induction of chemotherapy, one week after induction, at complete 
response, and at monthly intervals. The cats with lymphoma had increased AGP 
concentrations however, in contrast to the human literature, AGP was not correlated 
with either remission duration or survival time in cats [Correa et al. 2001]. 
 b.2) Carcinomas, sarcomas and round cell tumours 
In a further study that included 97 tumor-bearing and 51 healthy cats, mean AGP 
concentrations were significantly higher (P=0.0051) for tumor-bearing cats than for 
healthy controls. Importantly, the range of serum AGP concentrations for tumour-
bearing cats completely included that of the healthy population. The overlap 
between AGP values from patients with neoplasia and those from healthy individuals 
makes AGP a limited tool for monitoring the presence and progression of malignant 
disease in the cat [Selting et al. 2000]. 
c) ANAEMIA SECONDARY TO INFLAMMATORY DISEASE  
A German group characterized the possible pathogenic mechanisms causing anaemia 
secondary to inflammatory disease (AID) in 21 cats with naturally occurring 
inflammatory diseases in 2006. The study included 12 cats with abscesses, 6 with 
pyothorax and 3 with fat necrosis (secondary to trauma or surgery). The 
concentrations of AGP were increased in 14 out of 14 cats examined (range: 0.6-2.3 
g/L, median:  1.2 g/L and normal reference range: 0.1-0.48 g/L). Concentrations of 
AGP were increased up to 12 days after draining the abscesses. Increased 
concentrations of APP in conjunction with leukocytosis and clinical signs were 
indicative of the inflammatory processes in this population of cats [Ottenjann et al. 
2006]. 
d) SURGERY, INDUCED INFLAMMATION AND HOSPITALIZATION 
In Kajikawa´s study there was no significant difference in APP concentrations 
between male or female cats. Concentrations of AGP in sera from hospitalized cats 
were much higher than in clinically normal cats.  AGP levels increased in cats with 
experimentally induced inflammation (turpentine oil or E. coli LPS injection) and 
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those that underwent urinary surgery. The mean concentration of the APP reached 
a maximum 48 hours after injection. A correlation between AGP and SAA was 
detected although SAA was found to increase earliest [Kajikawa et al. 1999]. 
e) OTHER CONDITIONS 
Kann et al. measured AGP in 67 cats. Sick cats (animals with a wide and unknown 
spectrum of clinical disorders) had higher AGP concentrations than healthy 
individuals. An interaction between health status (sick/healthy) and gender was 
significant at P<0.05. AGP was correlated with SAA and Hp. The largest correlation 
was found between Hp and AGP, followed by SAA and AGP [Kann et al. 2012]. 
 
1.3.3 Haptoglobin  
Hp is a 54 kDa protein, which was firstly discovered, by Polonovski and Jayle in 1938 
[Quaye, 2008 and Adams et al. 2013]. Hp gene is expressed primarily in 
hepatocytes, however, it has been recently described in other locations such as 
adipose tissue, ovary, lungs, testis, arteries and placenta [Kalmovarin et al. 1991, 
Friedrichs et al. 1995 and Yang et al. 1995]. Hp has a pronounced antioxidant and 
anti-inflammatory action, preventing the deleterious effects associated with 
circulating free haemoglobin (Hb). In addition, Hp actively participates in 
polymorphonuclear leukocytes recruitment, free radical quenching, tissue repair 
and regeneration. Reduced expression (hypohaptoglobinaemia) or absence of the Hp 
protein (ahaptoglobinaemia) is associated with allergic (skin and lungs) and 
anaphylactic transfusion reactions [Shimada et al. 2002, Gilstad, 2003 and Larsen 
et al. 2006]. 
a) ANAEMIA SECONDARY TO INFLAMMATORY DISEASE  
Hp levels have been determined in cats with AID. Haptoglobin was increased in 13 
out of 14 cats examined (range: 5.3-13 g/L, median: 8.8 g/L and reference range: 
0.04-3.84 g/L). The Hp concentration showed an inverse correlation to the number 
of aggregated reticulocytes [Ottenjann et al. 2006]. 
b) SURGERY, INDUCED INFLAMMATION AND HOSPITALIZATION 
Similar to what was found with SAA and AGP, Kajikawa et al could not identify 
differences between males and females in both healthy and diseased cats regarding 
Hp concentrations. Hospitalized cats had higher Hp concentrations than clinically 
normal cats. Hp was also elevated before surgery or turpentine oil administrations 
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in those cats that were kept in small boxes. Hp levels increased after surgery and 
turpentine oil injection. SAA, AGP and Hp were considered acute phase reactants in 
feline patients [Kajikawa et al. 1999]. 
c) FIP AND FIV  
AGP and Hp have been analyzed in healthy cats, cats with naturally occurring FIP, 
cats with similar signs to FIP but negative diagnosis on histopathological examination 
and FIV cats. Both APP were significantly higher in FIP animals however, only AGP 
was useful to distinguish between groups. FIV cats had significantly elevated AGP 
and Hp levels too, illustrating that these APP are not specific for FIP [Duthie et al, 
1997]. 
SAA, AGP and Hp were evaluated in cats exposed to FCoV and cats that developed 
FIP. The study included 24 controls, 11 FCoV-exposed and 32 FIP cats. FIP cats had 
the highest Hp concentrations [Giordano et al. 2004]. 
d) OTHER CONDITIONS 
Haptoglobin concentrations were measured in 40 cats, comparing levels from 
healthy individuals to cats with a wide variety of diseases (“sick group”). Similar to 
SAA and AGP results, higher Hp concentrations were detected in sick cats compared 
to healthy subjects. An association between Hp levels and gender was present. 
Finally, correlation between different APP was studied and Hp and AGP showed the 
strongest correlation [Kann et al. 2012]. 
 
1.3.4 C-Reactive protein   
CRP was the first acute phase protein described. William S. Tillet and Thomas Francis 
discovered this reactant in 1930, studying the serum of patients with pneumococcal 
pneumonia [Tillet and Francis, 1930]. Plasma CRP is mainly produced and degraded 
by hepatocytes and its plasma half-life is about 19 hours [Ablij and Meinders, 2002; 
Pepys and Hirschfield, 2003]. Alternative generation sites have been found such as 
brain neurons in patients with Alzheimer´s disease [Yasojima et al. 2000], 
peripheral lymphocytes [Kuta et al. 1986] and within atherosclerotic plaques 
[Torzewski et al. 1998]. The main biologic function of CRP is determined by its 
ability to recognize pathogens and damaged cells of the host and to mediate their 
elimination by recruiting the complement system and phagocytic cells [Volanakis, 
2001]. CRP has been shown to be an independent predictor of future cardiovascular 
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events (myocardial infarction, stroke, peripheral arterial disease and sudden cardiac 
death) in multiple prospective epidemiological studies in human patients [Ridker, 
2003]. Prospective data also demonstrated that CRP is a stronger predictor of risk 
of cardiovascular events than is low-density lipoprotein cholesterol and it is also 
known as a marker of atherothrombotic disease [Ridker et al. 2002]. The excellent 
correlation of circulating CRP concentrations with the severity, extent, and 
progression of many different pathologies, and the prognostic significance of these 
associations, are consistent with CRP not just being a marker of disease but also 
contributing to pathogenesis [Pepys and Hirschfield, 2003]. CRP is considered a 
major acute phase protein in humans, dogs and non-human primates [Cray et al. 
2009]. 
a) SURGERY, INDUCED INFLAMMATION AND HOSPITALIZATION 
Kajikawa et al. introduced the concept that CRP is not a highly responsive protein 
in the acute response in the cat. In that study, CRP concentrations were increased 
in cats kept in small boxes before surgery or turpentine oil/LPS injection (as were 
SAA, AGP and Hp). CRP started to increase 8h after injection, similar to SAA and AGP 
but earlier than Hp, which increased from 24h after administration. Most of the APP 
reached the maximum level at 48 hours but when the magnitude of increase was 
compared, it was greater in SAA, AGP and Hp than CRP. Median SAA concentration 
before injection was 29.1 ±15.1 µg/ml whereas SAA levels 48h after injection were 
118.4 ±3.5. Similarly, AGP before administering the oil was 556.7 ±77.4 µg/ml and 
3179.4 ±227.6 48h after.  In contrast, median CRP concentrations before the 
procedure was 204.1 ±35.9 µg/ml and slightly increased to 269.6 ± 81.6 µg/ml 48 
hours later. Comparable findings were obtained for cats undergoing urinary surgical 
procedures. As a result, CRP has been considered an insensitive protein in the acute 
phase reaction in the cat since 1999 [Kajikawa et  al. 1999]. 
b) RETROVIRUS INFECTION AND INTERFERON-ω THERAPY 
Recently, a new report has been published assessing the effect of interferon-ω 
therapy in the immune response of cats naturally infected with retrovirus. All the 
acute phase proteins significantly increased in cats undergoing this therapy. From 
the beginning (day 0) until the end of treatment (day 65), a significant increase of 
CRP concentrations was noted.  Despite not being considered a useful biomarker of 
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inflammation in cats for years, this study showed that this APP behaves similarly to 
SAA and AGP [Leal et al. 2014]. 
 
1.3.5. Inflammation in feline cardiomyopathies 
Replacement fibrosis is a common histopathological hallmark of feline CM. The gross 
and histologic changes associated with end-stage hypertrophic cardiomyopathy (ES-
HCM) in cats have been described previously [Cesta el al, 2005].  The most common 
findings were myofibre disarray, extensive multifocal areas of fibrosis and thickened 
coronary arteries. The most severely affected cat had a markedly dilated left atrium 
with intra-auricular thrombi on gross inspection of the heart. Histologic examination 
showed areas of oedema and fibrosis surrounding islands of necrotic myocytes 
(myocardial infarctions). Interestingly, scattered lymphocytes, plasma cells and 
macrophages infiltrated the areas of fibrosis around the infarcts  
The underlying cause of restrictive cardiomyopathy (RCM) in cats remains unknown. 
It has been hypothesized that it could be secondary to hypereosinophilic syndrome 
[Fox,2004]. However there is not an adequate body of evidence in veterinary 
medicine and eosinophils are rarely seen in feline myocardium.  
A second hypothesis considers viral induced or an immune mediated pathway [Fox, 
2004]. Feline Panleukopenia (Feline Parvovirus) virus genome has been isolated in 
cats with cardiomyopathy [Meurs et al. 2000]. Myocardial inflammatory infiltrates 
including neutrophils and lymphocytes were detected in 55% of the cats with HCM, 
and both myocarditis and panleukopenia virus genome were identified in 11% of the 
hearts in that study. It is suggested that, as the virus affects cells undergoing rapid 
mitosis, myocardial infections might be expected to occur soon after birth. Cats that 
survive the viral myocarditis might later develop cardiomyopathy. Myocarditis might 
contribute somehow to development and progression of feline cardiomyopathies.   
Cats with endomyocarditis (ECM) show varying degrees of inflammation. Histologic 
findings were compared between 37 cats with ECM and 35 with RCM. In the ECM 
cats, 26 of the 37 exhibited predominantly neutrophil and macrophage infiltrates. 
Lymphocytes and plasma cells were present only in two cats and another two 
individuals had mixed inflammatory infiltrates. In contrast, RCM cases had marked 
left ventricular endocardial fibrosis without inflammation. However, small numbers 
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of lymphocytes were seen in 2 cats and neutrophils were visualized in one subject 
[Stalis et al. 1995]. 
Two forms of RCM have been identified: myocardial RCM and endomyocardial RCM. 
The latter is known as endomyocardial fibrosis (EMF). Although the main feature 
identified is extreme endocardial thickening, in some cases there is distinct 
endomyocarditis. Endomyocardial infiltrates are usually mononuclear cells and 
macrophages with occasional neutrophils [Fox, 2004].  
 
1.3.6. Inflammation in human HCM 
Cardiac histopathology, inflammatory cytokines, high sensitivity C-reactive protein 
(hsCRP) and cardiac phenotype using MRI have been employed to investigate the role 
of inflammation in the phenotypic expression of myocardial fibrosis in human HCM 
[Kuusisto et al, 2012]. 
In that study, endomyocardial biopsies were taken by fluoroscopic guidance from 
the right ventricle and from the interventricular septum. Interstitial and 
perivascular fibrosis was found in about 90% of cases. Inflammatory cell infiltration, 
including mononuclear inflammatory cells and eosinophilic granulocytes, was found 
in 37% of the patients. The degree of histopathological myocardial fibrosis 
significantly correlated with late gadolinium enhancement (LGE) in cardiac magnetic 
resonance (cMRI). A high intensity signal is seen when extracellular matrix is 
expanded because it retains the gadolinium. The grade of myocardial inflammatory 
cell infiltration correlated with fibrosis in histopathological samples (P=0.034) and 
with LGE in cMRI. Furthermore, circulating levels of hsCRP, IL-1β, IL-1RA, IL-6 and 
IL-10 were significantly higher in patients with HCM than in control subjects. 
Importantly, levels of hsCRP were significantly associated with histopathological 
myocardial fibrosis (p<0.05). All the other cytokine levels tended to be higher in 
patients with moderate or marked histopathological findings compared with those 
with no or mild findings. 
This study demonstrated that a low-grade myocardial and general inflammation 
response is present in human HCM. It is suggested that myocardial fibrosis in HCM 
may be an active process modified by an inflammatory response. 
The following pathogenic mechanism for myocardial fibrosis formation in HCM was 
proposed: the primary injury (mechanical stress due to disorganized cellular 
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architecture, myocardial ischaemia or neuroendocrinological activation) induces NF-
ĸβ up-regulation in the myocardium. NF-ĸβ, in turn, activates production of pro-
inflammatory cytokines, inflammatory cell invasion into the myocardium and 
activation of fibroblasts, finally leading to myocardial fibrosis. 
Feline and canine models of HCM share the same histopathological findings with 
human patients with HCM [Liu et al. 1993]. The 4 morphologic hallmarks 
(asymmetric patterns of wall thickening, disorganization of cardiac muscle cells, 
abnormal intramural coronary arteries and myocardial fibrosis) are present in 
human, canine and feline hearts although the frequency of these differs 
substantially among species (e.g. myocyte disorganization or asymmetric patterns 
are more common in humans than in dogs or cats). 
 
The CTnI test was initially designed for early diagnosis of MI in human patients. 
However, several factors influence cTnI release and measurements. Despite the 
increasing number of publications studying cTnI in small animals, many conflicting 
results have been reported. Consequently, veterinary clinicians struggle to interpret 
the test correctly. After a critical approach to literature review, the main goal of 
the two retrospectives studies was to investigate the relationship between cTnI and 
survival in dogs and cats taking into account every limiting and confounding factor 
described in previous publicatons (e.g. lack of standardisation of cTnI assay systems 
or increases of cTnI due to primary non-cardiac conditions). Furthermore, it has been 
proven that humans who have HCM, experience both systemic and myocardial 
inflammation. Histopathological similarities among human and cats with HCM exist 
and myocardial inflammatory infiltrates are commonly found in both. To the 
author´s knowledge, no previous reports addressing the presence of systemic 
inflammatory response in cats with cardiac disease have been published. As a result, 
the main purpose of the prospective study was to determine the characteristics of 
the acute phase response in cats with a particular interest in the subset of cardiac 
patients. 
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CHAPTER 2 
Retrospective study in dogs 
Serum cTnI and survival in canine cardiac diseases. 
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2.1 Aims and objectives 
• to investigate the relationship between cTnI concentrations and survival in dogs 
with cardiac disease.  
• to clarify if cTnI concentrations were associated with cardiac death in the 
individual patient.  
• to assess the impact of age, gender, cardiac disease, presence of CHF and 
arrhythmia on cTnI concentrations and survival in dogs with cardiac disease. 
2.2 Material and methods 
This was a retrospective study that included dogs admitted to the Small Animal 
Hospital of the University of Glasgow between August 2009 and September 2012 
which had cTnI measured. These animals were referred for further evaluation of 
suspected cardiac abnormalities detected on thorough clinical examination or ECG. 
Repeated samples from the same individual collected on different visits were 
excluded for statistical purposes. If several measurements were available, only the 
highest result was included in the analysis. After reviewing the clinical histories, 
only dogs with cardiac disease were included. No controls were recruited for this 
study. 
2.2.1 ANIMALS 
Dogs were eligible for inclusion where there was evidence of cardiac disease on 
physical examination and/or echocardiographic examination. All subjects were 
examined and scanned by a single experienced cardiologist (Dr. Paul Wotton). Dogs 
with a haematocrit below 37%, creatinine >155µmol/L in the absence of diuretic 
therapy, persistent systolic arterial blood pressure >180mmHg or concurrent disease 
(e.g. neoplasia or trauma) were excluded. 
2.2.2 CARDIAC BIOMARKER 
Samples were collected by jugular venipuncture and placed in plain serum tubes, 
which were allowed to clot and sent immediately for analysis on the same day. 
Cardiac troponin I was tested with an “Immulite® 2000 Troponin I” (Siemens) 
analyzer. The lower detection limit of the assay is 0.1ng/ml and the normal 
reference range for dogs is cTnI <0.16ng/ml. 
2.2.3 CLINICAL OUTCOME 
Survival times were calculated from the date of sampling to the date of death or 
euthanasia. The outcome was obtained either from the electronic records of the 
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primary clinicians or by contacting owners or referring practitioners by telephone. 
Animals that were euthanized or died from non-cardiac conditions were excluded 
from the study.  
2.2.4 CHF, ARRHYTHMIAS AND TYPE OF CARDIAC DISEASE. 
Dogs were further divided into subgroups based on the absence or presence of CHF. 
CHF was determined by evaluation of clinical signs, thoracic radiographs and 
ultrasonography (pulmonary oedema, pleural effusion or ascites).  Dogs were also 
divided into subgroups based on the presence or absence of arrhythmia on ECG. The 
heart rhythm was further characterized using a subjective severity scale. Finally, 
dogs were divided into six categories dependent on their final diagnosis considering 
clinical records, echocardiographic examinations, radiographs, ECG and fluid 
analysis. These categories included valvular disease, cardiomyopathy, cardiac 
neoplasia, congenital disease, idiopathic pericardial effusion, and rhythm 
disturbances in the absence of structural cardiac disease. 
2.2.5 STATISTICAL ANALYSIS 
Statistically analyses were performed using commercially available software. Data 
were non-normally distributed and results were compared using the Mann-Whitney 
U-test and graphically assessed with box-plots graphs. Median and ranges were used 
to provide descriptive statistics.Survival was analyzed using Kaplan Meier curves. 
ROC curves were created to assess the prognostic capability of cTnI and to identify 
the most useful cut-offs to predict cardiac death. Regression analysis was performed 
to identify if the cTnI results could have been influenced by confounding factors 
such as age, breed or type of disease. Statistical significance was defined as P <0.05. 
 
2.3 Results 
 2.3.1 STUDY POPULATION 
After the analysis of clinical histories, ninety-four dogs with a wide variety of cardiac 
diseases were finally included. Of these, 39 were intact males, 23 male neutered, 
22 female neutered and 10 were intact females. The median age of the population 
was 8 years old (range: 3 months-14 years). Retrievers were overrepresented, with 
Labrador the most common breed (Labrador n=16, Golden Retriever n=2, Retriever 
n=2). Other common breeds included in this study were Boxer (n=7), Spaniels 
(Cavalier King Charles n=6, Cocker n=5, Springer n=2), Terriers (West Highland White 
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n=2, Border n=1, Bull n=1, Terrier n=1), Newfoundland (n=5), Doberman (n=4), Great 
Dane (n=4), German Shepherd (n=3) and Dogue de Bordeaux (n=3). There were 2 
dogs each of the following breeds: Deerhound, Rhodesian Ridgeback, Weimaraner, 
Bulldog and Poodle; there was 1 dog each of the following breeds: Vizla, Saint 
Bernard, Jack Russell, Husky, Alaskan Malamute, Pointer and Collie. Finally, 9 cross-
breed dogs were also recruited.  Arrhythmia alone was the most common finding on 
cardiac auscultation of this population of dogs (n=32) whilst murmurs were audible 
in 26 dogs, combinations of murmur and arrhythmias were detected in 24 subjects, 
four dogs presented with muffled heart sounds and eight individuals had normal 
cardiac auscultations.  Forty two dogs presented with respiratory signs (cough, 
dyspnoea or tachypnea) and 23 had suffered collapsing episodes. Of these 23, 15 had 
arrhythmias whereas 8 had sinus rhythm. CHF was diagnosed in 32 dogs of the study 
group. 
Fifty-six dogs were presented with arrhythmias; auscultation in 32 dogs revealed an 
arrhythmia alone whereas 24 dogs were presented with a combination of arrhythmia 
and a murmur. Of these, there were 52 dogs with tachyarrhythmias and 4 with 
bradyarrhythmias. Supraventricular arrhythmias were more prevalent and atrial 
fibrillation was the most commonly diagnosed. Tables 2.1 and 2.2 summarize the 
rhythm alterations identified in dogs of this study population. There were 38 dogs 
that had no rhythm disturbances detected.  
 
 
 
VENTRICULAR Number of dogs 
VPCs 11 
AIVR 1 
V. tachycardia 8 
VPCs+ SPVCs 4 
 
 
 
 
 
 
 
SUPRAVENTRICULAR Number of dogs 
Sinus tachycardia 1 
Sinus tachy. + ectopics 3 
SPVCs 4 
SPV tachycardia 4 
SPV tach + block 1 
Atrial Fibrillation 12 
Atrial Fib + ectopics  3 
SUPRAVENTRICULAR Number of dogs 
3rd degree AV block 2 
Sick Sinus Syndrome 2 
TABLE 2.1. Tachyarrhythmias in dogs with cardiac 
disease. 
TABLE 2.2. Bradyarrhythmias in dogs with cardiac 
disease. 
**SPVCs, Supraventricular premature complexes; AIVR, accelerated idioventricular rhythm; 
VPCs, ventricular premature complexes 
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The heart rhythm was further characterized using a subjective severity scale. In this 
classification system 0 represented the absence of rhythm disturbances, 1 was used 
for mild, 2 for moderate and 3 was used for severe arrhythmias. In those animals 
with multiple rhythm disturbances (e.g. atrial fibrillation and ventricular premature 
complexes), the final severity score was obtained by adding 1 point to the score 
given to most severe arrhythmia present (e.g. slow atrial fibrillation (score =2) with 
premature ventricular complexes: final score = 3). There were 38 dogs in group 0 
(no rhythm disturbances), 17 in group 1, 21 in group 2 and 18 dogs in group 3. The 
arrhythmia severity score system is included in table 2.3. 
 
 
ARRHYTHMIA SEVERITY SCORE SYSTEM 
SCORE Rhythm 
Number of 
dogs (n) 
O = None Sinus /Sinus arrhythmia 38 
 
 
 
1 = Mild 
(n=17) 
Bradyarrhythmia SUPRAVENTRICULAR Sick sinus rhythm 2 
 
 
Tachyarrhythmia 
 
SUPRAVENTRICULAR 
Sinus tachycardia 1 
Slow SPV tachycardia 
(<160 bpm) 
3 
SPVCs 4 
VENTRICULAR AIVR 1 
Single/Sporadic/Uniform 
VPCs 
6 
 
 
 
 
2= Moderate 
      (n=21) 
Bradyarrhythmia SUPRAVENTRICULAR 3rd AV BLOCK 2 
 
 
 
 
Tachyarrhythmia 
 
SUPRAVENTRICULAR 
Fast SPV tachy (>160 
bpm) 
1 
Slow Atrial Fibrillation  
(<160 bpm) 
7 
VENTRICULAR  Frequent/Runs/Multiform 
VPCs 
5 
 
COMBINATIONS 
VPCs+SPVCs 3 
Sinus tachycardia + SPVCs 2 
Sinus tachycardia + VPCs 1 
 
 
3= Severe 
(n=18) 
 
 
 
Tachyarrhythmia 
SUPRAVENTRICULAR Fast Atrial Fibrillation  
(>160 bpm) 
5 
VENTRICULAR  Ventricular tachycardia 8 
 
 
COMBINATIONS 
Pairs/triplets VPCs + 
SVPCs 
1 
 Atrial fib + VPCs 3 
Fast SPV tachy + AV block 1 
 
 
Finally, dogs were classified depending on their final diagnosis in 6 different groups 
of disease. There were 29 dogs with MVD, 32 with cardiomyopathies, 8 with cardiac 
TABLE 2.3. Arrhythmia Score System. 
**SPV tachycardia, supraventricular tachycardia;  SPVCs, Supraventricular premature 
complexes; AIVR, accelerated idioventricular rhythm; VPCs, ventricular premature 
complexes;  AV block, atrio-ventricular block. 
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tumors, 12 with congenital cardiac diseases, 8 with IPE and 5 dogs with rhythm 
disturbances in absence of evident underlying structural cardiac disease. 
 
2.3.2 BIOMARKER CONCENTRATION 
 a) cTnI AND CONGESTIVE HEART FAILURE 
Those dogs that were in CHF had significantly (P=0.021) higher cTnI concentrations 
than patients with compensated cardiac diseases. Although both groups had median 
cTnI concentrations above the reference range, dogs in failure had median cTnI 
concentrations of 0.52ng/ml whereas it was 0.33ng/ml in compensated canine 
patients. In the latter, there were 18 out of 62 dogs (29%) with cTnI concentrations 
below the reference range (<0.16ng/ml). In contrast, normal cTnI concentrations 
were detected in only 2 dogs in failure whilst 30 of 32 had increased cTnI. 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 b) cTnI AND ARRHYTHMIA 
cTnI concentrations were significantly (P<0.0001) higher in dogs with arrhythmias 
than in those with sinus rhythm. Dogs with arrhythmias had median cTnI 
concentrations of 0.73ng/ml whereas dogs with sinus rhythm had median cTnI 
concentrations of 0.18ng/ml. There were 53 dogs (95%) in the arrhythmic group with 
FIGURE 2.1. Boxplot of cTnI concentrations in dogs with and without CHF. cTnI 
concentrations were significantly higher in dogs with CHF (P=0.0021). 32 dogs in failure (CHF+) 
were included in the study. This group had a median cTnI concentration of 0.52 ng/ml 
(range:0.1-180). On the other hand, there were 62 dogs without CHF (CHF-). Median cTnI 
concentration of this group was 0.33 ng/ml (range:0.1-173 ng/ml). The yellow triangle (  ) 
represents 5 values above 10 ng/ml whilst the blue (  ) represents 4 values higher than 10 ng/ml. 
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cTnI concentrations above the reference range  and 3 individuals (5%) with cTnI 
below 0.16ng/ml. These three patients with normal cTnI concentrations had single 
atrial ectopics, regular junctional tachycardia (160 bpm) and sick sinus syndrome. 
In contrast, 17 patients with sinus rhythm (45%) had cTnI concentrations <0.16ng/ml 
whilst 21 (55%) had increased cTnI concentrations.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Dogs with severe arrhythmias (e.g. ventricular tachycardia and fast atrial 
fibrillation) had significantly higher cTnI concentrations than dogs with sinus rhythm 
(P=0.000) and those with mild (P=0.002) and moderate (P=0.012) arrhythmias. Dogs 
with mild and moderate arrhythmias had significantly higher cTnI levels (P=0.015; 
P=0.000) than subjects with sinus rhythm. However, no difference in cTnI 
concentrations between dogs with mild and moderate arrhythmias was found 
(P=0.218). Although all groups had median cTnI concentrations above the reference 
range, animals with severe arrhythmias had median cTnI significantly high (median 
cTnI=2.43ng/ml) in comparison with animals with moderate (median cTnI= 
0.61ng/ml) and mild (median cTnI =0.42ng/ml) 
 
FIGURE 2.2. Boxplot of cTnI concentrations in dogs with and without arrhythmias. Dogs 
with arrhythmias had significantly higher cTnI concentratios than dogs with sinus rhythm 
(P=0.0000). There were 38 dogs which presented without arrhythmias. Those had a median cTnI of 
0.18 ng/ml ( range: 0.1-4.8 ng/ml).Whereas 56 dogs presented with rhythm disturbances. Those 
had median cTnI of 0.73 ng/ml ( range: 0.1-180 ng/ml). The blue triangle (  ) represents 9 values 
above 10 ng/ml 
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a) cTnI AND TYPE OF CARDIAC DISEASE 
Dogs whose final diagnosis was cardiomyopathy had significantly higher cTnI 
concentrations than dogs with acquired valvular disease (P=0.012), congenital 
cardiac disease (P=0.002) and rhythm disturbances (P=0.028). There were no 
differences between dogs with cardiomyopathy and those with cardiac tumours (P 
=0.087) or those with idiopathic pericardial effusion (P=0.09). Moreover, those 
patients with cardiac tumors had significantly (P=0.018) higher cTnI concentrations 
than dogs with congenital cardiac disease. No differences between the other groups 
were found. 
Median cTnI concentrations were below the reference range only in those dogs with 
congenital cardiac disease whereas it was 1.92ng/ml in dogs with cardiac tumors, 
0.61ng/ml in those with cardiomyopathies, 0.37ng/ml in individuals with acquired 
valvular disease, 0.25ng/ml in dogs with rhythm disturbances and 0.183ng/ml in 
subjects with idiopathic pericardial effusion. 
 
 
 
 
FIGURE 2.3. Boxplot of cTnI concentrations in dogs with mild, moderate and severe 
arrhythmias. Dogs with mild arrhythmias (n=17) had a median cTnI concentration of 0.42 ng/ml  
(range: 0.1-7.6 ng/ml) ; dogs with moderate arrhythmias (n=21) has a median cTnI of 0.61 ng/ml 
and those with severe arrhythmia (n=18) had a median cTnI of 2.43 ng/ml. Dogs with severe 
arrhythmias (e.g. ventricular tachycardia and fast atrial fibrillation) had significantly higher cTnI 
concentrations than dogs with sinus rhythm (P=0.000) and those with mild (P=0.002) and 
moderate (P=0.012) arrhythmias. The blue triangle (  ) represents 2 values above 70 ng/ml and 
the red triangle (   ) represents 1 value above 70 ng/ml. 
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 c)  cTnI AND SURVIVAL 
There were 39 dogs that were alive when survival information collection finished 
(27th February 2014) whilst 55 dogs died before this date due to their cardiac disease. 
Non-survivors had significantly (P=0.003) higher cTnI concentrations than those that 
survived. Median cTnI concentration for non-survivors was 0.49ng/ml whereas it was 
0.25ng/ml for survivors. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The correlation between cTnI levels and survival was further studied with Kaplan 
Meier curves. In order to create the curve, dogs were divided in 2 groups: dogs with 
increased cTnI concentrations (>0.16ng/ml) and dogs with non-elevated cTnI 
concentrations (<0.16ng/ml). There were 74 and 20 dogs included in each category, 
respectively. Dogs with increased cTnI concentrations had significantly shorter 
survival times than those with cTnI within the reference range. Dog with increased 
cTnI survived a median of 29 months whereas dogs with non-elevated cTnI 
concentrations survived a median of 44 months. 
The difference between the curves was quantified to assess statistical significance. 
As the comparative analysis depends upon the whole curve and not upon isolated 
points, Log-Rank  test was the system of analysis of choice. Log-Rank test for the 
FIGURE 2.4.  Boxplot of cTnI concentrations in survivors and non-survivors. Non 
survivors (n=55) had a median cTnI of 0.49 ng/ml ( range: 0.10-180 ng/ml) whereas survivors 
(n=39) had median cTnI of 0.25 ng/ml ( range: 0.10-127 ng/ml). Non-survivors had 
significantly higher cTnI concentrations than survivors (P = 0.003). The yellow triangle (  ) 
represents 2 values over 10 ng/ml and the blue triangle (  ) represents 7 values above 10 
ng/ml 
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data in this retrospective study was P=0.006, thus these two curves were 
significantly different. Consequently, the probability of survival of dogs with non-
elevated and elevated cTnI concentrations was significantly different. Survival times 
were significantly shorter in those dogs with elevated cTnI concentrations. 
The ability of the troponin test to predict cardiac mortality in dogs with primary 
cardiac diseases was assessed with ROC curves. The AUC of the ROC curve was 0.69, 
demonstrating the potential of cTnI testing to predict outcome in these patients.  
However, the best cut-off for predicting cardiac death was cTnI >0.33ng/ml which 
produced a sensitivity of 76% and a specificity of 65%, revealing that the test 
produces considerable numbers of false positives and negatives. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 d) DOGS WITH INCREASED cTnI AND PROLONGED SURVIVAL 
Log-Rank 
P=0.006 
Wilcoxon 
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FIGURE 2.5. Kaplan Meier curve (A) and ROC curve (B) for cTnI and survival in dogs 
with cardiac disease 
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There were 39 dogs that were alive in the end of study (February 2014). Of these, 
13 had non-elevated cTnI concentrations whereas 26 survivors had elevated cTnI 
(range: 127-0.18ng/ml). Last blood sample was collected in September 2012 thus 
these patients survived 1.5 years despite having increased cTnI concentrations.  
Further analysis of this subset of patients, revealed that median age was 8 years old, 
median cTnI concentration was 0.38ng/ml (range: 127-0.18ng/ml), 15 dogs had 
arrhythmias (4 dogs had 3-score arrhythmias, 5 had 2-score arrhythmias and 6 had 1 
score-arrhythmias) and 5 had CHF. Regarding their final diagnosis, 12 dogs were 
diagnosed with CM, 5 with acquired valvular disease, 4 with congenital disease, 3 
had IPE and 2 had primary rhythm disturbances. cTnI concentrations and clinical 
information from this group of patients are summarized in table 2.4.  
Arrhythmias might play an important role in the release of cardiac troponin. The 
review of data collected from dogs with non-cardiac diseases but increased cTnI 
concentrations (higher than 1ng/ml) in the same study period, revealed that a high 
proportion of these patients presented with arrhythmias. There were 16 out of 29 
dogs with non-cardiac disease and cTnI >1ng/ml that presented with rhythm 
disturbances. Tachyarrhythmias were also the most prevalent in this group of dogs. 
cTnI concentrations and clinical data from this subset of patients are summarized in 
table 2.5. 
 
 e) REGRESSION ANALYISIS  
Univariable and multivariable regression analysis revealed that cTnI was not 
associated with age or gender (P= 0.21, P=0.13). However, cTnI was associated with 
the presence of arrhythmia (P=0.05) and CHF. 
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[cTnI] Age Breed 
Final 
diagnosis 
CHF score Arrhythmia 
Survival 
(years) 
127 3 Weimaraner Occult DCM N 3 V.TACH 3 
31.3 8 Doberman DCM N 3 
bursts of VPCs (300 
bpm) 
2 
7.58 10 Siberian Husky 
Tachycardia 
induced 
CM 
N 2 
SUPRAVENTRICULAR 
TACHYCARDIA 300 
bpm  (atrial flutter?) 
2 
4.8 8 Labrador IPE Y 0 N (120 bpm) 4 
1.98 1 Newfoundland Occult DCM N 1 VPCs 4 
1.34 10 Crossbreed IPE N 0 N (100 bpm) 3 
0.94 10 Labrador MVD N 1 VPCs 4 
0.92 5 Boxer ARVC N 3 
VPCs (pairs-triplets) 
- APCs 
3 
0.92 11 Labrador DCM N 0 
Sinus rhythm ECG 
(arrhythmia on 
auscultation) 
2 
0.65 8 Dalmatian MVD N 1 VPCs 2 
0.64 8 Doberman DCM N 3 V. TACH 2 
0.47 7 Doberman Occult DCM N 0 N 3 
0.41 12 Crossbreed MVD N 1 SVPCs 3 
0.35 1 
Alaskan 
Malamute 
VSD N 0 N 1 
0.31 5 
Dogue de 
Burdeaux 
DCM N 2 
Atrial fibrillation 
(100-110 bpm) 
3 
0.31 9 Cocker Spaniel DCM Y 2 VPCs and SPV tachy. 2 
0.31 6 
Dogue de 
Burdeaux 
DCM N 2 
Atrial fibrillation 
(140-180 bpm) 
2 
0.27 10 Toy Poodle MVD, PH Y 0 N 3 
0.25 10 Crossbreed SPV Tachy. N 1 
SPV tachycardia and 
AV disassociation 
(100 bpm) 
2 
0.25 11 Labrador MVD N 2 
Atrial fibrillation 
(130 bpm) 
2 
0.24 4 Boxer 
Aortic 
stenosis 
N 0 N 2 
0.24 8 
Springer 
Spaniel 
Sick sinus 
syndrome 
N 1 Sick sinus syndrome 2 
0.23 7 Cocker Spaniel DCM Y 0 N 3 
0.216 2 Bulldog IPE Y 0 N 2 
0.18 6 Boxer 
Aortic 
stenosis 
N 0 N 3 
0.18 6 Newfoundland 
Subaortic 
stenosis 
N 0 N 2 
TABLE 2.4. Dogs with cardiac disease, increased cTnI and prolonged survival. 
**DCM, dilated cardiomyopathy; CM, cardiomyopathy; IPE, idiopathic pericardial effusion; MVD, mitral valve disease; 
ARVC, arrhytyhmogenic right ventricular cardiomyopathy, VSD, ventricular septal defect; PH, pulmonary 
hypertension;  SPV tachycardia, supraventricular tachycardia;  SPVCs, Supraventricular premature complexes; AIVR, 
accelerated idioventricular rhythm; VPCs, ventricular premature complexes;  AV block, atrio-ventricular block; AV-
disassociation, atrio-ventricular disassociation. 
 63 
 
[cTnI] 
Age Final diagnosis Arrhythmia Dox. Hct Creat 
Survival 
(days) 
588 3 
Pancreatitis/ 
peritonitis/Acute 
renal/ liver failure 
V.TACH and RT 
phenomenon 
NO 63.7 / 1 
180 10 HSA - Spleen V.TACH NO 33.9 103 197 
115 11 
Anaemia 
Thrombocytopaenia 
VPCs 
(R-T phenom.) 
NO 14.7 163 0 
68.6 7 HSA - splenic AIVR NO 16.9 78 888 
63.5 8 Splenic mass 
Sinus tachy and 
multiform VPCs 
NO 12.7 93 1055 
24.2 9 
Iliac thrombi - 
Hypertension- renal 
disease 
SPV tachy 
(250 bpm) 
NO 64.2 228 5 
16.2 1 SRMA NO NO 47 99 1246 
14.2 9 HSA - skin NO YES 38.9 92 724 
8.49 12 HSA- skin RBBB YES 38 127 54 
8.21 6 
Mediastinal 
lymphoma 
NO NO 55 120 1 
7.9 11 Insulinoma (Susp) NO NO 51.6 64 58 
6.8 6 Cardiac contusion NO NO 20.5 / 372 
6.4 12 Lung mass 
SPCVs ( VPCs in 
previous visits) 
NO 61.4 92 138 
6.27 7 Lymphoma NO NO 53.7 / 383 
6.04 11 Splenic sarcoma VPCs NO 64.5 72 24 
5.21 6 Lymphoma NO YES 35.9 64 139 
4.35 1 
Megaoesophagus/ 
Pneumonia / IM 
myositis 
VPCs NO 47.4 111 16 
3.8 7 Open (Lungs) NO NO 38.6 99 0 
3.13 8 
Haemoptysis and 
dyspnoea UO 
1st AV block - 
VPCs 
NO 42.7 79 1 
2.41 8 
cruciate ligament 
disease 
Sinus 
tachycardia 
NO / 84 638 
2.39 9 splenic HSA NO NO 38.1 123 24 
1.77 8 IMHA NO NO / / 299 
1.72 8 
neutropenia 
Borrelia+ 
NO NO 39.3 / 35 
1.5 6 
Multicentric 
lymphoma 
NO YES 43.9 86 490 
1.34 9 Brain neoplasm 
SPV tachycardia 
(260 bpm) 
NO 46 93 0 
1.3 11 
Hypothyroidism  and 
CRF 
SPV tachy 
(300 bpm) 
NO 34.3 / 552 
1.22 8 Lymphoma VPCs YES 44.6 / 85 
1.22 8 Lymphoma NO YES 36.3 126 27 
1.2 10 Abdominal neoplasia 
Sinus tachy and 
VPCs 
NO 30.1 102 0 
 TABLE 2.5. Unpublished data compiling clinical information from dogs with non-
cardiac diseases and cTnI concentrations higher than 1ng/ml. 
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2.4 Discussion 
The results from this retrospective study confirmed there is an association between 
cTnI and outcome in dogs with cardiac conditions. Patients with increased cTnI (cTnI 
>0.16ng/ml) had a median survival time of 29 months whereas those dogs with 
normal cTnI concentrations (cTnI <0.16ng/ml) had a median survival time of 44 
months. Median cTnI concentration was 0.49ng/ml for non-survivors whilst it was 
0.25ng/ml for survivors and this difference was statistically significant. However, 
when the efficacy of the test was assessed with ROC curves (AUC = 0.69), low 
specificity (65%) and sensitivity (76%) were obtained. Similar results were observed 
in a report that included 202 dogs with MVD. The AUC of the ROC curve in that study 
was 0.63 and, employing a cut-off of 0.025ng/ml, a sensitivity of 82% and a 
specificity of 43% were produced [Hezzell et al. 2012]. The overlap of cTnI 
concentrations between survivors and non-survivors and the resultant low prognostic 
sensitivities and specificities have been also described in short- and long-term 
survival studies in critically ill dogs with systemic inflammation [Langhorn et al. 
2013 and 2014c]. Therefore, caution should be exercised as some animals escape 
the rule of “higher cTnI concentrations = shorter survival times”. Cut-off 
concentrations obtained with outcome predictive systems should not be used to 
predict cardiac death in individual patients and decisions of euthanasia should not 
be made based on cTnI results. 
The association between cTnI concentrations and survival in dogs with cardiac 
disease has barely been explored before. One study reported shorter survival times 
with increased cTnI concentrations in dogs with cardiac disease. Patients with cTnI 
concentrations between 0.151 and 1ng/ml had a median survival time of 24 months 
whereas dogs with cTnI greater than 1ng/ml survived no longer than 3 months. Dogs 
that survived more than 1 year, 2 years and 3 years had a median cTnI concentration 
of 0.18ng/ml, 0.07ng/ml and 0.05ng/ml, respectively [Fonfara et al. 2010].  This 
association between cTnI levels and outcome has been demonstrated in dogs with 
cardiomyopathy and mitral valve disease in 3 additional studies. In the first, dogs 
with cardiomyopathy and cTnI <0.20ng/ml survived 357 days whereas those patients 
with cardiomyopathy and cTnI >0.20ng/ml had a median survival time of 112 days 
[Oyama and Sisson, 2004].  In another report, cTnI was detectable in 6 out of 15 
dogs with mitral valve disease (MVD) and congestive heart failure. In those, median 
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survival time was 68 days whereas those with undetectable cTnI levels (9/15) 
survived for 390 days [Linklater et al. 2007]. Finally, cTnI was also associated with 
decreased survival times for all-cause mortality in 202 dogs with naturally MVD. 
However, cTnI was not found to be independently associated with survival in those 
dogs that died or were euthanized because of cardiac disease [Hezzell et al. 2012].   
In the present study, the presence of an arrhythmia was significantly associated with 
higher cTnI concentrations. In dogs with arrhythmias (n=56) the median cTnI 
concentration was 0.73ng/ml whereas in dogs in sinus rhythm this was 0.18ng/ml. 
Moreover cTnI concentrations correlated with the severity of the arrhythmia. Dogs 
with severe arrhythmias had significantly higher cTnI concentrations than those with 
moderate or mild rhythm disturbances. In dogs with severe arrhythmias the median 
cTnI concentration was 2.43ng/ml compared with 0.61ng/ml and 0.42ng/ml in 
animals with moderate or mild rhythm abnormalities, respectively. Controversial 
results have been published regarding the association between cTnI and arrhythmias 
in dogs with cardiac conditions. cTnI concentrations correlated with VPC/24h and 
the severity of arrhythmia in 20 boxers with and without ARVC [Baumwart et al. 
2007]. In another study, which included 336 Doberman Pinschers, cTnI was able to 
predict VPCs (AUC = 0.79/ SY = 71%/ SPY = 87%) but no significant linear association 
between number of VPCs/24 hour and cTnI levels was found [Wess et al. 2010]. 
Arrhythmias were detected in 16 of 23 dogs (70%) with cTnI concentrations 
>1.01ng/ml (the group with highest cTnI values in that study population) in another 
report. Of these 16 dogs, seven were diagnosed with atrio-ventricular block, one 
with sick sinus syndrome, four with ventricular tachycardia and 4 with ARVC 
[Fonfara et al. 2010]. cTnI concentrations were significantly increased in 21 
Doberman Pinchers, Great Danes and Boxers with ECG (1 or more ventricular 
premature complexes during performance of 4 min ECG, n = 11) or echocardiographic 
(n=20) evidence of occult cardiomyopathy [Oyama et al. 2007]. In contrast, no 
difference in median cTnI concentrations was found between 26 dogs with 
cardiomyopathy with and without arrhythmias [Oyama and Sisson, 2004]. 
cTnI concentrations have been demonstrated to be elevated in dogs with several 
non-cardiac conditions as anaemia [Gow et al. 2011], renal failure [Porciello et al. 
2008 and Sharkey et al. 2009], GDV [Schober et al. 2002 and Burgener et al. 
2006], pyometra [Hagman et al. 2007 and Pelander et al. 2008], blunt chest 
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trauma [Schober et al. 1999], snake envenomation [Segev et al. 2008, Pelander 
et al. 2010,Langhorn et al. 2014a], chemotherapy [Christiansen et al. 2002, 
DeFrancesco et al. 2002 and Selting et al. 2004], exercise [ McKenzie et al. 2007 
and Tharwat et al. 2013] and infectious diseases [Mastrorilli et al. 2007, Lobetti 
et al. 2002 and Diniz et al. 2008]. Arrhythmias are not uncommon in these clinical 
scenarios. Rhythm alterations were frequently detected in dogs with non-cardiac 
diseases included in the studies mentioned above. In 85 dogs with GDV, 
electrocardiographic abnormalities were detected in 68 (80%) and 36 out of 68 had 
ventricular arrhythmias. cTnI concentrations for dogs with no or mild ECG changes 
were significantly lower than values for dogs with moderate and severe ECG 
abnormalities [Schober et al. 2002]. Electrocardiographic abnormalities were 
detected in 33 out of 150 of Erhlichia canis infected dogs in another study. Dogs with 
severe ECG changes had higher cTnI than dogs with mild or moderate ECG 
abnormalities. High concentrations were detected in dogs with VPCs (median cTnI 
2.15ng/dl) and supraventricular tachycardia (0.22ng/dl) [Diniz et al. 2008]. In 48 
dogs suffering from snake envenomation, arrhythmias were found in 14 of them 
(29%) and sinus tachycardia was the most prevalent (57%). Cardiac arrhythmias were 
correlated with cTnT but not cTnI concentrations [Segev et al. 2008]. In another 
study with 24 envenomed dogs, 6 dogs had ECG abnormalities and 3/6 had increased 
cTnI levels [Pelander et al. 2010]. Finally, arrhythmias were identified in 9 out 34 
dogs with Babesiosis. Those showing VPCs had high cTnI levels. There was a 
significant correlation between the presence of VPCs and high cTnI concentrations 
[Lobetti et al. 2002]. 
Importantly, cTnI has been demonstrated to be elevated in human patients with 
angiographycally normal coronary arteries and benign arrhythmias as paroxysmal 
supraventricular tachycardia (PSVT). This dysrhythmia is usually managed without 
difficulty and rarely results in adverse clinical outcomes. As a result, the prognostic 
significance of elevated troponins in patients with PSVT has been questioned 
[Redfearn et al. 2005, Chow et al. 2010, Carlberg et al. 2011 and Xue et al. 
2014].  
The role of arrhythmias in the release of cardiac troponin in small animals remains 
obscure. We hypothesized that arrhythmias might be a contributing factor to cardiac 
troponin release in small animals too (“tachycardia induced elevation of cTnI”). 
 67 
 
Tachyarrhythmias were a common finding in dogs in this study with high cTnI.Some 
of these patients with marked elevation of cTnI concentrations and severe 
arrhythmias presented prolonged survival. Myocardial ischemia secondary to the 
presence of arrhythmia may contribute to the magnitude of cTnI release in these 
patients.  
Regression analysis failed to show correlation between cTnI and gender or age. 
However, cTnI increased significantly with increasing age in 176 healthy dogs and 81 
dogs with MVD in previous reports.  Age is thought to cause myocardial changes 
leading to cTnI leakage as the aged heart, even in the absence of demonstrable 
cardiovascular disease, loses up to 35% of its total myocyte number [Oyama and 
Sisson, 2004 and Ljungwall et al. 2010]. 
Although our results demonstrated that cTnI was significantly associated with the 
presence of CHF, conflicting results have been published before. No difference in 
median cTnI concentration was found in 37 dogs MVD and 26 dogs with CM with and 
without CHF [Oyama and Sisson, 2004]. In another prospective study, only six out 
of 15 dogs with MVD and class IV CHF had detectable levels of cTnI, nevertheless 
these patients had shorter survival times than those with cTnI concentrations within 
the reference range [Linklater et al. 2007]. However, in 35 dogs with acquired 
and/or congenital cardiac conditions serum cTnI varied with severity of congestive 
heart failure. In that study, dogs displaying clinical signs of congestive heart failure 
had the highest cTnI levels. Dogs in CHF with clinical signs (class II and class IIIA of 
the ISACHC – International Small Animal Cardiac Health Council - classification) had 
significantly higher cTnI values than controls and dogs with CHF without clinical signs 
(class IA and IB) [Spratt et al. 2005]. cTnI concentrations are thought to increase 
late in the course of the cardiac disease (higher values are expected in advanced 
stages) and correlate with the severity of the cardiac condition [Fonfara et al. 2010, 
Ljungwall et al. 2010 and Hezzell et al. 2012].  
The retrospective nature of the current study resulted in a number of limitations. 
Animals that were euthanized were categorized as non-survivors. Dogs could have 
been misclassified regarding their cause of death (cardiac, non-cardiac) as many of 
them died at home or were put to sleep and concurrent diseases cannot be ruled 
out completely. Haematology and biochemistry were not available for every patient 
thus anaemic and azotaemic dogs could have been inadvertently included. 
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Furthermore, the ideal scenario would have been utilization of age-matched controls 
in survival studies. 
One of the major limitations of this study is that, when multiple cTnI measurements 
were available,  only the highest was  taken into account. Little is known about the 
fluctuations in cTnI concentration in the progression of the different canine cardiac 
diseases. Therefore, this analysis  makes statistical results difficult to interpret. 
Results employing CTnI concentrations at admission would have been more useful 
for clinical purposes.  
The results of this study confirm that high cTnI concentrations are associated with 
shorter survival times in dogs with cardiac diseases. However, due to the overlap of 
cTnI concentration between survivors and non-survivors, and the low specificities 
and sensitivities produced, caution should be exercised when interpreting individual 
results. The role of arrhythmias in cTnI leakage remains unknown in small animals 
and it requires further investigation. Arrhythmias are commonly detected in dogs 
with cardiac or non-cardiac disease and increased cTnI levels. Clinical decisions 
should not be made on the basis of cTnI results alone. Nevertheless, dogs with 
increased troponin values require medical attention and a full cardiac examination. 
Meticulous cardiac auscultation and continuous ECG monitoring should be 
recommended in dogs with increased cTnI concentrations. 
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CHAPTER 3 
Retrospective study in cats: 
Serum cTnI and survival in feline cardiac and non-cardiac 
disease. 
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3.1 Aims and objectives 
• To study cTnI concentrations in cats with a wide variety of cardiac diseases. 
• To test the ability of cTnI to distinguish between cats with different types of 
cardiomyopathy. 
• To evaluate the ability of cTnI to discriminate between cats with cardiac, thyroid 
and systemic diseases. 
• To investigate the relationship between cTnI concentrations and survival in cats 
with cardiac disease.  
• To clarify if cTnI concentrations could accurately predict cardiac death in the 
individual patient.  
• To assess the impact of age, gender, cardiac disease, presence of CHF and 
arrhythmia on cTnI concentrations and survival in cats with cardiac disease. 
 
3.2 Material and methods 
This was a retrospective study that included cats admitted to the Small Animal 
Hospital of the University of Glasgow between 2009 and September 2012, which had 
cTnI measured in blood samples collected as part of a normal clinical investigation.  
Repeated samples from the same individual collected on different visits were 
excluded for statistical purposes. If several measurements were available, only the 
highest result was included in the analysis. The clinical histories were reviewed and 
they were classified in 3 different categories regarding their main disease: cats with 
cardiac disease, cats with hyperthyroidism and cats with systemic diseases. No 
controls were recruited for the present study. 
 
3.2.1 ANIMALS 
a) Cats with cardiac disease 
Cats were eligible for inclusion where there was evidence of cardiac disease on 
physical examination. The presence of arrhythmias, gallop sounds and murmurs or 
combinations of these were considered valid inclusion criteria. 
Cats with a haematocrit below 23%, creatinine >180 µmol/L in the absence of 
diuretic therapy, thyroxine >50 nmol /L, persistent systolic arterial blood pressure 
>180 mmHg or concurrent disease (e.g. neoplasia or trauma) were excluded from 
the cardiac disease group. 
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b) Hyperthyroid cats 
The inclusion criteria for this group was a thyroid hormone level >50 nmol/L. Cats 
with haematocrit below 23%, creatinine >180 µmol/L, persistent systolic arterial 
blood pressure >180 mmHg or concurrent disease (e.g. neoplasia or trauma) were 
excluded from the hyperthyroid group. Cats with signs of cardiac disease on physical 
examination and increased thyroxine levels were included in this group. 
c) Cats with systemic diseases 
Cats were included in this group if they were diagnosed with a systemic non-cardiac 
disease and they did not show evidence of cardiac disease on physical examination. 
Animals with haematocrit below 23%, creatinine >180 µmol/L, thyroxine >50 nmol 
/L or persistent systolic arterial blood pressure >180 mmHg were excluded. 
 
3.2.2 CARDIAC BIOMARKER 
Samples were collected by jugular venipuncture and placed in plain serum tubes, 
which were allowed to clot and submitted for analysis on the same day. Cardiac 
troponin I was tested with an “Immulite® 2000 Troponin I” (Siemens) analyzer. This 
is a chemiluminescent immunometric assay. The bead is coated with monoclonal 
murine anti-troponin I antibody and the liquid phase consists of alkaline phosphatase 
(bovine calf intestine) conjugated to polyclonal anti-troponin I antibody. This assay 
has a lower detection limit of 0.1ng/ml. The normal reference range for cats is 
<0.16ng/ml. 
 
3.2.3 CLINICAL OUTCOME 
Survival analysis was performed for cardiac cases only, due to the low number of 
cats in the other groups. Survival times were calculated from the date of sampling 
to the date of death or euthanasia. The outcome was obtained either from electronic 
records of the primary clinicians or by contacting owners or referring practitioners 
by telephone. Animals that were euthanized or died from non-cardiac conditions 
were excluded from the study. 
 
3.2.4 STATISTICAL ANALYSIS 
Statistical analyses were performed using Minitab statistical software. Data were 
non-normally distributed and results were compared using the Mann-Whitney U test 
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and graphically assessed with box-plots graphs. Median and interquartile ranges 
were used to provide descriptive statistics. 
Survival was analyzed using Kaplan-Meier curves. Cats were censored if they were 
alive at the end of the study period. ROC curves were created to assess the 
prognostic capability of cTnI and to identify the most useful cut-offs to predict 
cardiac death and cardiac death within a year. 
Regression analysis was performed to identify if the cTnI results could have been 
influenced by confounding factors such as age, breed or type of disease. Statistical 
significance was defined as P <0.05. 
 
3.3 Results 
3.3.1 STUDY POPULATION CHARACTERISTICS: 
a) Total population 
In total 141 samples were available for analysis. 53 were repeat samples and were 
excluded. The remaining samples (n=68) were placed in the three categories: 
cardiac disease (n=51), hyperthyroid disease (n=9), systemic disease (n=8). 
b) Cardiac disease 
Fifty one cats were included in the cardiac disease group. Of those, 16 were female 
(4 entire and 12 neutered) and 35 were male (3 entire and 32 neutered). The most 
common breed was domestic shorthair (n=30), followed by exotic shorthair (n=11), 
British shorthair (n=3), Maine Coon (n=3), Domestic Longhair (n=3) and Sphynx (n=1). 
The median age was 6 years old (range: 1-15 years). 
Murmurs were the most common finding on physical auscultation (n=38), however 
gallop sounds were detected in almost half of the population studied (n=24) and 15 
animals presented with audible arrhythmias. 
Electrocardiograms were available for these 15 animals. The most frequent rhythm 
disturbances in this population were VPCs (n=9). Other arrhythmias were SPVCs 
(n=2), atrial fibrillation with VPCs (n=2), VPCs and SPVCs combined (n=1) and 1 cat 
presented with second degree A-V block. 
Fifty out of the total 51 cats were scanned by the same experienced cardiologist 
(Dr. Paul Wotton). The most prevalent disease was HCM (n=29) followed by 
unclassified cardiomyopathy (UCM) (n=10) and RCM (n=9). A diagnosis of HCM was 
made based on maximal end-diastolic thickness of the left ventricular posterior wall 
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(LVPWd) or interventricular septum (IVSd) greater than 6 mm. For RCM, the inclusion 
criteria were normal thickness of the left ventricular walls and a restrictive left 
ventricular filling pattern (high E:A ratio on transmitral flow). The UCM category 
included those with normal thickness of the walls, normal ventricular dimensions, 
reduced systolic function and absence of a restrictive pattern on transmitral flow. 
One cat had pulmonic stenosis and one cat had second degree AV block. One cat had 
cardiomegaly on thoracic radiographs, an arrhythmia and gallop sounds, but the 
disease was not characterized as echocardiography was not undertaken. 
CHF was defined as presence of pleural or pericardial effusion seen on 
echocardiographic examination as well as presence of pulmonary oedema or pleural 
effusion on thoracic radiographs. Using these criteria, 28 animals were considered 
to be in CHF whereas 23 animals were not. 
c) Hyperthyroid disease 
Nine cats were included in this category. Six cats were female neutered and the 
other 3 male neutered. Most were Domestic Shorthairs (n=8) and there was one 
Siamese. The median age was 14 years old (range: 7-15 years). 
Three animals presented with audible murmurs, 2 had gallop sounds and 2 showed 
arrhythmias (SPVCs and VPCs). Five experienced some degree of respiratory distress 
(tachypnoea or dyspnoea). Six out of 9 animals underwent echocardiographic 
examination and all of them had cardiac abnormalities. 
d) Systemic disease 
Eight cats met the inclusion criteria for this group. The group comprised 1 intact 
male, 6 neutered males and 1 neutered female. There were 6 Domestic Shorthairs, 
1 Domestic Longhair and 1 Persian. The median age was 3.5 years old (range: 1-14 
years). These patients were finally diagnosed with idiopathic epilepsy, 
bronchopneumonia, pulmonary neoplasia, asthma and collapsing episodes of 
unknown origin. 
None of these animals presented with cardiac abnormalities on physical 
examination. Two animals were scanned and no abnormalities were detected on 
echocardiography. 
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3.3.2 BIOMARKER CONCENTRATIONS 
a) Cats with cardiac disease 
There were 49 cats (96%) with cardiac disease with increased cTnI concentration. 
Only two cats (4%) included in his category had cTnI concentrations below the 
detection limit of the assay (<0.1ng/ml).  
The range of cTnI in cats with cardiac disease was between 0.1 and 35ng/ml and the 
median cTnI concentration was 1.03ng/ml.  
cTnI concentrations from cats with HCM, UCM, and RCM were compared using the 
Mann-Whitney U test. cTnI concentrations were not significantly different between 
disease types. 
Cats with HCM (n=29) had a median cTnI concentration of 0.81ng/ml (range: 0.1-
35ng/ml), whereas it was 1.03ng/ml for cats with RCM (range: 0.26-9.53ng/ml) and 
2.47ng/ml for UCM cats (range: 0.16-21.2ng/ml).  
Three cats with HCM had cTnI values below the detection limit (0.1ng/ml), whereas 
all UCM cats (n=10) and RCM cats (n=9) had cTnI above the reference range. 
 
 
 
 
 
 
  
 
 
 
Cats that were in CHF had significantly higher cTnI concentrations than cats without 
CHF (P<0.0001). Median cTnI concentration from animals in failure was 2.185ng/ml 
(range of 0.27-35ng/ml), whereas cats without failure had a median cTnI 
concentration of 0.41ng/ml (range of 0.1-4.76ng/ml).  
 
FIGURE 3.1 Dotplot of cTnI concentrations in cats with cardiac disease. Note 
that most of the cats had cTnI between 0 and 3ng/ml, demonstrating why no statistically 
significant difference was found between types of cardiomyopathy. 
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b) Cats with hyperthyroidism 
All the cTnI measurements were above the reference range in the cats with 
hyperthyroidism. The median concentration of cTnI in this group was 0.757ng/ml 
(ranging from 0.16 to 2.14ng/ml). 
c) Cats with non-cardiac systemic diseases 
Four cats with systemic disease (50%) had increased cTnI concentrations while the 
other four had cTnI levels below the detection limit. Two out of the four animals 
with elevated cTnI were presented with collapsing episodes of unknown origin and 
the other two were finally diagnosed with primary respiratory diseases. The median 
cTnI concentration for this group was 0.165ng/ml (range 0.1ng/ml to 0.23ng/ml). 
 
3.3.3 COMPARISON BETWEEN GROUPS 
The cTnI concentrations in cats with cardiac disease were significantly higher than 
those from cats with systemic disease (P =0.0076). In contrast, there was no 
significant difference between cTnI levels in cats with cardiac disease and those 
with hyperthyroid disease (P=0.48). The difference between hyperthyroid and 
systemic disease cats did not reach statistical significance either (P=0.06). 
 
FIGURE 3.2 Boxplot of cTnI concentrations in cats with (+) and without (-) CHF. CHF 
was diagnosed in 28 cats, with median cTnI of 2.185ng/ml (range: 0.27-3ng/ml). Twenty-three 
cats had compensated cardiac disease (CHF-). These cats had a median cTnI concentration of 
0.41ng/ml (range 0.1-4.76ng/ml). Cats in CHF had significantly higher cTnI concentrations than 
cats without CHF (P <0.0000).   The yellow triangle (  ) represents 3 values over 10ng/ml. 
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3.3.4 SURVIVAL ANALYSIS IN CATS WITH CARDIAC DISEASE 
Twenty eight (55%) cats died or were euthanized because of the progression of their 
cardiac disease during the study period. 
Non-survivors had significantly higher cTnI concentrations than survivors (P=0.0001). 
The median cTnI concentration in non-survivors was 2.11ng/ml (range: 0.27-
35ng/ml) whereas the median cTnI concentration in survivors was 0.41ng/ml (range: 
0.1-4.76ng/ml). 
No cats with aortic thromboembolism (ATE) at the time of sampling were included 
in the present study. However, two animals died from ATE. The first one was an 8 
years old, male neutered, Sphynx diagnosed with RCM and a cTnI concentration of 
1.73ng/ml. This patient died 8 days from the date of sampling. The other cat was a 
5 year old, male neutered, Maine Coon with HCM and a cTnI value of 2.68ng/ml who 
survived for 7 months before suffering an ATE episode. 
 
 
 
 
 
FIGURE 3.3 Boxplot of cTnI concentrations in cats with cardiac, hyperthyroid and 
systemic diseases. There were 51 cats with cardiac disease, with median cTnI of 1.03ng/ml 
(range: 0.1-35ng/ml); 9 cats with hyperthyroid disease, with median cTnI of 0.757ng/ml (range 
0.16-2.14ng/ml) and 8 cats with systemic disease, with median cTnI of 0.165ng/ml (range: 0.1-
0.23ng/ml).   The yellow triangle (  ) represents 3 values over 10ng/ml. 
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In order to produce Kaplan-Meier (K-M) curves, cats with cardiac disease were 
categorized in 4 different subgroups depending on their cTnI concentrations. Group 
1 included cats with cTnI concentrations above 5ng/ml, group 2 cats with cTnI levels 
between 0.5-5ng/ml, group 3 cats with cTnI between 0.15-0.5ng/ml and finally 
group 4 consisted of cats with cTnI values lower than 0.15ng/ml. 
All cats in group 1 (n=6) were dead at the end of the study. In group 2 (n=26) 79% 
were dead at the end of the study. In group 3 (n=12) 25% were dead at the end of 
the study. All of group 4 (n=6) were alive at the end of the study.  
The non-continuous nature of the K-M curves emphasizes that they are not smooth 
functions but rather step-wise estimates; thus, calculating survival can be difficult 
[Rich et al. 2010], although a “rough estimation” of survival can be done. For 
example, if a cat is included in group 4 (coloured in blue), its probability of surviving 
12 months is 100 percent. Conversely, if a cat is categorized in group 3 (green), its 
probability of surviving a year is around 50%. 
The difference between these curves was quantified in order to assess statistical 
significance. The 4 curves were found to be significantly different using a log rank 
test. Consequently, the probability of survival of cats with cTnI concentrations of 
FIGURE 3.4. Boxplot of cTnI concentrations in survivors and non-survivors cats with 
cardiac disease. 28 cats died during the study period, non-survivors had a median cTnI of 
2.11ng/ml (range: 0.27-35ng/ml). On the other hand, 23 cats remained alive; survivors had a 
median cTnI of 0.41ng/ml (range: 0.1-4.76ng/ml). Non-survivors had significantly higher cTnI 
concentrations than survivors (P=0.0001).  The yellow triangle (  ) represents 3 values over 
10ng/ml 
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>5ng/ml, 0.5-5ng/ml, 0.15-0.5ng/ml and <0.1 was significantly different. Survival 
times were significantly shorter in cats with higher cTnI levels. 
Animals with cTnI concentrations above 5ng/ml (group 1) had significantly 
(P=0.0001) lower survival times (median 0.933 months) than cats with cTnI between 
0.5 and 5ng/ml (group 2) which survived a median of 14.9 months.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The ability of the troponin test to predict cardiac mortality in cats with primary 
cardiac diseases was assessed with ROC curves. Two different ROC curves were 
plotted, one for cTnI as a predictor of cardiac death and another for cTnI as 
predictor of cardiac death within one year. The area under the curve (AUC) was used 
to compare them. The AUC of cTnI as a predictor of cardiac death was 0.82 and the 
AUC of cTnI as a predictor of cardiac death within one year was 0.778. Both were 
close to 0.8, which is considered to be good accuracy for a diagnostic test.  
The best cut-off for predicting cardiac death was 0.64ng/ml, which produced a 
sensitivity of 80.4% and a specificity of 70%. The best cut-off to predict cardiac death 
within a year was 1.73ng/ml, corresponding to a sensitivity of 72.22% and specificity 
of 72.73%. 
FIGURE 3.5. Kaplan-Meier curve for survival analysis in cats with cardiac disease. Cats 
were allocated in 4 groups regarding their cTnI concentrations. Cats with cTnI <0.15 are represented 
in blue (n=6); cats with cTnI between 0.15 and 0.5 appear in yellow (n=12), cats with cTnI levels 
between 0.5 and 5 are seen in green (n=26) and cats with cTnI above 5 are represented in red (n=6). 
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3.3.5 REGRESSION ANALYSIS AND ANOVA 
Univariable and multivariable analysis revealed that age, gender or type of 
cardiomyopathy were not statistically associated with cTnI. In contrast, cTnI was 
significantly correlated with CHF. Higher troponin values were found in animals in 
CHF. Using a cTnI concentration of 1.13ng/ml as a cut-off, 83% of the animals in CHF 
were correctly classified (sensitivity 73% and specificity 91%). 
 
3.4 Discussion 
To the author´s knowledge, this is the first study that has demonstrated that cTnI is 
increased in several feline cardiac disease phenotypes. Some authors have previously 
reported that cats with HCM have increased cTnI values, however there are no 
previous reports regarding cTnI in UCM and RCM [Herdon et al. 2002, Connolly et 
al. 2003, Borgeat el al. 2014 and  Langhorn et al. 2014b]. However, cTnI seems 
not to be a useful test to distinguish between HCM, RCM and UCM as the difference 
between concentrations in these groups was not statistically significant. 
No histopathological examinations were performed in the cases included in this 
study; thus it was impossible to establish a causal relationship for cTnI release. 
However, abnormal coronary arteries with thickened walls and narrowed lumens are 
a common finding in cats with HCM [Fox, 2003]. These abnormal vessels are 
FIGURE 3.6. ROC curves for cTnI and survival in cats with cardiac disease. A, cTnI as 
predictor of cardiac death (AUC=0.8269). B, cTnI as predictor of cardiac death within a 
year (AUC =0.778) 
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commonly surrounded by areas of “replacement fibrosis” caused by ischaemia. End-
stage HCM, the final phase of the disease, is seen in some cats. The hallmark 
histological feature of end stage HCM is multifocal myocardial scarring (large regions 
of replacement fibrosis) for which myocardial infarction is considered the most likely 
cause. The small vessel disease present in HCM may lead to alterations of blood flow, 
causing ischaemia, subsequent myocardial cell death and replacement fibrosis. 
Moreover, intracardiac thrombi and thromboembolism appear to be very common in 
this subset of cats, thus coronary arterial thromboembolism is likely to occur [Cesta 
et al. 2005]. Some authors have suggested that the myocardiocyte disarray seen in 
human patients with HCM can contribute to ischaemia [Varnava et al. 2001]. As 
with HCM, RCM also shows a broad spectrum of pathological phenotypes. The 
endomyocardial form, known as endomyocardial fibrosis (EMF), is associated with 
marked replacement fibrosis involving the endocardium or endomyocardium [Fox, 
2004]. Commonly both atria are enlarged in RCM; in some cases atrial hypertrophy 
is evident, whereas in others the atrial walls are severely thinned. This is thought to 
be as a consequence of marked myocyte loss and collagen replacement. Similar to 
HCM cats, intracardiac thrombi and arterial thromboembolism are frequently 
observed. The term UCM is used when there are structural markers of RCM without 
proof of impaired diastolic ventricular filling [Côté et al, 2011b]. 
Replacement fibrosis and ischaemia are, thus, common in feline cardiomyopathies 
and are the most likely causes of myocardial damage and cTnI release in these 
patients. Some similar histopathological findings are common to these 3 clinical 
types of feline cardiac disease and could be the explanation for the lack of 
difference in cTnI concentrations between them. 
Only one cat was presented with pulmonic stenosis. This patient had a troponin value 
of 0.11ng/ml. No reports describing cTnI values in cats with congenital diseases have 
been published. Dogs with congenital disease have lower cTnI values that those with 
acquired heart diseases and further studies are required to see if a similar finding 
may be present in cats [Oyama and Sisson 2004, Spratt et al. 2005  and Fonfara 
et al. 2010].  
No cats with ATE at the time of sampling were included in this study. However, two 
animals later died from ATE; one of them had a cTnI concentration of 1.73ng/ml and 
died 8 days after sampling. The second cat had a cTnI value of 2.68ng/ml and died 
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7 months after being sampled. A previous study included 2 animals with ATE and 
these cats had the highest troponin concentrations of the population examined 
[Herndon et al. 2002]. Several different factors may have influenced the 
progression to ATE in our two cases, such as therapeutic protocol or type of disease. 
Further studies are needed to see if cTnI is a good predictor of ATE in cats. 
In the present study cTnI has been shown to be a good predictor of survival regardless 
of type of cardiomyopathy in cats. Cats with cardiac disease and cTnI levels above 
5ng/ml survived for a median time of 0.933 months while cats with cardiac disease 
and cTnI concentrations between 0.5 and 5ng/ml survived a median time of 14.9 
months. The best cut-off for predicting cardiac death was 0.64ng/ml, with a 
sensitivity of 80.4% and a specificity of 70%. 
Two recent papers have focused on the usefulness of cTnI as a predictor of mortality 
in cats with cardiac diseases. The first one specifically recruited purebred cats 
(Maine Coon, British Shorthair, Norwegian Forest and Exotic Shorthairs) with 
suspected familial HCM and demonstrated that both cTnI and cTnT concentrations 
at admission were prognostic for survival [Langhorn et al. 2014b]. The second study 
showed that a circulating concentration of cTnI greater than 0.7ng/ml was a 
significant predictor of cardiac death in cats of any breed with HCM. Importantly, 
cTnI remained significant even if the size of the left atrium or the presence of CHF 
remained uncertain [Borgeat et al. 2014].  
In the present study, the regression analysis showed that cTnI was correlated with 
CHF. Those animals that were in CHF had significantly higher cTnI values and 
significantly lower survival times. Controversial information has been published 
about CHF and cTnI in cats. One study also showed that cats with CHF at the time 
of cTnI measurement had significantly higher (P=0.0095) concentrations than did 
cats with no CHF [Herndon et al. 2002]. However, in another study the authors 
were not able to demonstrate a statistically significant difference in cTnI levels 
between cats with CHF due to cardiomyopathy and those without (P=0.16) [Connolly 
et al. 2003]. Any discrepancy between studies may be related to low numbers. This 
study has shown that, in a well characterized population of cats, cTnI may 
differentiate cats with CHF from cats without CHF, but it is important to be aware 
that three previous studies have all shown that whilst cats with dyspnoea due to 
congestive heart failure tend to have higher cTnI concentrations than cats with non-
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cardiac dyspnoea, there was a high degree of overlap between the groups. cTnI is 
considered to be unsuitable to distinguish between causes of dyspnoea in cats 
[Herndon et al. 2008, Connolly et al. 2009a and Wells et al. 2014] 
Cardiac biomarkers have previously been shown to be elevated in cats with 
hyperthyroidism [Connolly et al. 2005 and Sangster et al. 2014] and this study 
confirms this finding. This study has also shown that cTnI cannot distinguish between 
cardiomyopathy secondary to thyroid disease and any of the primary 
cardiomyopathies HCM, RCM and UCM. Structural cardiac changes due to elevated 
circulating thyroid hormone levels in cats are well known. Tachycardia, 
hypertension, increased erythropoietin release, activated renin-angiotensin-
aldosterone system and chronic sympathetic stimulation are common features and 
can lead to further cardiac remodeling [Côté et al. 2011c] 
cTnI concentrations were significantly higher in cats with cardiac disease in 
comparison with cTnI from patients with systemic disease where cardiac disease, 
renal disease, anaemia and systemic hypertension had been excluded (P= 0.0076). 
However 50% of the animals included in the latter group had cTnI concentrations 
above the reference range. The cause of the increased cTnI in this group is 
uncertain. cTnI has been shown to increase in many non-cardiac conditions in both 
human and veterinary patients. Anaemia [Lalor et al. 2014], azotaemia [Porciello 
et al. 2008], cardiac contusion [Kirbach et al. 2000], non-cardiac causes of 
dyspnoea [Herndon et al. 2008, Connolly et al. 2009a and Wells et al. 2014] and 
hyperthyroidism [Connolly et al. 2005 and Sangster et al. 2014] have been shown 
to cause increased troponin I in cats. Exercise [McKenzie et al. 2007 and Tharwat 
et al. 2013], snake envenomation [Segev et al. 2008, Pelander et al. 2010 and 
Langhorn et al. 2014a], chemotherapy [Christiansen et al. 2002, Defrancesco et 
al. 2002 and Selting et al. 2004], vector-borne diseases as Ehrlichiosis [Diniz et al. 
2008 and Koutinas et al. 2012], Babesiosis [Lobetti et al. 2002], Dirofilariasis 
[Carretón et al. 2011, 2012 and 2013] and Chagas disease [Barr et al. 2005], 
Leptospirosis [Mastrorilli et al. 2007] gastric volvulus and dilatation [Schober et al. 
2002 and Burgener et al. 2006], pyometra [Hagman et al. 2007 and Pelander et 
al. 2008] have all been shown to result in increased cTnI concentrations in dogs. 
cTnI is not a specific clinical marker; it indicates the presence of myocardial injury 
but does not define the underlying cause. Of the four cats with systemic disease that 
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had elevated cTnI in this study, two had respiratory disease and two were presented 
with non–cardiogenic causes of collapse. In these cases elevation of cTnI may have 
been caused by hypoxia.  
The regression analysis failed to show a significant relationship between cTnI and 
age, sex or type of cardiac disease. This supports the findings of Borgeat et al. 
(2014), as no correlation was found between age and cTnI in that study. However, 
some studies found a significant interaction between age and cTnI levels in dogs 
[Oyama and Sisson, 2004 and Ljungwall et al. 2010]. They theorized about the 
aged heart and myocyte loss in the absence of cardiac disease. These findings, may 
suggest a difference between cats and dogs and needs further investigation. 
The retrospective nature of the current study resulted in a number of limitations. 
Animals that were euthanized were categorized as non-survivors. Cats could have 
been misclassified regarding their cause of death (cardiac, non-cardiac) as many of 
them died at home or were euthanized and concurrent diseases cannot be ruled out 
completely. Haematology and biochemistry were not available for every patient, 
thus anaemic and azotaemic cats could have been inadvertently included. The final 
number of patients included in the study was small reducing the power of the 
statistical calculations. In an ideal scenario age-matched controls should have been 
recruited for the survival studies. Finally, animals included in the systemic disease 
group did not undergo echocardiographic examination and therefore subclinical 
cardiac disease could not be ruled out. 
In summary, this study has shown that increased cTnI is associated with long-term 
mortality in cats of any breed with a wide variety of cardiac diseases, not only HCM. 
Despite the fact that higher troponin values are associated with shorter survival 
times, decisions on euthanasia should not be made based on cTnI results alone as a 
significant overlap exist between survivors and non-survivors. Clinicians should 
consider cTnI as an additional tool in their routine diagnostic investigations, but 
always being aware of the limitations of this biomarker and the numerous non-
cardiac diseases that can cause elevation.  
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CHAPTER 4 
Prospective study in cats 
APP and cardiac biomarkers in feline cardiac and non-cardiac 
diseases. 
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4.1 Aims and objectives 
• To determine the concentration of four different APP in a well characterized 
population of cats. 
• To assess the usefulness of APP to distinguish cats with cardiac, hyperthyroid or 
non-cardiac systemic diseases. 
• To investigate the elevation of cardiac biomarkers in cats with non-cardiac 
diseases. 
• To analyze the relationship between cardiac biomarkers and markers of 
inflammation in cats with a wide variety of diseases. 
• To identify possible confounding factors for both cardiac biomarkers and markers 
of inflammation in cats. 
4.2 Material and methods 
The present prospective study protocol was approved by the Research Ethics 
Committee of the School of Veterinary Medicine, University of Glasgow. Every animal 
included in the present study received humane care with strict ethical and 
professional standards. Cats were eligible for inclusion if they were admitted to the 
Small Animal Hospital from January to June 2014 and collecting blood was part of 
the clinical investigation of their primary clinical condition. Full echocardiographic 
examination was intended in all cats, however in animals with non-cardiac 
conditions only brief echocardiography was done as time limitations were 
established by the Ethic and Welfare Committee. Informed owner consent to 
participate was obtained for all cats. Individuals were assigned to four different 
categories depending on their final diagnosis: cats with cardiac disease, cats with 
hyperthyroidism, cats with systemic diseases other than cardiac or hyperthyroidism 
and cats with comorbidities (animals with combinations of diseases included in the 
previous categories). Furthermore, cats with cardiac disease were further classified 
depending on the presence or abscence of CHF. CHF was diagnosed combining 
clinical signs, echocardiography, abdominal ultrasonography and thoracic 
radiographs (pleural effusion, pulmonary edema and peritoneal effusion). No healthy 
animals were recruited for the present study. 
4.2.1. ANIMALS 
 a) GROUP I. CATS WITH CARDIAC DISEASE 
Cats were eligible for inclusion if evidence of cardiac disease was present on physical 
examination and confirmed on ultrasonography. The presence of arrhythmias, gallop 
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sounds and murmurs or combinations of these were considered valid inclusion 
criteria. All the individuals were scanned by experienced echocardiographers, 
confirming the presence of structural cardiac disease. 
Hypertension, hyperthyroidism (defined as thyroxine higher than 50 nmol/L) or 
evidence of concurrent diseases were criteria of exclusion.  
b) GROUP II. CATS WITH SYSTEMIC DISEASE 
Cats diagnosed with systemic non-cardiac diseases were included in this group. 
Animals with concurrent hyperthyroidism (thyroxine levels >50nmol/L) or cardiac 
disease were excluded. However, animals were included in this group if 
abnormalities were found on cardiac auscultation but echocardiographic findings 
were normal. Cats with abnormal thoracic auscultation that were not scanned were 
excluded, as significant underlying cardiac disease could not be ruled out. 
c) GROUP III. CATS WITH HYPERTHYROIDISM 
Cats with serum thyroxine levels above 50 nmol/L were assigned to this group. Both 
untreated cats and those undergoing treatment for hyperthyroidism were included 
in this category. The presence of a concurrent systemic disease was a criterion of 
exclusion. 
d) GROUP IV. CATS WITH COMOBIRDITIES 
This group included cats with heart disease or hyperthyroidism and simultaneous 
extracardiac disorders. The diagnosis of hyperthyroidism was made if cats had 
thyroxine levels above 50 mol/L. Animals were considered to have underlying 
cardiac conditions if they had abnormalities on cardiac auscultation and abnormal 
echocardiographic findings. Animals with systemic disease and abnormalities on 
cardiac auscultation, which were not scanned, were included in this category.  
 
4.2.2. STUDY PROTOCOL 
a) Sample collection and storage 
Blood was obtained by venipuncture and placed in plain serum tubes.  Blood was 
allowed to clot for 15-20 minutes at room temperature, centrifuged and then serum 
was carefully separated and stored at -20 degrees C until the moment of analysis. 
Samples were aliquoted into 4 vials and were stored for a maximum of 6 months 
before analysis. When possible, 100 µL were used for SAA and  Hp measurements,  
50 µl for AGP, 50 µL for CRP at Acute Phase Protein Laboratory (Glasgow University, 
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UK) and 300 µl were sent on dry ice to IDEXX Laboratories (West Yorkshire, UK) for 
hscTnI and NT-pro-BNP analysis immediately. 
 
 
 
 
 
 
 
 
 
 
 
 
b) Echocardiography 
A full echocardiographic study was performed in all cats apart from those animals 
with non-cardiac conditions in which echocardiography was not part of the 
investigations for their primary conditions. In these cats (group II – patients with 
systemic disease), only a brief echocardiographic study was done as time limitations 
were established by the Ethics and Welfare Committee. Echocardiographic 
examinations were performed in non-sedated cats in right lateral recumbency. The 
examination included two dimensional, M-mode and Color-Doppler images. Animals 
which underwent brief echos were considered to have structural cardiac disease if 
the ventricular septum and/or left ventricular free wall measured at the end of 
diastole was greater than 6 mm, left atrium - aorta ratio was greater than 1.5, 
abnormalities were observed on Color Doppler and/or systolic function was reduced. 
 c) Biomarker analysis 
 c.1. SAA 
SAA was determined using an Automated Latex Agglutination Turbidimetric 
Immunoassay (Eiken SAA TIA, MAST®). This turbidimetric immunoassay was 
developed for use with human serum and employs anti-human SAA rabbit and mouse 
monoclonal antibodies. However, it has been previously validated in canine, feline 
and equine serum with acceptable reliability [Christensen et al. 2012]. This assay 
range is 5-500 µg/ml and normal reference value is less than 8µg/ml. 
A B 
FIGURE 4.1. Transport and aliquoting serum samples. A, Polypropylene storage boxes with 109 
serum samples were sent on ice to Reactiv Lab for analysis. B, Serum samples were divided in 4 aliquots to 
measure 6 different biomarkers of inflammation (SAA, Hp, AGP and CRP) and myocardial damage (cTnI and 
NTproBNP). 
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c.2. Hp 
Hp was determined by measuring the peroxidase activity of 
haptoglobin/haemoglobin complex (Hp-Hb).The reaction mixture is prepared with 
haemoglobin derived from sheep. The level of peroxidase activity of Hp-Hb is 
determined spectrophotometrically [Eckersall,2002]. The test has been previously 
used in cats with urinary tract obstruction [Schmidt et al. 2015]. Normal reference 
range for cats is 0.27-3.79 g/L and the detection limit of the assay is 0.05 g/L. 
c.3. AGP: 
Agar gel Immuno-diffusion was the test of choice for AGP determinations. Sheep 
anti-AGP antibodies were incorporated into melted 1% agarose gel. The detection 
limit of the assay is 200 µg/ml and concentrations above 500 µg/ml were considered 
significant. 
c.4.CRP  
Quantitative determination of CRP was performed using a highly sensitive two-site 
enzyme-linked immunoassay (Cat CRP ELISA®, Kamiya Biomedical Company). The 
company has previously validated the test in cats and it has been also employed to 
assess the acute phase response in cats receiving interferon-ω therapy [Leal et al. 
2014]. However, this kit is available for research use only. 
The lower detection limit of the assay is 0.0 mg/ml and the reference range for 
feline patients is 0.1-0.2 mg/ml. 
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FIGURE 4.3.  Double antibody sandwich ELISA test for CRP determination. 
A, Microtitre plates are coated with anti-CRP. B, 1:8000 dilution of the sample is added 
to each well. C, Unbound proteins are removed by washing. D, Addition of antibodies 
conjugated with HRP. E, After washing and removing the unbound conjugated 
antibodies, Tetramethylbenzidine was pipetted into each well .F, Spectrophotometer. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
B A 
C D 
FIGURE 4.2. Immuno-diffusion test for AGP determination. A, Sheep anti-
AGP antibodies were fixed in 1% agarose gel. The cover which protects the plate against 
external contamination was marked to identify the position of the samples. B, Serum 
samples were added into wells with a micropipette. C, After 20 hours of incubation, 
white precipitin rings were visible around the wells at the equivalence zone. D, 
Standard curve. 
 
A B C 
D E F 
 91 
 
 
c.5. HscTnI  
HscTnI was tested using a chemiluminescent immunoassay (Access AccuTnI®, 
Beckman Coulter, Inc). This cTnI test employs paramagnetic particles as solid phase. 
Materials bound to the solid phase are held in a magnetic field while unbound 
materials are washed away. The detection antibody is conjugated with alkaline 
phosphatase and when its chemiluminescent substrate is added, light is produced. 
The light is measured by spectrophotometry. The detection limit of the assay is 
<0.01 ng/ml and the normal reference range for cats is <0.04 ng/ml. 
c.6. NT-proBNP 
A two-site enzyme-linked immunoassay (Feline Cardiopet Plus ELISA®, IDEXX) was 
the test of choice in the present study. This sandwich assay method incorporates 
sheep antibodies and one monoclonal antibody specific for feline NT-proBNP.  
The lower detection limit of the assay is 24 pmol/L whereas the higher is 1500 
pmol/L. The algorithm supplied by IDEXX for interpretation of measured NT-proBNP 
in cats states that in those animal whose NT-proBNP concentrations are lower than 
100 pmol/L, clinically significant cardiomyopathy is highly unlikely. For those whose 
NT-proBNP levels are between 100-270 pmol/L, clinically significant cardiomyopathy 
is unlikely but early disease may be present. Finally, in animals with concentrations 
higher than 270 pmol/L, clinically significant cardiomyopathy is highly likely. 
 
4.2.3. STATISTICAL ANALYSIS 
Statistical analysis was performed using commercially available software (Minitab, 
version 17.1.0). Variables were tested for normality and 2-sample T-tests were 
employed to compare normally distributed data whilst Mann-Whitney U-tests were 
used for non-normally distributed variables. The data were graphically assessed with 
box-plots and median and ranges were used to provide descriptive statistics. 
Univariable and multivariable regression analysis were performed to identify 
variables (e.g. age, breed, anaemia, azotemia or type of disease) that were 
potential confounders of biomarker concentrations. Finally, ROC curves were 
plotted to assess the usefulness of biomarkers as predictors of CHF and determine 
optimal cut-off points. Statistical significance was defined as P <0.05. 
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4.3 Results 
4.3.1. STUDY POPULATION 
In total 109 serum samples were collected, but nine were repeat samples and 
excluded from further analysis. In addition, the serum of one cat that was receiving 
Oxyglobin at the moment of sampling was also discarded. This product may produce 
alterations in chemistry values determined by colorimetric methods [Adamantos et 
al. 2005]. In consequence, 99 subjects were finally included in this prospective 
study.  
Of the 99 cats, 54 were neutered males, 31 neutered females, 10 intact males and 
four intact females. Regarding breeds recruited, 76 were Domestic Shorthair (DSH), 
six Ragdoll, three Siamese, three Bengal, two Maine Coon, two Domestic Longhair 
Biomarker Method Detection limit Reference range Laboratory 
SAA 
Automated  Latex 
Agglutination Turbidimetric 
Immunoassay  
(Eiken SAA TIA, MAST®) 
5-500 µg/ml <8 µg/ml 
Acute Phase 
Laboratory, 
University of 
Glasgow, UK 
Hp Haemoglobin Binding Assay 0.05 g/L 0.27-3.79 g/L 
CRP 
Two-site enzyme linked 
immunoassay  
(CAT CRP ELISA®,  Kamiya 
Biomedical Company) 
0.0 mg/ml 0.1-0.2 mg/ml 
AGP Agar Gel Immunodiffusion 200 µg/ml <500 µg/ml 
Virology Laboratory, 
Veterinary 
Diagnostic Services, 
University of 
Glasgow 
hscTnI 
Chemiluminescent 
immunoassay  
(Access AccuTnI®, Beckman 
Coulter, Inc) 
0.01 ng/ml <0.04 ng/ml 
IDEXX Laboratories 
(West Yorkshire) 
NT-proBNP 
Two-site enzyme-linked 
immunoassay  
(Feline Cardiopet Plus ELISA®, 
IDEXX) 
24 -1500 pmol/L <100 pmol/L 
TABLE 4.1.Methods of analysis of cardiac and inflammatory biomarkers used in this 
study. 
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and one each of Burmese, Birman, Persian, Russian Blue, Tonkinese, Korat and 
British Shorthair. The median age of this population was 9.7 years (range: 5 months 
- 19 years) and the median weight was 4.3 kg (range: 1.40 - 7.20 Kg). Biomarker 
results in the study population are summarized in Table 4.2.  
 
 
 
   
 
a) GROUP I. Cats with cardiac disease 
After six months of recruitment, 22 cats met the inclusion criteria for this category. 
Group I included 10 neutered males, six neutered females, five intact males and one 
intact female. Sixteen of these were DSH and there was one cat each of Maine Coon, 
Ragdoll, Russian Blue, Bengal, Burmese and Domestic Longhair. The median age was 
8.5 years (range: 7 months - 17 years) and median weight was 4.6 Kg (range: 2.6 - 
6.9 Kg). The most common finding on physical examination was an audible murmur 
(13/22), generally grade III/VI or louder. Sporadic premature beats were detected 
in one cat and isolated gallop sounds in another. Combinations of a murmur and 
gallop sounds were detected in two animals whilst the combination of a murmur and 
arrhythmia was audible in one cat only. Arrhythmias were shown to be VPCs and 
SPVCs on electrocardiographic recordings, respectively. No abnormalities on cardiac 
auscultation were recorded in four cats. However, these four patients were 
presented in significant respiratory distress secondary to CHF, confirmed by 
transthoracic ultrasonography. 
All the individuals had structural cardiac disease confirmed by echocardiography. 
The most prevalent disease was HCM (11/21), followed by UCM (6/21) and RCM 
 hscTnI 
(ng/ml) 
NT-proBNP 
(pmol/L) 
SAA 
(µg/ml) 
Hp 
(g/L) 
AGP 
(µg/ml) 
CRP 
(mg/ml) 
n 97/99 97/99 95/99 96/99 96/99 86/99 
Median  0.07 115 5 1.06 560 0.19 
Range 0.01-4.96 24-1500 5-240 0.05-20.03 200-2420 0.02-0.48 
Undetectable 8 12 62 0 2 0 
Non-elevated 26 34 2 87 39 52 
Elevated (n) 63 51 31 9 55 34 
Elevated (%) 65% 53% 33% 9% 57% 40% 
TABLE 4.2. Panel of cardiac and inflammatory biomarkers in the study population. It 
includes the number of animals which were tested for each substance (n), median concentration of 
the biomarker in the population (Median), the range of concentration, number of cats with 
biomarker concentrations below the detection limit (Undetectable), those with biomarker 
concentrations within the reference range (non-elevated) and number (n) and proportion (%)  of 
cats with increased biomarker concentrations. 
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(1/21). Two animals presented with congenital cardiac disease (VSD and mitral valve 
dysplasia) and one showed dynamic left ventricular outflow tract obstruction. One 
cat admitted to the Out of Hours Service underwent incomplete echocardiographic 
examination, a dilated left atrium and pleural effusion was confirmed on echo 
however a definitive diagnosis was not made. 
CHF was defined as presence of pleural/pericardial effusion seen on 
echocardiographic examination and/or presence of pulmonary oedema or pleural 
effusion on thoracic radiographs. Following these criteria, 11 cats were in CHF in 
the present study. Biomarker results in group I are summarized in Table 4.3. 
 a.1. Influence of congestive heart failure 
Animals in CHF had significantly higher concentration of hscTnI (P=0.0086), NT-
proBNP (P=0.0001) and AGP (P=0.002) than cats with stable cardiac diseases. 
However, no differences in SAA (P=0.0554), Hp (P=0.5114) or CRP (P=0.08) 
concentrations were found between these two categories. 
Median hscTnI concentration in cats without CHF was 0.15 ng/ml (range: 0.02 - 0.74 
ng/ml) whereas from cats in CHF it was 0.43 ng/ml (range: 0.12 - 3.82 ng/ml). 
Median NT-proBNP was 320 pmol/L in cats with no CHF (range: 24 - 1095 pmol/L) 
whereas cats in CHF had a median NT-proBNP concentration of 1434 pmol/L (range: 
594 - 1500 pmol/L). One cat had NT-proBNP levels below the detection limit of the 
assay and two had concentrations within the reference range. These three 
individuals were all included in the no-failure category. All the animals in CHF had 
NT-proBNP higher than 270 pmol/L (reference value for clinically significant 
cardiomyopathy given by IDEXX Laboratories) and seven cats with fully compensated 
cardiac disease had NT-proBNP above this reference value. Finally, cats in CHF had 
a median AGP concentration of 780 µg/ml (range: 360 - 1680) whereas it was 320 
µg/ml (range: 220 - 840 µg/ml) for cats with no CHF. Median SAA concentration in 
cats with CHF was 29.20 µg/ml whereas in cats with compensated cardiac disease it 
was <5 µg/ml. Six cats in failure had elevated SAA concentrations whereas only 2 
compensated cats had SAA above the reference range. However, there was no 
statistically significant difference between these two groups (P=0.0554).  
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FIGURE 4.4. Boxplots illustrating hscTnI, NT-proBNP and AGP concentrations in cats with 
cardiac disease. Cats in CHF had significantly* higher hscTnI, NT-proBNP and AGP concentrations 
in comparison to cats with compensated cardiac disease. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The performance of hscTnI, NT-proBNP and AGP as predictors of CHF in cats was 
examined with ROC curves. The greatest AUC and test with the best predictive 
ability for CHF in feline patients was NT-pro BNP. The AUC for this marker was 0.98, 
revealing an excellent behavior of NT-proBNP to diagnose CHF in cats. The AUC for 
hscTnI and AGP were 0.84 and 0.89 respectively.  
An NT-proBNP concentration higher than 1234 pmol/L was the optimal cut off point 
for prediction of CHF in cats with cardiac disease, with a sensitivity of 90.91% and a 
specificity of 100%. Employing this cut off point, 95.45% of cats in CHF included in 
group I would have been correctly diagnosed.   
The logistic regression analysis found no benefit in combining these three biomarkers 
(as a “panel of cardiac biomarkers”) to predict CHF in cats with primary cardiac 
disease. 
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b) GROUP II. CATS WITH SYSTEMIC DISEASES 
There were 43 cats that met the requirements for inclusion in this group. Twenty three of 
these cats were neutered males, 15 were neutered females, 4 intact males and 1 intact 
female. This group included 32 DSH, two Ragdolls, two Siamese and there was one cat each 
of Bengal, Birman, British Shorthair, Domestic Longhair, Korat, Persian and Tonkinese. The 
median weight of this group of cats was 3.73 Kg (range: 1.4 - 7.2 kg) and the median age 
was 9 years (range: 5 months - 19 years). 
Brief echocardiographic examinations were performed on 35 of these patients (81%) and no 
structural abnormalities were identified. Five of the 35 scanned cats had soft murmurs 
(grade II/VI or less) on auscultation. These five cats had normal echocardiographic studies 
and three of them were anaemic. Eight cats from group II did not undergo echocardiographic 
examination due to their fractious nature or poor health; all of these had normal cardiac 
auscultations. Biomarker concentrations obtained from cats included in group II are 
summarized in table 4.3. 
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FIGURE 4.5 . ROC curves for NT-proBNP, hscTnI and AGP as predictors of CHF in 
cats with cardiac disease. A, ROC curve for hscTnI, this test had an AUC of 0.8347. B, ROC 
curve for NT-proBNP, its AUC was  0.9835. C, ROC curve for AGP whose AUC was 0.8926. 
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  hscTnI 
(ng/ml) 
NT-proBNP 
(pmol/L) 
SAA 
(µg/ml) 
Hp 
(g/L) 
AGP 
(µg/ml) 
CRP 
(mg/ml) 
C
ar
d
ia
c 
n 22/22 22/22 22/22 22/22 22/22 21/22 
Median 0.32 985 5 1.05 530 0.16 
Range 0.02-3.82 24-1500 5-191.30 0.76-10.94 220-1680 0.04-0.33 
Undetectable 0 1 13 0 0 0 
Non-elevated 2 2 1 21 10 15 
Elevated (n) 20 19 8 1 12 6 
Elevated (%) 95% 83% 38% 4% 54% 29% 
        
Sy
st
e
m
ic
  
n 43/43 42/43 41/43 41/43 41/43 42/43 
Median 0.04 49.50 5 1.10 680 0.21 
Range 0.01-1.43 24-945 5-168.50 0.05-20.03 200-2420 0.09-0.40 
Undetectable 7 8 27 1 1 0 
Non-elevated 17 22 1 34 13 21 
Elevated (n) 19 12 13 6 27 21 
Elevated (%) 44% 29% 32% 15% 66% 50% 
        
T4
 
n 10/11 10/11 9/11 10/11 10/11 11/11 
Median 0.18 458 5 0.99 380 0.17 
Range 0.04-0.29 24-1500 5-66.5 0.68-3 300-600 0.13-0.25 
Undetectable 0 1 6 0 0 0 
Non-elevated 1 0 0 10 7 9 
Elevated (n) 9 9 3 0 3 2 
Elevated (%) 90% 90% 33% 0% 30% 18% 
        
C
o
m
o
rb
id
it
ie
s n 22/23 23/23 23/23 23/23 23/23 12/23 
Median 0.075 87 5 1.03 560 0.20 
Range 0.01-4.96 24-1097 5-123 0.54-14.80 200-2040 0.02-0.48 
Undetectable 1 2 16 0 1 0 
Non-elevated 6 10 0 21 9 7 
Elevated (n) 15 11 7 2 13 5 
Elevated (%) 68% 48% 30% 9% 57% 42% 
TABLE 4.3. Panel of cardiac and inflammatory biomarkers in 4 groups of disease: cardiac, 
systemic, hyperthyroidism (T4) and comorbidities. n, animals which were tested for each 
substance; Median, median concentration of the biomarker in the population; Range, range of 
concentration; Undetectable, number of cats with biomarker concentrations below the detection limit; 
Non-elevated, those with  normal biomarker concentrations /within the reference range; Elevated (n) 
number and proportion (%)  of cats with increased biomarker concentrations. 
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c) GROUP III. Cats with hyperthyroidism 
After six months of recruitment, eleven hyperthyroid cats were included in the 
present study. Nine of these eleven patients were neutered male, one was a 
neutered female and the other one was an intact female. All recruited hyperthyroid 
cats were DSH. The median age of group III was 13 years ( range: 6 - 18 years) and 
median weight was 4.13 kg (range:2.5-5.5 kg). Of the eleven cats, thoracic 
auscultation abnormalities were detected in six individuals. Four cats had audible 
murmurs and 2 had gallop sounds. Echocardiographic examination was performed on 
nine hyperthyroid cats and abnormalities were detected in five of them. Three cats 
were in CHF. Biomarker concentrations from hyperthyroid cats are included in table 
4.3. 
d) GROUP IV. Cats with comorbidities 
Group IV population comprised 23 cats with two or more concurrent conditions 
included in the previous groups hence, cardiac, systemic or hyperthyroid diseases 
(e.g HCM and inflammatory bowel disease or hyperthyroidism and mediastinal 
neoplasia). Of these, twelve were neutered males, nine neutered females and one 
intact female and one intact male.  There were 17 DSH, three Ragdolls, one Siamese, 
one Bengal and one Maine Coon which fullfilled  the inclusion criteria. The median 
age of the group was 8 years ( range: 10 months to 17 years) and median weight was 
4.1 kg ( range: 2 - 7 kg). Nineteen of the twenty-three cats had abnormal thoracic 
auscultations. Murmurs were audible in fourteen cats, gallops sounds were detected 
in one cat, three individuals had an audible arrhythmia and one cat had a murmur 
and gallop sounds combined. Electrocardiography showed VPCs in three cases. 
Nineteen cats underwent echocardiographic examination. The four cats that were 
not scanned had abnormal cardiac auscultation and  the following concurrent 
conditions: pulmonary neoplasia, gastric lymphoma and hepatopathy (n=2). As these 
cats had systemic diseases but the absence of concurrent cardiac disease could not 
be ruled out, they were included in group IV instead of group II. Of the nineteen cats 
that were scanned, 16 had some kind of abnormality on their echocardiographic 
studies, with compensated HCM the most common finding. Two cats had pleural 
effusion and one of these also had a small volume of pericardial effusion. The first 
was a two-year old, male neutered ragdoll with biatrial enlargement whose final 
diagnosis was feline infectious peritonitis (Feline Coronavirus antibody titre greater 
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than 1280, hyperproteinemia, hyperglobulinemia, anaemia and abnormal 
appearance of the right kidney) and concurrent hypertrophic cardiomyopathy and 
CHF. The second case was a cat finally diagnosed with feline systemic reactive 
angioendotheliomatosis after a post-mortem examination, as vascular proliferative 
lesions were present in the myocardium, liver and kidneys. The echocardiographic 
examination of this patient revealed normal atrial size, good systolic function, mild 
pericardial effusion, moderate pleural effusion and hypertrophy of the left 
ventricular free wall and interventricular septum. The results of this group are 
compiled in table 4.3. 
 
4.3.2. COMPARISON BETWEEN 4 STUDY GROUPS 
Cats with cardiac disease had significantly higher hscTnI and NT-proBNP 
concentrations than cats with systemic diseases (P<0.001, P<0.001) and 
comorbidities (P=0.010, P<0.001). No differences regarding cardiac biomarker levels 
were found between cats with cardiac disease and hyperthyroidism (P=0.13; 
P=0.30). Hyperthyroid cats had significantly higher NT-proBNP concentrations than 
cats with systemic disease (P<0.001) and comorbidities (P=0.03).  Hyperthyroid cats 
had significantly higher hscTnI concentrations than cats with systemic diseases 
(P=0.02) but not when compared with those with comorbidities (P=0.25). Finally, 
cats with comorbidities showed significantly higher hscTnI and NT-proBNP levels 
than cats with systemic disease (P= 0.04; P =0.03). 
Regarding the APP results, no significant differences in either SAA or Hp 
concentrations were detected between the four groups of disease. Cats with 
systemic diseases had significantly higher AGP and CRP concentrations than cats with 
hyperthyroidism (P=0.008; P=0.01) but no differences were identified when 
compared with cats with cardiac diseases (P=0.14; P =0.08) or those with 
comorbidities (P=0.34; P=0.55). 
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4.3.3. IDENTIFYING POSSIBLE CONFOUNDING FACTORS 
Regression analysis was performed to identify potential associations between 
biomarker concentrations and characteristic of the population of cats included in 
this study. Biomarker concentration was adjusted for age, gender, breed, weight, 
absolute haematocrit value, anaemia (haematocrit <30%), albumin concentration, 
absolute creatinine concentration, azotemia (creatinine >180 µmol/L) and 
treatment (antibiotics and/ or anti-inflammatory drugs). 
Univariable regression analysis provided evidence of dependence of hscTnI and NT-
proBNP on circulating creatinine concentration (P=0.012; P=0.002) and the presence 
of azotemia (P=0.005; P<0.001).  
Creatinine was measured in 90 out of 99 cats in the present study. Median creatinine 
concentration in the population was 132.5 µmol/L, 75 patients had non-elevated 
FIGURE 4.7.  Boxplot of AGP(C) and CRP (D) concentrations in the 4 study groups : 
cardiac, systemic, hyperthyroid and comorbidities.  
 
C D 
FIGURE 4.6.  Boxplot of hscTnI (A) and NTproBNP (B) concentrations in the 4 study groups: 
cardiac, systemic, hyperthyroid and comorbidities.  2 values above 2ng/ml ;  1 value above 
2 ng/ml. 
 
A B 
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levels and 15 were azotaemic (>180 µmol/L).  Increased hscTnI concentrations were 
found in 63 cats of the total population and 51 individuals had increased NT-proBNP 
values. There were 19 cats with systemic disease with increased hscTnI 
concentrations. Of these, 6 cats had normal plasma creatinine concentrations, 
haematocrit and echocardiographic examination. On the other hand, there were 12 
patients with systemic disease that had increased NT-proBNP. Four of these, had 
normal creatinine, haematocrit and echocardiographic examinations. 
SAA concentrations were associated with body weight (P=0.03), haematocrit 
(P=0.004) and the presence of anaemia (P=0.03). However, after adjusting for 
weight, anaemia and haematocrit using multivariate analysis the associations were 
no longer statistically significant (P=0.063).  There was an inverse relationship 
between SAA and haematocrit. AGP concentrations were associated with weight 
(P=0.005), albumin levels (0.008), haematocrit (P<0.001) and anaemia (P<0.001). 
When AGP concentrations were adjusted for haematocrit, weight and albumin levels 
using multivariable analysis, the association between AGP and albumin was no longer 
significant (P=0.44). Similarly to SAA, one could expect higher AGP concentrations 
in individuals with lower haematocrit values. 
Haematocrit values were available from 72 cats out of the 99 included in the study.  
The median haematocrit was 34.4%. There were 22 cats with haematocrit values 
below 30% whereas 50 were above this reference range. SAA was increased in 31 
cats whereas AGP was elevated in 55. 
No associations were found between Hp or CRP with the variables age, weight, 
gender, anaemia, haematocrit, albumin, creatinine, azotaemia or treatment. 
 
4.4. Discussion 
4.4.1. APP 
Each animal species has its own major APP that must be considered the marker of 
choice for diagnostic purposes [Paltrinieri, 2008]. While CRP and SAA are 
considered major APP in the dog, SAA and AGP are thought to play a major role in 
the APR in the cat. However, data regarding APP levels in cats are scarce and mostly 
focused on general aspects of feline APP biology [Ceron et al. 2005; Paltrinieri, 
2008]. 
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The concentrations of four positive acute phase reactants were determined in this 
well-characterized population of 99 cats. AGP was the most frequently increased 
acute phase protein in the study population as 57% of the patients had elevated 
concentrations. Interestingly, CRP was the second most commonly elevated, being 
above the reference range in 40% of the patients whereas SAA was increased in 33% 
and Hp in 9% of the cats. 
Most of the studies on feline AGP have focused on infectious diseases, with particular 
interest in FIP. Many studies illustrated that AGP is not exclusive or pathognomonic 
for FIP as cats with FIV or exposed to FCoV but asymptomatic had increases in AGP 
concentrations [Duthie et al. 1997; Giordano et al. 2004; Paltrinieri et al. 2007a, 
Paltrinieri et al. 2007b]. Indeed, cats with lymphoma [Correa et al. 2001], tumor 
bearing cats [Selting et al. 2000], cats with anaemia secondary to abscesses, 
pyothorax and fat necrosis [Ottenjann et al. 2006], cats infected with Chlamydiae 
[TerWee et al. 1998], and cats with a wide variety of conditions [Kann et al. 2012] 
have been shown to have increased AGP concentrations.  
One of the most interesting findings of the present study is the possible usefulness 
of AGP as a predictor of CHF in cats with cardiac conditions. Cats with CHF had 
significantly higher concentrations of hscTnI, NT-proBNP and AGP. In addition, APP 
concentrations in cats with cardiac disease were not significantly different 
compared to those obtained from cats with systemic diseases.  ROC curves revealed 
that AGP is as good as hscTnI and NT-proBNP as a predictor of CHF in cats with 
cardiac conditions. However combining these three biomarkers did not provide 
additional information.   
Importantly, mean AGP was not significantly different in cats with systemic disease 
and those with cardiac disease.  Given that AGP was significantly higher in cats with 
cardiac disease and CHF when compared with cats with stable cardiac disease, hence 
concurrent systemic disease in the former cannot be completely rule  out. However, 
these patients underwent several physical examinations and clinical tests, making 
this scenario unlikely. 
There is a growing body of evidence in both human and veterinary medicine to 
suggest that inflammation plays an important role in the aetiopathogenesis of CHF 
(“The cytokine hypothesis of CHF”). It is thought that CHF progresses, at least in 
part, as a result of the local and systemic effects exerted by these cytokines [Araujo 
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et al. 2009]. CRP is elevated in human patients with CHF [Pye et al. 1990; Huang 
et al. 2004] and it has been proven to predict short and long-term CHF development 
in patients with stable coronary heart disease and patients with myocardial 
infarction [Berton et al. 2003; Suleiman et al. 2003; Sabatine et al. 2007; 
Williams et al. 2008]. CRP has been also associated with a significant improvement 
in the prediction of adverse events in cardiovascular disease, beyond that observed 
with conventional risk factors [Kaptoge et al. 2012]. Controversial data have been 
published regarding CRP concentrations in dogs with cardiac disease and CHF. One 
study showed that dogs in CHF had significantly higher CRP concentrations compared 
to the healthy controls [Cunningham et al. 2012] whereas there was no association 
with CHF in three other studies [Rush et al. 2006; Ljungvall et al. 2010; 
Cunningham et al. 2013]. To the authors’ knowledge, this is the first study to 
evidence increased AGP concentrations in cats with cardiac disease in CHF. 
AGP has been shown to be present in several extra-hepatic tissues including the 
myocardium and active synthesis has been proven in endothelial cells [Siegel et al. 
1985; Sörensson et al. 1999]. This study was not designed to find causal 
relationships and further investigations will be required to clarify the association 
between CHF and increased AGP concentrations in cats. 
Notably, SAA was undetectable in a significant number of patients despite being 
considered a major APP in the cat. There were 62 out of 95 cats with SAA 
concentrations below the reference range (<5µg/ml). Two large studies on SAA 
concentrations in cats have been published. The first compared SAA concentrations 
in healthy cats (n=45) and cats with a wide variety of conditions (n=312). SAA 
concentrations from controls were significantly lower in comparison with those 
obtained from diseased cats. However, among different disease groups, those cats 
with enteritis (n=9), oral disorders (n=14) and liver disorders (n=21) had SAA 
concentrations not significantly different than controls [Sasaki et al. 2003]. The 
second study examined a population of 175 cats. Of these 110 had normal SAA 
concentrations whereas 65 (37%) had increased SAA concentrations [Tamamoto et 
al. 2013]. Similarly, in the present study only 33% of the subjects had increased SAA 
concentrations. No differences between cats with cardiac disease, hyperthyroidism, 
comorbidities or systemic disease in terms of SAA concentrations were found. Thus, 
SAA might be a useful marker for some, but not for all feline inflammatory 
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conditions. Furthermore, SAA is believed to be one of the APPs most rapidly 
responsive in the cat [Eckersall and Bell, 2010]. Major proteins are often observed 
to increase markedly within the first 48 hours after the triggering event and often 
have a rapid decline due to their short half-life. Moderate and minor proteins 
increase more slowly and may be observed more often during chronic inflammatory 
processes [Cray et al. 2009]. Hence, these results might mirror the presence of 
chronic conditions or animals with treated (well-controlled) diseases in our study 
population.  
Multiple regression analysis demonstrated an inverse relationship between AGP, SAA 
and haematocrit. Increased SAA values have been described in cats with 
experimentally induced feline infectious anaemia [Korman et al. 2012] and 
increased AGP concentrations have been described in cats with anaemia secondary 
to inflammatory diseases (abscesses, pyothorax and fat necrosis) [Ottenjann et al. 
2006]. In view of these results, hematology analysis should be performed when 
interpreting SAA and AGP measurements. 
CRP is considered a major acute phase protein in dogs, humans and non-human 
primates while it is thought to be an insensitive protein in the feline acute phase 
reaction [Kajikawa et al. 1999; Ceron et al. 2005; Cray et al. 2009; Eckersall and 
Bell 2010; Jain et al. 2011]. As a consequence, data regarding CRP concentrations 
are scarce and it has not been well studied in the cat. Conflicting results have been 
published regarding the role of CRP in the feline APR. One study revealed that, in 
contrast to the considerable elevations of SAA, Hp and AGP after turpentine oil 
administration or urinary surgical procedures only small increases were observed in 
CRP concentrations in cats [Kajikawa et al. 1999]. Another study assessed the 
usefulness of interferon-ω therapy in cats naturally infected with retrovirus. In that 
study, CRP behaved similarly to SAA and AGP, increasing significantly after 65 days 
of treatment [Leal et al. 2014]. CRP was the second most commonly increased APP 
in the present study. Group II (systemic disease) and Group IV (comorbidities) had 
median CRP concentrations slightly above the reference range. Thus, CRP may also 
have a value as a biomarker in some conditions and further investigations are 
required to determine its role in feline inflammation. 
Hp is considered a minor APP in the cat. Increased Hp concentrations have been 
described in cats with anaemia secondary to inflammatory diseases [Ottenjann et 
 105 
 
al. 2006], cats which were given subcutaneous turpentine oil or LPS and cats that 
underwent urinary surgery [Kajikawa et al. 1999], cats with FIP and FIV infections 
[Duthie et al. 1997; Giordano et al. 2004] and cats with a wide variety of 
unspecified conditions [Kann et al. 2012]. In contrast to previous publications, Hp 
was only elevated in 9 out of 96 cats in the present prospective study. Regression 
analysis did not show any association between anaemia and Hp. Thus the usefulness 
of Hp as an inflammatory biomarker in feline medical conditions seems to be less 
promising than expected. 
4.4.2. Cardiac biomarkers 
The two cardiac biomarkers behaved similarly. ROC curve analysis revealed that both 
markers were useful to distinguish cats with CHF from the group of cats with 
compensated cardiac disease although NT-proBNP was superior. Indeed, NT-proBNP 
has been shown to provide a reliable means of discriminating cats with CHF from 
those with primary respiratory causes of dyspnea in several studies [Collins, 2013; 
Wess et al. 2008; Fox et al. 2009; Connolly et al. 2009b] whereas cTnI seems to 
be unsuitable for the same purpose [Herndon et al. 2008; Connolly et al. 2009a; 
Wells et al. 2014]. Nevertheless, recent publications have demonstrated the 
potential of cTnI as a prognostic biomarker in cats with cardiomyopathy [Langhorn 
et al. 2014b; Borgeat et al. 2014].  Even more, cTnI has been proven to be superior 
over NT-proBNP as a prognostic marker in cats with HCM [Borgeat et al. 2014]. 
Clinicians should then know that these biomarkers seem to offer different 
information; while NT-proBNP is better as a CHF predictor, cTnI appears to be 
superior at predicting poor outcomes in cats with cardiac disease. 
Hyperthyroid cats had increased NT-proBNP and hscTnI concentrations in the present 
study. These findings were predictable, as cardiac biomarkers have been previously 
demonstrated to be elevated in cats with hyperthyroidism [Connolly et al. 2005; 
Menaut et al. 2012; Sangster et al. 2014]. Our prospective study not only supports 
these findings but also confirms that cardiac and hyperthyroid cats cannot be 
distinguished from their APP concentrations. 
One of the strengths of this prospective study is that most of the animals underwent 
echocardiographic examination to prevent misclassification of the patients with 
subclinical cardiac disease. Heart scans were performed in 84 out of 99 cats, 
including 35 out of 43 cats with systemic diseases. Despite this, many cats in group 
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II had increased hscTnI (44%) and NT-proBNP (29%) concentrations. Cardiac 
biomarker elevations are not uncommon in patients with conditions other than 
primary cardiac diseases. In cats, cTnI has been proven to be elevated in 
hyperthyroidism [Connolly et al. 2005; Sangster et al. 2014], azotemia [Porciello 
et al. 2008], anaemia [Lalor et al. 2014], blunt chest trauma [Kirbach et al. 2000], 
and non-cardiogenic causes of dyspnea [Herndon et al. 2008; Connolly et al. 
2009a; Wells et al. 2014]. On the other hand, NT-proBNP has been demonstrated 
to be elevated in cats with hyperthyroidism [Menaut et al. 2012; Sangster et al. 
2014] and hypertension [Lalor et al. 2009]. The latter identified a significant 
positive correlation between NT-proANP and plasma creatinine concentration but 
this correlation was not present with NT-proBNP. In contrast, the presence of 
azotemia was a significant confounding factor in the evaluation of NT-proBNP in the 
present study.  In fact, an NT-proBNP and plasma creatinine association has also 
previously been described in human and canine patients [McCullough and Sandberg, 
2003; Luchner et al. 2005; Boswood et al. 2008; Schmidt et al. 2009] No 
associations between these markers and anaemia were found in the present study.  
 
LIMITATIONS  
An important limitation of this study was the storage of the samples. Serum samples 
were kept at -20°C for a maximum of 6 months.  Recently, a 4-month stability study 
was carried out revealing that cTnI recovery decreased below acceptable limits 
(down to 72%) when samples were stored for 4 months at -20°C [Langhorn et al. 
2014b]. Previous studies have shown apparently normal NTproBNP bioreactivity in 
feline samples stored for up to ten years at -80°C however, slight but significant 
reductions have been observed in human samples stored at -20°C for two years 
[Cauliez et al. 2008; Lalor et al. 2009]. This could have resulted in a minor 
degradation of cardiac biomarkers in the samples. Secondly, biochemistry and 
hematology were not available for every cat included in this study. Thirdly, many 
recruited cats were already on treatment (antibiotic or anti-inflammatory drugs) at 
the moment of sampling and APP are known to fluctuate in response to medication 
[Tamamoto et al. 2009]. Fourthly, samples were collected from cats with a wide 
variety of conditions and no controls were recruited. This may have an influence on 
interpretation as it has been shown that magnitude of increase of some APP differs 
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between illnesses [Sasaki et al. 2003]. Fifthly, echocardiography was not performed 
in all cats. 
 
CONCLUSION 
In conclusion, in this well characterized population of cats the most commonly 
increased APP was AGP followed by CRP, SAA and Hp, respectively. This is opposite 
to the recommendation of measuring SAA and Hp as inflammatory panel in cats. 
Further investigations, including these 4 APP, are required to understand their real 
role in the feline APR.  
APPs were shown to be unsuitable to distinguish between cats with cardiac, 
hyperthyroid and non-cardiac diseases.  
AGP was as good as NT-proBNP or hscTnI to distinguish between cats with cardiac 
disease with and without CHF. This possible role of AGP as a marker of CHF has not 
been described before and further research should be done. 
NT-proBNP and hscTnI concentrations were significantly higher in cats with cardiac 
disease and hyperthyroidism than in cats with systemic disease. However, both 
cardiac biomarkers were elevated in a substantial number of cats with non-cardiac 
non-hyperthyroid systemic diseases. 
No correlation was found between cardiac and inflammatory markers making the 
theory of myocardial damage/troponin release induced by inflammation less likely 
in patients with non-cardiac diseases. 
A positive association was detected between cardiac biomarkers and plasma 
creatinine concentrations and between anaemia and SAA and AGP concentration. 
Haematology and biochemistry analysis are required in order to interpret biomarker 
results properly. 
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FINAL CONCLUSIONS AND FUTURE RESEARCH 
The number of publications studying cTnI in small animal veterinary medicine has 
significantly increased in the last decade.  Several factors may influence cTnI release 
and measurement. In consequence, many conflicting results have been reported 
challenging the ability of clinicians to interpret the test. 
Two essential recommendations to read cTnI results are : 
It is imperative to consider cTnI as a non-specific biomarker of myocardial injury. 
An elevation of cTnI indicates the presence of myocardial injury but does not define 
the underlying cause. cTnI is a highly specific biochemical marker (we are certain 
about its cardiac origin)  but non-specific clinical marker (we are uncertain the 
cause). Elevations are not uncommon in veterinary patients with conditions other 
than primary cardiac disease. Therefore, raised cardiac troponin alone will never 
allow practitioners to make a clinical diagnosis. Full blood work and cardiac 
examination should be done in patients with elevated cTnI. 
Secondly, the lack of standardization of cTnI assay systems has meant an inability to 
compare absolute values between methods. Reference ranges and cut-off values 
obtained in previous studies with different analyzers are not interchangeable and 
should not be used in practice to make clinical decisions. Practitioners should use 
reference ranges given by their laboratory. 
Results of this study confirm that high cTnI concentrations are associated with 
shorter survival times in dogs and cats with cardiac disease. Animals with higher cTnI 
concentrations had shorter survival times. However, cTnI was superior to predict 
cardiac death in cats than in dogs. Several factors may have affected these results. 
There was a wide clinical and morphologic heterogeneity of canine cardiac diseases 
included in the study. Pathophysiological mechanisms may vary notably between 
cardiomyopathies, valvular, congenital and/or pericardial diseases and this could 
directly impact on the magnitude and velocity of cTnI release. In contrast, the feline 
population was more homogenous as most of the cats suffer from cardiomyopathy. 
Furthermore, a high incidence of arrhythmias was present in the canine population. 
The role of arrhythmias in cTnI release remains unknown. Significantly higher cTnI 
levels were found in those dogs with more severe arrhythmias but some of them 
experienced fairly good outcomes. The author hypothesizes that the presence of an 
arrhythmia (especially tachyarrhythmias) may cause a significant transient increase 
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of cTnI that would cease once the rhythm is controlled. Therefore, the author 
believes the prognostic value of cTnI in dogs which present with arrhythmias should 
be interpreted with caution. Finally, due to the overlap of cTnI concentration 
between survivors and non-survivors in both canine and feline patients, clinical 
decisions should not be done relying merely on cTnI results.   
Assessing the relationship between arrhythmias, cTnI and survival is an enthralling 
area of research. Comparative studies with serial cTnI measurements in dogs with 
well controlled arrhythmias versus animals with uncontrolled rhythm disturbances 
will be of particular interest. 
Results of the prospective study demonstrated that AGP was the most commonly 
elevated APP in our well-characterized population of cats. AGP was followed by CRP, 
SAA and Hp concentrations respectively.  
The feline APR is still uncharted territory, the information available is scarce and 
conflicting. CRP is considered a non-responsive protein in the APR in this species and 
measurement of SAA and Hp is recommended to assess inflammation in cats. 
Clarifying the real role of CRP, AGP, SAA and Hp in feline APR represents an 
intriguing line of future research. 
A considerable number of cats with non-cardiac diseases had increased hscTnI and 
NT-proBNP. Cardiac biomarkers were associated with plasma creatinine levels. 
Nevertheless, there was still a group of patients with normal echo, normal 
haematocrit and non-azotaemic with increased cardiac markers. Several authors 
have proposed inflammation as a source of troponin release in dogs with non-cardiac 
diseases. In the present study, the relationship between cardiac and inflammatory 
markers did not reach statistical significance. However, in cats with cardiac disease 
AGP was significantly higher in animals in CHF and turned out to be as good predictor 
of CHF in cats as NT-proBNP and hscTnI. Thus, inflammation may be involved in the 
release of cardiac biomarkers in some but not all feline conditions. Further 
investigations regarding the usefulness of AGP as a predictor of CHF and cardiac 
death in cats would also be an attractive future work. 
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